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The development of new screening methods for the early detection of cancer 
remains one of the foremost challenges facing modern cancer research. The emergence of 
new analytical technologies and their application to “omics”-based approaches has 
provided researchers with powerful new tools for molecular biomarker discovery that may 
benefit early screening of cancer. This dissertation outlines several key advances made 
toward the application of urinary metabolomics to cancer biomarker discovery. The term 
urinary metabolomics here refers to the investigation of small metabolites in urine as 
potential disease biomarkers. The advantage of using this approach lies in its noninvasive 
sampling characteristics and robust analytical feasibility. The dissertation begins with the 
development of two analytical methods for the determination of sarcosine in urine for the 
early detection of prostate cancer. The next three papers discuss the analytical challenges 
facing the determination of pteridine derivatives in biological samples and present a new 
method to adjust their levels to patient hydration status and time since last urination. 
Briefly, pteridines and their derivatives function as intermediates in the metabolism of 
various vitamins and cofactors, where altered levels of pteridines have been reported in the 
urine of patients with several types of epithelial cancers, among other diseases. The 
following paper explores the possibility of using urinary metals as potential cancer 
biomarkers in a proof-of-concept study. The final two papers investigate the biological 
variation of urinary pteridines in order to better understand how urinary metabolites 
naturally fluctuate, and apply this information to a new method for the comprehensive 
determination of pteridine derivatives in urine. Taken together, this body of research 
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1.1. CHALLENGES FACING EARLY CANCER DETECTION 
  Cancer is among the leading causes of death worldwide with over 8 million deaths 
reported in 2013.1 Moreover, the global burden of cancer is expected to increase as risk 
factors for developing cancer, such as smoking, obesity, and sedentary lifestyles, become 
more prevalent.2 Early cancer detection can reduce disease mortality by identifying 
premalignant and malignant tumors at an early stage of development when treatment may 
be more effective. However, conventional screening methods, such as medical imaging, 
mammograms, and colonoscopies, often involve invasive procedures that may be 
uncomfortable for patients or require advanced medical facilities that limit accessibility 
and affordability. False positives that result when a screening method cannot distinguish 
indolent and aggressive disease further contribute to the problem of overdetection and 
expose patients to unnecessary treatment. Overdetection resulting from insensitive 
mammograms and prostate specific antigen (PSA) screening has become especially 
problematic in the management of breast and prostate cancers, respectively. 3-5 For 
example, the extent of overdetection in breast cancer management is estimated to be as 
high as one in three breast cancers, prompting the American Cancer Society in 2016 to 
recommend new guidelines aimed at reducing the frequency of mammogram screening by 
raising the suggested age for women to begin screening and decreasing the frequency of 
periodic screening among women over 50.6 In this way, new screening methods for 
detecting cancer earlier and more reliably are needed to better identify individuals who are 
at increased risk for developing cancer. 
 
1.2. THE EMERGENCE OF URINARY METABOLOMICS 
  Modern research on early cancer detection has shifted focus onto the development 
of molecular biomarkers capable of reflecting underlying cancer biology. Whereas 
  
2 
conventional screening methods have limited spatial and temporal resolution that require 
the tumor to grow to a minimum size before detection is possible, molecular biomarkers 
are capable of providing details prior to disease onset and throughout the natural 
progression of the disease. Collectively, the applications of advanced high-throughput 
technologies to reveal the biochemistry of cancer and other diseases is referred to “omics” 
approaches, and can be classified by type of molecule studied. For example, genomics is 
concerned with the genetics of a given condition, while proteomics is concerned with the 
proteins involved in a given condition, and metabolomics involves the investigation of 
small metabolites in relation to a given condition, among other specialty subclasses. 
Previous efforts to characterize the genomes and proteomes of cancer have revealed 
remarkable complexity and heterogeneity, even among histologically similar tumors.7 
Nevertheless, the discovery of potential screening biomarkers from these genomic and 
proteomic studies has remained limited by difficulty in implementing such screening 
methods. Specifically, genomic analysis can readily reveal whether an individual is at 
increased risk for developing cancer, but analysis of genes alone cannot provide 
information on whether a malignant tumor already exists. Moreover, genomic analyses are 
generally limited to tissue samples for which an invasive biopsy from the suspected cancer 
site must be taken. Transcriptomics, concerned with the relationship between gene 
expression and disease, is an emerging “omics” approach that successfully bridges 
genomics with a responsive set of molecular biomarkers with better translatability to bodily 
fluids, such as serum.8 Protein biomarkers have greater applicability to cancer screening 
methods than genetic markers while maintaining a high degree of disease specificity. 
Nevertheless, protein analysis in a clinical diagnostic setting requires specialized analytical 
techniques and invasive sampling techniques. In contrast, metabolites represent the final 
response of an organism to environmental, genetic, and disease factors 9, 10. The 
responsiveness of metabolites to disease phenotype enables monitoring of subtle changes 
in the pathophysiology of multifactorial diseases, such as cancer11. Although the 
relationship between cancer development and cellular metabolism is complex and can be 
unique to individual tumors, cancer metabolism is often characterized by increased 
glycolysis and increased fatty acid synthesis, among other metabolic processes needed to 
support rapidly dividing cells, collectively referred to as the Warburg effect.12-15 
  
3 
Furthermore, metabolites may be sampled noninvasively in a myriad of biospecimen types, 
such as exhaled breath, saliva, and urine, with a greater variety of analytical techniques 
than is possible for genomic or proteomic biomarkers.16, 17. 
  Among these biospecimen types, urine confers several advantages to cancer 
screening applications and is particularly well-suited for metabolite analysis17, 18. Namely, 
urine can be sampled noninvasively and economically in large volumes suitable for long-
term storage. Urine further does not contain proteins, immunological factors, cells, and 
other matrix components common to serum and tissue lysates that require substantial 
pretreatment of samples prior to analysis. Nevertheless, the application of metabolomics-
based approaches to cancer biomarker discovery in urine has only recently benefitted from 
the remarkable technological breakthroughs that have supported other “omics” strategies. 
Although urinary metabolites have been studied in relation to cancer for decades (e.g. 19, 
20), urinary metabolomics presents several challenges that comprise some of the major 
themes of this dissertation. For example, unlike genes or even proteins, metabolites can 
occur physiologically where their urinary levels become altered in the presence of cancer. 
This consideration requires the application of rigorous statistical models to determine 
whether a given metabolite concentration will be considered abnormal. The significance of 
this feature is highlighted by the shortcomings of the PSA test for prostate cancer in which 
PSA and other kallikrein proteins can become elevated due to benign prostatic hypertrophy 
and other conditions.21 Moreover, urinary metabolites must be adjusted to patient hydration 
status and time since last urination. As this dissertation will later present, conventional 
strategies for rendering these corrections may be flawed or inappropriate for a given study 
population. Finally, the human urine metabolome is remarkably complex with over 4000 
reported metabolites,22 a feature that complicates the sensitive and specific determination 
of urinary metabolites due to the high potential of interfering compounds. This dissertation 
will outline the development of several analytical methods embedded with innovations to 
overcome these challenges. These new developments in the application of urinary 
metabolomics to cancer biomarker discovery have led to significant progress in a rapidly 
expanding and evolving field. 
  
4 
1.3. ANALYTICAL TECHNIQUES USED IN URINARY METABOLOMICS 
  Quantitative techniques for urinary metabolites can select from a rich variety of 
standalone and hyphenated analytical platforms for the optimal detection of selected 
metabolites. Mass spectrometry is a preferred detection method given its excellent 
sensitivity and multiplexing capacity. For quantitative analyses, tandem mass 
spectrometers in particular can provide fast acquisition times, a variety of possible scan 
modes, and wide dynamic ranges that allow these instruments to monitor trace level 
metabolites to primary metabolites such as amino acids within a single run. Tandem mass 
spectrometry may be further hyphenated with separation techniques, such as gas 
chromatography, liquid chromatography, or capillary electrophoresis for enhanced 
separation of urinary compounds and increased multiplexing capacity. Briefly, gas 
chromatography – tandem mass spectrometry (GC-MS/MS) is useful for the quantitative 
analysis of volatile compounds, and through the use of chemical derivatization, an 
additional subset of normally non-volatile compounds. However, the small number of 
volatile compounds present in urine and the potential selectivity issues and complicated 
procedures involved with chemical derivatization have generally limited its application for 
this purpose.23 
  Liquid chromatography continues to be the most widely used separation technique 
in the determination of urinary metabolites. The technique is best suited for the analysis of 
non-volatile and thermally labile compounds that comprise the overwhelming majority of 
urinary metabolites. The analytical capabilities of the technique have recently benefited 
from new column technologies including the development of novel stationary phase 
chemistries and reduced particle sizes that enable highly selective separation of metabolites 
in urine matrices. Liquid chromatography can further readily interface with a range of 
detector types, including mass spectrometry, UV absorbance, and fluorescence. However, 
liquid chromatography – tandem mass spectrometry (LC-MS/MS) continues to be the most 
common configuration given its superior sensitivity and selectivity and relative 
accessibility compared with other analytical techniques. Moreover, reference level 
accuracy can be obtained with this configuration through the use of stable isotope internal 
standards and isotope labelling strategies. For this reason, LC-MS/MS has been 
implemented in clinical diagnostic settings for the quantitative determination of various 
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metabolic biomarkers. This dissertation covers several advances made in the development 
of multiplexed LC-MS/MS methods for the simultaneous determination of pteridines and 
other compounds. 
  Finally, capillary electrophoresis presents another high-resolution separation 
technique for the analysis of highly polar or ionic compounds. Capillary electrophoresis 
has found limited applications in urinary metabolomics and cancer biomarker discovery 
given its poor reproducibility and challenges associated with its hyphenation to certain 
detector types, such as mass spectrometry. However, recent innovations in interface 
designs and advanced separation modes have overcome many of these earlier challenges.24, 
25 Taken together, these technological innovations have enabled extensive metabolic 
profiling in urine, resulting in the discovery of new putative biomarkers for the early 
detection of cancer. 
 
1.4. URINARY PTERIDINES AS MODEL BIOMARKERS 
Recent urinary metabolomics studies have revealed an array of putative biomarkers 
ranging from modified nucleosides26 to kynurenine pathway intermediates27 to pteridines28 
to many others. Among these, the clinical investigation of urinary pteridines has best 
exemplified progress made in the application of urinary metabolomics to cancer biomarker 
discovery through the translational challenges that have been overcome and is discussed in 
great detail later in this dissertation. Briefly, pteridines and their derivatives function as 
intermediates in the metabolism of several vitamins and cofactors. Pteridines are one of the 
most widely studied classes of metabolites in urine, owing to their original isolation in 
urine and the resulting analytical methods that were developed for their quantitation in 
urine.29 Although many of these early studies examined the putative roles of pteridines in 
cancer given their relationships to the DNA nucleotide and folic acid metabolic pathways, 
and reported elevated levels of several such pteridines in certain epithelial cancers,30-34 the 
clinical investigation of urinary pteridines and their biological function in cancer have until 
recently been frustrated by limited analytical capabilities. However, the biological function 
of some pteridines, such as 5,6,7,8-tetrahydrobiopterin (BH4) and neopterin, have been  
elaborately studied and provide important context for the probable roles of other pteridine 
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derivatives in cancer. Briefly, BH4 is derived from guanosine triphosphate and functions 
as an essential cofactor for several notable classes of enzymes, including amino acid 
hydroxylases involved with neurotransmitter biosynthesis, nitric oxide synthase which 
regulates vasodilation and neuroprotection, and alkylglyercol monooxygenase which 
mediates the biosynthesis of ether lipids involved with structural components, chemical 
signaling, and more. For this reason, BH4 deficiencies can present a spectrum of clinical 
disorders, and is consequently used as a screening biomarker for several diseases. 
Meanwhile, neopterin and its derivatives are produced selectively in monocytes, 
macrophages, dendritic cells, and endothelial cells following activation by the cytokines 
and interferon gamma (IFN-γ) released by T lymphocytes and natural killer cells in a 
similar manner to BH4.35 As a result, neopterin has been studied extensively as a marker 
for activated cellular immune response in an array of medical conditions, ranging from 
bacterial and viral infections to autoimmune diseases to cancer. In addition to BH4 and 
neopterin derivatives are many other pteridines and related lumazines that have been 
reported in humans, but whose biological function and biosynthetic pathways remain to be 
established.34. This dissertation presents several analytical methods for the determination 
of these compounds in urine and cell lysates in order to better understand their roles in 
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Metabolites impart a significant importance to the understanding of biological 
reactions, and consequently, to the development of diagnostic and therapeutic techniques 
for specific diseases. Furthermore, there has been recent interest in metabolite 
concentrations present in urine for potential noninvasive disease diagnosis. The detection 
of specific metabolites, however, presents certain analytical difficulties such as low or 
ambiguous specificity of the techniques. This study developed a new technique, utilizing 
oxidative, enzymatic production of formaldehyde from the metabolite to produce a pH-
induced change observed by fluorescein in acetone. This probe displays high sensitivity 
towards pH imbalances, and coupled with high enzymatic specificity, forms an accurate 
method to measure metabolite concentrations. Sarcosine was used as a model analyte in 
this study due to its potential for serving as a prostate cancer biomarker. Sarcosine was 
treated with sarcosine oxidase to generate formaldehyde, which was further oxidized to 
formic acid, and subsequently measured by the corresponding change in fluorescein. A 
good linearity was revealed with a correlation coefficient of 0.9961 and a detection limit 
of 20 nmol·L−1. This method was applied to sarcosine analysis in nine urine samples. The 
results suggest that this is a viable, cost-effective technique for determination of sarcosine 
in urine samples without interferences such as alanine. 
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Tests for prostate-specific antigen (PSA), a common marker for prostate cancer 
diagnostics, cannot accurately differentiate between benign prostate conditions and active 
prostate cancer.1 This well-practiced technique, which relies upon an abnormally high 
presence of the antigen in serum, thought to be correlated with increased prostate gland 
size, is also well-known for being both false positive- and negative-prone.2 It has further 
been shown that the mortality rate does not significantly improve with PSA screening.3 
This lack of sufficient diagnostic techniques for prostate cancer highlights the need for 
more effective screening methods. 
 
Whereas many diagnostic techniques rely on the presence of antigens, like PSA, 
metabolites can serve and equally important diagnostic role. Indeed, metabolites, as the 
intermediates and products of metabolic exchanges, have an intimate relationship with 
systemic changes in an organism. An important implication of this is that of carcinogenesis; 
while cancer has been traditionally seen in terms of gene regulation, affecting control and 
signal processes, disjoint from metabolites, it is becoming increasingly apparent that 
metabolites operate as key functions in the development of several types of cancer through 
numerous mechanisms, such as modulating various signal transduction systems.4  
 
Effective analysis and quantification of such metabolites in applicable media may 
then characterize the progression of certain cancers when practical difficulties would 
otherwise exist.5,6 An example of this concept, applied to prostate cancer, was utilized in 
an attempted metabolomic profiling of biopsy-positive prostate cancer patients and biopsy-
negative prostate control individuals that suggested a correlation between sarcosine levels 
and progression of the disease.7 This finding brought about great interest in determining 
sarcosine in various media, and although the correlation between sarcosine and prostate 
cancer has since been refuted8,9, it adds stress to the importance of metabolites, such as 




Analytical methods for direct determination of metabolites from cells, plasma, or 
urine often include a combination of liquid chromatography and gas chromatography with 
mass spectroscopy. However, the major disadvantages of these techniques are high 
instrumentation costs and the interferences from other chemicals; for example, in the case 
of sarcosine, alanine has the same exact mass as sarcosine and often co-elutes with it, 
traditionally complicating normal chromatographic techniques.10 Although 
chromatographic techniques have been reported to fully separate alanine and sarcosine, 11,12 
these techniques require instrumentation not generally available to clinics.  
 
Substrate-specific enzymes, however, have shown to be useful analytical 
reagents.13,14 One class in particular is the oxidoreductases, which often produce reactive 
oxygen species (ROS), such as peroxidase and hydrogen peroxide, respectively, being first 
reported in 1846.15 In the case of sarcosine, sarcosine oxidase serves as a catalyst in the 
oxidative demethylation of sarcosine, an intermediate metabolite, to glycine, 
formaldehyde, and hydrogen peroxide. Direct determination of sarcosine can be difficult, 
but indirect quantification can be achieved by this reaction. Indeed, an established 
analytical assay for sarcosine includes the sarcosine oxidase-mediated demethylation of 
sarcosine to hydrogen peroxide, which reacts with 4-aminoantipyrine and phenol to yield 
quinoneimine dye (Scheme 1)16. The disadvantage is that such colorimetric analyses can 
be skewed in complex matrices like urine and blood. 
 
Scheme 1. Colorimetric assay of sarcosine via production of quinoneimine dye. 
 
Sarcosine + O2 + H2O + Sarcosine Oxidase  → Glycine + Formaldehyde + H2O2 
2H2O2 + Phenol + 4-aminoantipyrine + Peroxidase → 4H2O + Quinoneimine Dye 
 
A proposed solution to this skewing is the fluorimetric determination of sarcosine. 
One particular subset of fluorescein derivatives, including the commonly used 2’,7’-
dichlorofluorescein diacetate (DCFH-DA), is currently being recognized for its high 
specificity to reactive oxygen species. Many of these compounds have reported detection 
limits in the nanomolar concentration range, providing useful probes for oxidative stress in 
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cellular systems.17,18,19,20 Their premise was based upon the theory that non-fluorescent 
fluorescein derivatives will fluoresce upon oxidation by hydrogen peroxide and other ROS, 
and that this fluorescence is directly proportional to the concentration of ROS present.21 
 
Indeed, this subset of fluorescein derivatives is growing every day, and the 
specialized probes cited above formed the original basis of the proposed method for their 
relative structural and synthetic simplicity to newer compounds. Although this type of 
probe has the capability to indirectly quantify sarcosine by production of hydrogen 
peroxide via sarcosine oxidase, there exists several limitations: (1) as fluorescein 
derivatives, they are highly sensitive to pH changes and (2) hydrogen peroxide 
decomposition needs to follow a radical pathway.  Under optimal conditions, the oxidation 
of sarcosine is significantly favorable to the further oxidation of formaldehyde to formic 
acid. The associated pH change from this was found to be more significant than that 
oxidation of fluorescein by radicals formed by hydrogen peroxide decomposition. In 
addition to this, the basic conditions under which sarcosine oxidation occurs seemed to 
have favored the decomposition of hydrogen peroxide into water and oxygen gas, not 
radicals. Furthermore, synthetic preparation of these specialized fluorescein derivatives is 
often complex, and the direct purchase is expensive, when compared with pure fluorescein. 
In this study, a novel and low cost enzymatic technique has been developed for 
determination of sarcosine in urine samples, not by measuring ROS formed from hydrogen 
peroxide decomposition, but the pH change associated with formaldehyde being oxidized 
to formic acid. 
 
1.2. Reaction Mechanism 
The developed method relies simply on the pH sensitivity of ordinary fluorescein. 
Under acidic conditions (pH<4), the non-fluorescent lactone form of fluorescein exists in 
high concentrations. Prepared in acetone, it is nearly the only form present and is 
furthermore readily soluble. Upon exposure to a basic reagent, lactoid fluorescein will 
readily change to the highly fluorescent monoanionic and dianionic forms. Thus, changes 
to the pH of a standard reagent can be quantitatively determined by the lactoid fluorescein, 
even with low concentrations and/or volumes. For the determination of sarcosine, this can 
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be achieved by an enzymatic oxidation of sarcosine to glycine, resulting in hydrogen 
peroxide and formaldehyde as byproducts, and subsequent oxidation of formaldehyde to 
formic acid and methanol (Scheme 2). In the presence of NaOH and heat, the Cannizzaro 
reaction proceeds converting the formaldehyde to formic acid and methanol while 
degrading the hydrogen peroxide without forming interfering radicals. The conditions of 
the Cannizzaro reaction catalyze the decomposition of hydrogen peroxide to water and 
oxygen gas with minimal ROS being formed. The resultant decrease in pH from the formic 
acid results in a quantifiable deviation from the standardized pH of the solution without 
interference from radicals from hydrogen peroxide. In this way, the coupling of an enzyme 
and ordinary fluorescein provides two advantages: (1) high specificity for sarcosine, and 
(2) a relatively cost-effective alternative to current methods such as DCFH-DA and LC-
MS analysis. 
 
Scheme 2. Proposed method for the determination of sarcosine. 
 
Sarcosine + O2 + H2O + Sarcosine Oxidase  
C37  Glycine + Formaldehyde + H2O2 
 
 
Formaldehyde   CNaOH 50, Formic acid + Methanol 
 
H2O2  
CNaOH 50,  O2 + H2O 
 
Lactoid Fluorescein in acetone (non-fluorescent)   AcidFormic Dianion Fluorescein 
(fluorescent) 
 
The combination of the two steps, substrate-specific enzymatic production of 
formaldehyde followed by conversion to formic acid coupled with subsequent fluorimetric 
analysis by fluorescein, supplies an effective, indirect, analytical technique for metabolite-
specific determinations without interference from ROS. This idea was demonstrated by the 
determination of sarcosine in urine and further comparison to the same samples being 




2.1. Preparation of Sarcosine Oxidase 
Sarcosine oxidase from Corynebacterium sp. (lyophilized powder, 5-10 units/mg) 
was purchased from Sigma-Aldrich (Saint Louis, MO, USA). A 20 mmol·L⁻¹ potassium 
phosphate solution was prepared from ultra-pure water and potassium phosphate 
monobasic, and the pH was adjusted to 8.3 with 1 mol·L⁻¹ sodium hydroxide. To 1 mL of 
buffer was added 0.7 mg enzyme. The reagent was prepared fresh and chilled at 4 degrees 
Celsius. 
 
2.2. Preparation of Sarcosine Stock Solution 
The sarcosine and Tris-HCl buffer used in this study were purchased from Sigma-
Aldrich (Saint Louis, MO, USA). Ultra-pure water was generated using a Milli-Q 
Advantage A10 water purification system, 18MΩ (Millipore, Billerica, MA, USA). A 200 
mmol·L⁻¹ Tris-HCl buffer was prepared with ultra-pure water and Tris base, and the 
resulting pH was adjusted to 8.3 with NaOH. This represented the optimal pH of sarcosine 
oxidase and fluorescein. A stock 2.5 µmol·L⁻¹ sarcosine solution was prepared in the 
buffer.  
 
2.3. Analysis of Sarcosine Standard Solutions 
Into a 250 µL Corning Costar 96 flat bottom plate were added insertions of the 
sarcosine stock solution. These insertions were based on the sarcosine concentration range 
(200-1400 nmol·L⁻¹) reported by LC-MS/MS analysis of urine samples diluted 750 times. 
This insertion was supplemented with enough Tris-HCl buffer to make 75 µL. The plate 
was then heated to 37 oC. To this was added 25 µL cold enzyme reagent, and the plate was 
then incubated at 37 ᵒC for 30 minutes. Upon incubation, the plate was chilled to room 
temperature, 5 µL 500 mmol·L⁻¹ NaOH inserted, and re-incubated at 50 ᵒC for 10 minutes 
to ensure complete formation of formic acid. The plate was then cooled to room 
temperature again, and fluorescence readings were taken. Upon which 5 µL 15 nmol·L⁻¹ 
fluorescein dissolved in acetone was added, resulting in a total volume of 110 µL per 
sample. The plate was then shaken in double orbital fashion for two minutes and analyzed 




2.4. Analysis of Urine Samples 
Urine samples (n=10) were provided by the Central Missouri Urology Clinic. The 
set was comprised of five normal samples and five prostate cancer positive samples. Prior 
to subjection to the method outlined in this study, the samples were analyzed via liquid 
chromatography with tandem mass spectroscopy.9 The supernatant of the samples were 
then properly diluted in buffer solution whereby 75 µL was inserted into the well plate. 
The procedure then followed that of the sarcosine standards.  
 
2.5. Instrumentation 
Fluorescence emission spectra were obtained with a BMG Labtech Fluorstar 
Omega (Ortenberg, Germany) plate reader equipped with a xenon lamp. Excitation and 
emission wavelengths were attuned to 485 nm and 520 nm, respectively.  The lamp was 
allowed sufficient time to warm prior to measurement. Data was collected and analyzed 
via BMG Omega software. 
 
3. RESULTS AND DISCUSSION 
3.1. Spectral Properties 
It is well observed that fluorescein can exist in several forms: the highly 
fluorescent dianion form, the moderately fluorescent monoanion form, and three neutral 
tautomers: the quinoid, lactone, and zwitterionic. Furthermore, fluorescein is highly 
sensitive to both pH and solution, and the proportion of the forms present is consequently 
dependent upon those as well. The colorless, nonfluorescent lactone form has the greatest 
proportion (>99%) in acidic conditions (pH<4.3), while the highly fluorescent dianion 
form is found best in pH conditions greater than 6.37.22 Dissolution in acetone, however, 
achieves an equally high proportionality of the lactone form while providing a relatively 
acidic environment (pH=6.1) similar to that of urine. Therefore, addition of base raises 
the concentration of the fluorescent forms to the optimal conditions of fluorescein 
(pH=8.3). Figure 1 illustrates the difference between fluorescein fluorescence in acetone 




Figure 1. Emission spectra of 300 μmol·L−1 fluorescein in (1) acetone (pH= 6.1) and (2) in 




3.2. Linearity, detection limits, and reproducibility 
Sarcosine standard solutions were incubated with sarcosine oxidase in basic 
conditions to generate formic acid in order to produce a measureable pH change. A stable 
calibration curve (Figure 2) was obtained from a set of sarcosine standards ranging from 
23 nmol·L−1 to 1704 nmol·L−1. A fairly linear relationship was observed over this range 
with a correlation coefficient of 0.9961. The limit of detection was determined to be 20 
nmol·L−1 with a signal-to-noise (S/N) of 3. Reproducibility was measured (n=5), yielding 
a standard error of 4.2%. Based on this data, it was concluded that this technique is 






Figure 2. Calibration plot constructed from sarcosine standards ranging from 23 to 1704 




3.3. Determination of Sarcosine from Urine 
Ten urine samples were analyzed via liquid chromatography with tandem mass 
spectroscopy (with known interferences from alanine) and via the proposed fluorimetric 
determination of sarcosine. Analyte concentrations were compared for the undiluted urine 
samples with the comparisons shown below (Table 1). Three preparations of each sample 
were prepared to provide validating statistical significance. Consequently an acceptable 
degree of reproducibility was established. All samples fell within the calibrated range 
except for one which initially yielded an undetectable amount of sarcosine. Similarly this 
sample produced a significantly low value by LC-MS/MS techniques as well. This zero 
value may be credited to the relatively high limit of detection (20 nmol·L−1) of the 
fluorimetric method compared with that of LC-MS/MS (0.6 nmol·L−1). In order to supply 
a non-zero value, the urine sample was diluted less until a detectable signal was achieved, 
and the base urine concentration was subsequently calculated. Nonetheless, the data 
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suggests the fluorimetric method generally produces lower sarcosine concentrations than 
the LC-MS/MS technique. This is expected because the LC-MS/MS technique utilized 
provides only a partial, if any, separation of alanine and sarcosine whereas the fluorimetric 
method, due to its enzymatic nature, displays a much higher specificity for sarcosine.  
 
Table 1. Reported sarcosine concentrations in urine samples (n=10) by two methods: (1) 
LC-MS/MS and (2) fluorimetric method, and their corresponding percent differences. 
 
LC-MS/MS (mmol·L⁻¹) Fluorimetric (mmol·L⁻¹) Percent Difference 
342.53 320.18±10.13 -6.53 
278.50 251.22±6.54 -9.80 
695.90 545.84±22.43 -21.56 
195.92 201.15±4.33 2.67 
1061.19 572.39±32.11 -46.06 
136.68 195.45±4.99 43.00 
268.33 248.28±12.15 -7.47 
185.71 136.37±7.36 -26.57 
333.45 315.78±4.23 -5.30 
149.89 45.82±4.97 -69.43 
 
Although a general decrease in sarcosine concentrations has been observed, the 
decrease is not statistically significant (P-value = 0.23, paired t-test). This insignificance is 
actually expected; LC-MS/MS is a very precise analytical tool, much more so than 
fluorimetry. Despite its insignificance, the general decrease can reasonably be attributed to 
the utilization of the enzyme. The fluorimetric assay consisted of two general types of 
interferences: non-enzymatic oxidation of fluorescein, and inhibitors and substitutive 
substrates of sarcosine oxidase. The former, including urine acidity and oxidative 
components, was neglected due to the 750-fold dilution of the urine in 200 mmol·L⁻¹ Tris-
HCl buffer. These buffered urine solutions were observed to have an equivalent pH as the 
sarcosine standards. Furthermore, it was found that the average pH of the unbuffered urine 
samples varied only slightly to that of unbuffered sarcosine. Since the change in 
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fluorescence, not the final fluorescence, was used to determine sarcosine, the very minor 
deviations in buffered urine pH were negated. The employment of a strong buffer in very 
dilute samples also increases the application of the assay to other biological fluids, because 
the buffering capacities of said fluids can also be negated when compared with that of the 
strong buffer. Although inhibitors to sarcosine oxidase (including many inorganics) are 
likely present in urine to a small extent, sarcosine oxidase was provided in excess to the 
estimated sarcosine to counter this fact. One key substitutive substrate was present, 
however, d-Alanine. To assess the impact of its interference, d-alanine standard was 
compared with d-alanine treated with sarcosine oxidase under similar conditions using LC-
MS/MS. An insignificant percentage (0.34%) of the d-alanine was found to be degraded 
by sarcosine oxidase. This determination corroborates previously reported numbers. Thus 
by eliminating possible interferences, it can reasonably concluded that the general decrease 
observed by the fluorimetric method can be attributed to the use of sarcosine oxidase. 
 
A comparison plot of the two methods is shown below (Figure 3). It is evident that 
the rate of change reported by the fluorimetric assay is much more pronounced as sarcosine 
concentrations lower, compared with that of the LC-MS/MS method, implying increased 
relative sensitivity of the fluorimetric method to lower concentrations of sarcosine. This is 
reasonable: prior to fluorescein exposure, the pH of the sample was significantly above the 
pKa of the buffer (pKa=8.06). Thus, as the sample pH approached the pKa of the buffer by 
production of formic acid, the buffering capacity was increased, explaining why lower 
sarcosine concentrations experienced a greater respective change in fluorescence than 
higher concentrations. This certainly presents a limitation to the fluorimetric assay 
described herein, but also implies an enhanced sensitivity to sarcosine concentrations near 







Figure 3. Correlation between the fluorimetric and LC-MS/MS techniques used to analyze 




Furthermore, sarcosine levels, as well as any other metabolite, can vary greatly 
among urine samples due to a large array of factors such as fluid intake, prevalent diseases, 
diet, and more. Thus for clinical purposes, sarcosine alone cannot be used as a marker. As 
such, a ratio of sarcosine levels to creatinine, analyzed with LC-MS/MS acting as a sort of 
internal standard, was constructed. Although creatinine was not determined using the 
fluorimetric method, there are a host of quantitative methods for creatinine, and 
furthermore, creatinine may also be determined by the fluorimetric assay by converting it 
to creatine with creatinine amidohydrolase, and subsequent conversion to sarcosine by 
creatine amidinohydrolase. This ratio can be used for cancer comparisons, and although 
diagnostic comparisons between cancer positive and cancer negative samples were outside 
the scope of this current study, this data was readily available and further illustrates that 










Spiked recovery tests were conducted utilizing three different sarcosine 
concentrations. The sarcosine was added to the same urine sample prior to dilution in the 
following doses: 20 mmol·L⁻¹, 100 mmol·L⁻¹, and 500 mmol·L⁻¹. Analyte recovery in the 
low concentration was 86.45%, while recovery in the middle concentration was 106.32%, 
and recovery in the high concentration was 102.45%.  
 
4. CONCLUSION 
This study aimed to present a novel fluorimetric technique for determination of 
sarcosine in urine by enzymatic production of formic acid to produce a pH change 
subsequently measured by fluorescence change of fluorescein. The utilization of the highly 
specific sarcosine oxidase has eliminated interferences caused by the presence of alanine, 
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at least to a further extent than the LC-MS/MS technique used alongside the fluorimetric 
method. Although sarcosine has been successively separated in other LC-MS/MS 
techniques, the concept of a fluorimetric method provides a much more economical 
determination of sarcosine than these more advanced chromatographic techniques. The 
methodology presented here can further be applied to a large array of analytes which can 
act as substrates to enzymes, especially to oxidases. For example, d-amino acid oxidases 
(DAO) act on a similar mechanism as sarcosine oxidase, producing a keto acid, and 
ammonia and hydrogen peroxide as byproducts. In this case, the keto acid may be evaluated 
directly very similarly to the one described here. Even though the sensitivity of this 
technique is lower that the LC-MS/MS method, it provided a fast and low cost technique 
for sarcosine analysis.  The real novelty of the study is the coupling of the highly-specific 
enzymatic approach with the economical fluorimetric analysis to provide an alternative 
technique for sarcosine analysis in complex matrices, such as urine; thus, the basis of a 
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Since sarcosine and D,L-alanine co-elute on reversed-phase HPLC columns and the 
tandem mass spectrometer cannot differentiate them due to equivalent parent and fragment 
ions, derivatization is often required for analysis of sarcosine in LC/MS systems. This study 
offers an alternative to derivatization by employing partial elimination of sarcosine by 
enzymatic oxidation. The decrease in apparent concentration from the traditionally merged 
sarcosine-alanine peak associated with the enzymatic elimination has been shown to be 
proportional to the total sarcosine present (R2=0.9999), allowing for determinations of 
urinary sarcosine. Sarcosine oxidase was shown to eliminate only sarcosine in the presence 
of D,L-alanine, and was consequently used as the selective enzyme. This newly developed 
technique has a method detection limit (MDL) of 1 µg/L (ppb) with a linear range of 3 ppb 
- 1 mg/L (ppm) in urine matrices. The method was further validated through spiked 
recoveries of real urine samples, as well as the analysis of 35 real urine samples. The 
averages recoveries for low, middle, and high sarcosine concentration spikes were 111.7%, 
90.8%, and 90.1%, respectively. In conclusion, this simple enzymatic approach coupled 
with HPLC/MS/MS is capable of resolving sarcosine from D,L-alanine without the need 
for chemical derivatization or specialty chromatography columns. 
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Metabolic diagnostics is a developing area in disease identification, deviating from 
the traditional antigenic-based diagnostics [1]. As the intermediates, final products, and 
byproducts of cellular processes, metabolites are highly representative of biochemical 
changes within the body. Likewise, it has been shown that metabolites are highly involved 
in carcinogenic processes through a number of modes, and consequently, they may be used 
as diagnostic analytes [2]. However, a number of analytical techniques lack the specificity 
required in the complex matrices, such as serum, blood, and urine, in which these 
metabolites are naturally found, presenting significant analytical difficulties to the 
elucidation of the diagnostic roles of the metabolites [3,4]. 
 
This was recently highlighted in 2009 by the metabolomic profiling of biopsy-
positive prostate cancer patients and biopsy-negative prostate control individuals that 
suggested a correlation between urinary sarcosine levels and progression of the disease [5]. 
This claim was later refuted by two independent studies [6,7], which in the process placed 
further stress on the requirement of specificity for the analytical techniques employed. In 
particular, these sarcosine-based studies relied on a combination of liquid and gas 
chromatography with mass spectrometry. These methods, however, have inherent issues in 
the case of biological sarcosine. Gas chromatography is not well-suited for the separation 
of matrices involving non-volatiles, lending separation to liquid chromatography. In 
biological assays, L-alanine is co-present with sarcosine, and exists as an isomer of 
sarcosine. In untreated samples using reversed-phased columns, sarcosine and D,L-alanine 
co-elute, requiring further sample preparation for liquid chromatography such as chemical 
derivitazation [8]. Indeed, derivatization-based separation of sarcosine and D,L-alanine has 
been achieved by at least two independent studies [9,10], improving upon previous studies 
on sarcosine as a marker for prostate cancer [11]. The isomerism of the two compounds 
affects mass spectrometry as well, each possessing an identical precursor mass, 89.0932 
Daltons. Furthermore, fragmentation in tandem mass spectrometry fails to resolve the two 
isomers due to equivalent fragmentation. Thus, without specialized, chemical preparation 
of the samples, sarcosine and D,L-alanine cannot be accurately determined by the methods 




One preparation technique, overlooked by these traditionally chemical-based 
studies, involves the use of biological catalysts as analytical reagents. Indeed, substrate-
specific enzymes have been shown to be highly effective in analytical chemistry [13,14]. 
In the case of sarcosine, there already exists a fluorimetric assay for urinary sarcosine 
employing enzymatic oxidation of sarcosine to detectable byproducts [15]. Despite its 
success, this technique lacks the robustness of chromatographic - mass spectrometric 
techniques while maintaining a complex reaction scheme. It does, however, effectively 
demonstrate that enzymatic selection for sarcosine over D,L-alanine in urine samples can 
be used for sarcosine analysis. 
 
Since alanine and sarcosine co-elute on reversed-phase columns in high 
performance liquid chromatography with tandem mass spectrometry (HPLC/MS/MS) 
techniques, one large, merged peak that represents the total sum of urinary alanine and 
sarcosine is observed. Hence, selective enzymatic degradation of one of the species, such 
as enzymatic oxidation of sarcosine by sarcosine oxidase, will result in a marked decrease 
from the original peak. If the percent sarcosine degraded is known, then it follows that the 
resulting decrease in apparent concentration is proportional to the original amount of 
sarcosine. In this way, analysis of sarcosine involves only partial enzymatic elimination of 
the analyte, not indirect determination from byproducts and subsequent reactions. This idea 
is examined herein by the determination of sarcosine in urine as well as further comparison 
with the fluorimetric method [15] (as shown in Scheme 1). 
 
Scheme 1. Proposed reaction scheme for the determination of sarcosine. 
 
Sarcosine + Alanine  
𝑆𝑎𝑟𝑐𝑜𝑠𝑖𝑛𝑒 𝑂𝑥𝑖𝑑𝑎𝑠𝑒,   37℃
→                   Sarcosine byproducts + Alanine 
 
Thus, an alternative, enzymatic approach combined with HPLC/MS/MS, has been 




2. MATERIALS AND METHODS 
2.1. Chemicals 
Sarcosine oxidase from Corynebacterium sp. (lyophilized powder, 5-10 units/mg) 
was purchased from Sigma-Aldrich (Saint Louis, MO, USA). Glycylglycine used as an 
enzymatic buffer, sodium hydroxide as a pH modifier, as well as three standards, including 
sarcosine, D,L-alanine, and creatinine were also purchased from Sigma-Aldrich (Saint 
Louis, MO, USA). Additionally, acetonitrile (LC/MS grade) and formic acid (99.9%) used 
in the preparation of the mobile phase was purchased from Sigma-Aldrich (Saint Louis, 
MO, USA). Ultra-pure water was generated using a Milli-Q Advantage® A10 water 
purification system (Millipore, Billerica, MA, USA). Synthetic urine was purchased from 
LoSo-UriSub™, CST TECHNOLOGIES, Inc., (Great Neck, NY, USA). L-glutamine 
isotope (C5H10
15N2O3) was obtained from Cambridge Isotope Laboratories (Andover, MA, 
USA) 
 
2.2. Preparation of Glycylglycine Buffer and Sarcosine Oxidase 
A 0.2 M glycylglycine solution was prepared from ultra-pure water and 
glycylglycine, and the pH was adjusted to 7.4 with 1 mol·L⁻¹ sodium hydroxide. A buffered 
sarcosine oxidase stock solution was prepared from these reagents from which standard 
reagents of 1.77×10-7 units/mL were prepared fresh and kept at 4 oC until use. This 
concentration of sarcosine oxidase was found to have the highest specific activity with its 
sarcosine substrate in the range of 1 ppb to 1 ppm (data not shown). 
 
2.3. Preparation of Sarcosine Stock Solution 
Stock solutions of sarcosine were prepared from ultra-pure water and sarcosine 
standard. The stock solutions were prepared at 10, 100, and 1000 ppb for no more than two 
weeks at 4 oC. 
 
2.4. Analysis of Sarcosine Standards 
Sarcosine and creatinine were added in equivalent concentrations ranging from 1 
ppb to 1000 ppb as well as 50ppb D,L-alanine and 50ppb L-glutamine to a final volume to 
500μL of ultra-pure water. Upon thorough mixing, the vial contents were subjected to 
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HPLC/MS/MS analysis to determine pre-enzymatic concentrations. After pre-analysis, the 
same sample was then heated to 37 oC, and 500 µL of cold enzyme reagent was added. The 
direct addition of the enzyme resulted in a 2-fold dilution. The vial was then incubated at 
37 oC for 30 minutes. The sample was quickly cooled down to room temperature, and 
injected into HPLC/MS/MS for post-enzymatic sarcosine concentration. Samples were not 
run in parallel (pre- and post-enzymatic) because even minute differences in sample 
sarcosine concentrations significantly affected enzymatic activity toward the lower limit of 
the linear range. 
 
2.5. Analysis of Urine Samples 
Urine samples (n=35) were provided by the Central Missouri Urology Clinic. The 
samples were comprised of 15 normal samples and 20 prostate cancer positive samples. 
The urine samples were centrifuged to remove the particulates. The supernatant was diluted 
250-fold with ultra-pure water whereupon 250 µL of these diluted urine samples were 
transferred into a sample vial with 250 µL ultra-pure water. This resulted in a final 500-
fold dilution of the urine samples. Pre- and post-enzymatic analyses as well as enzymatic 
reaction followed similar protocol as that of the sarcosine standards. 
 
2.6. HPLC/MS/MS Analysis 
A Luna phenyl-hexyl column (3.0 μm, 3.0×150 mm, Phenomenex, USA) and a 
Shimadzu UFLC system (Columbia, MD) comprised of a degasser (DGU-30A3), two 
pumps (LC-20 AD XR), an autosampler (SIL-20AC XR) and a column oven (CTO-20A) 
were used for the separation of sarcosine. HPLC was performed at 25°C under a flow rate 
of 250 μL/min using a gradient system with the mobile phase consisting of A: 0.2% formic 
acid in water and B: 0.2% formic acid in acetonitrile (100%). The gradient program was: 
initial 98% A and 2% B; linear gradient to 60% A and 40% B in 5 min; return to initial 
conditions in 0.1 min at a flow rate of 250 μl/min, followed by equilibration for 10 min. 
Run-to-run time was 15 min. The sample injection volume was 10 μL. An API 4000Q trap 
MS/MS system (Applied Biosystems, Foster City, CA) was used for the quantification of 
sarcosine in urine samples. Sarcosine and alanine were detected in multiple-reaction 
monitoring (MRM) mode (m/z 89.9/44) with ESI-positive ionization along with L-
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glutamine serving as an internal standard (m/z 148/130). Creatinine was also quantified in 
MRM positive mode (m/z 114/44.1) to account for the renal dilution [16]. Creatinine has 
been used in many clinical studies as an internal standard since its concentration strictly 
corresponds to urine dilution [8,16,17]. All species were determined simultaneously. 
 
3. RESULTS AND DISCUSSION 
3.1. Interference of Alanine 
To assess the impact of its interference, an untreated D,L-alanine standard was 
compared with D,L-alanine treated with sarcosine oxidase under identical experimental 
conditions using the HPLC/MS/MS outlined above. An insignificant percentage (0.28% ± 
0.12% for n=3 trials) of the D,L-alanine was found to be degraded by sarcosine oxidase. 
Such consistently low degradation suggests that sarcosine oxidase fails to act appreciably 
on D,L-alanine. Indeed, these results corroborate that reported in the fluorescence study 
[15]. It is therefore suggested that the sarcosine oxidase acts selectively toward sarcosine 
in the presence of D,L-alanine. Since D,L-alanine is being treated quantitatively as 
sarcosine, the proportionality of the molar signals was assessed through the ion affinities 
of the two species to identify possible correction factors. It was found that alanine 
possessed an equivalent ion affinity to sarcosine (n=5 for 5 ppb, 50 ppb, and 500 ppb) 
(Figure 1). This implies that no additional proportionality calculations are necessary since 
the mass spectrometer resolved both compounds identically. 
 
3.2. Enzymatic Degradation of Sarcosine 
Sarcosine standard solutions were incubated with sarcosine oxidase in order to 
partially eliminate it from the merged sarcosine-alanine peak. In order to accurately 
quantify sarcosine, the determination of the amount of sarcosine degraded is necessary. 
This was determined by treatment of standard sarcosine samples with sarcosine oxidase 
under similar conditions. The enzymatic degradation of the sarcosine standards 






Figure 1. Extracted ion chromatogram (XIC) of the standard sarcosine and D,L-alanine 




Partial, constant degradation was observed between 50 ppb and 500 ppb Indeed, 
the curve flattens as the enzyme becomes saturated, implying degradation occurs as a 
function of available substrate. As an enzymatic assay, a time dependence exists, in 
addition to the concentration dependence; however, after the designated reaction time 
where the majority of the sarcosine has been degraded, slight variations in reaction times 
afford only negligible degradation differences. Indeed, this degradation curve, which 
showed decent reproducibility among repeated trials (N =3), was constructed with each 
data set to improve the analytical quality of the assay. Most importantly, these results reveal 
the relationship between the original amount of sarcosine and the absolute amount of 
sarcosine degraded shown as the following: 
 







Figure 2. Percent degradation of sarcosine standard solutions from 5 ppb to 500 ppb with 




3.3. Linearity, Detection limits, and Reproducibility 
Sarcosine was determined from known and unknown samples by first constructing 
an initial, pre-enzymatic calibration curve from sarcosine standards and the resultant peak 
areas. Since enzyme was added directly to the pre-enzymatic samples, all initial 
concentrations were consequently halved. Post-enzymatic peak areas were used in the pre-
enzymatic calibration curve and subsequently doubled to yield dilution-corrected post-
enzymatic concentrations. The difference between the pre-enzymatic and post-enzymatic 
concentrations, representing the absolute amount of sarcosine degraded, was then 
determined. The percent degradation corresponding to the absolute amount of sarcosine 
degraded was found from the enzymatic degradation data. Normalization of the observed 
decrease in sarcosine concentration by the percent degraded, as given by the equation 
above (Equation 1), then afforded the original sarcosine concentration. Thus, the 








A stable calibration curve was obtained from a series of sarcosine standards ranging 
from 1 ppb to 500 ppb spiked with 50ppb D,L-alanine. A highly linear relationship was 
observed over this range with a correlation coefficient of 0.9999. The method limit of 
detection was determined to be 1ppb at a signal-to-noise (S/N) ratio of 3. Reproducibility 
was measured (n=3), yielding a relative standard deviation (RSD) of 1.8% for these 
sarcosine standards. Based on this data, it is suggested that this technique is applicable over 
the given concentration range under the given chemical environment. 
 
By considering the matrix effects of real samples, synthetic urine was used to 
replace the buffer solution in the preparation of the sarcosine standards. The pH was 
adjusted to physiological conditions (pH = 7.4) with 1.0 M NaOH. The synthetic urine was 
also diluted by a factor of 500 to mimic real urine sample analysis. This high dilution factor 
served to minimize matrix effects such as pH differences among real urine samples. 15N 
isotope-labeled glutamine was added to vials at a concentration of 50 ppb as an internal 
standard. The calibration curve was reconstructed with samples ranging from 1 ppb to 1 
ppm (R2=0.9996). The limits of quantitation and detection were found to be 3 ppb and 1 
ppb, respectively, in this new matrix. These limits correspond closely with those generated 
by the fluorimetric study (compare with limit of detection of 2 ppb). Despite its comparable 
limit of detection, the fluorimetric assay is limited by its sole analysis of sarcosine; the 
HPLC/MS/MS technique presented herein may be applied to the simultaneous analysis of 
numerous chemical species, such as creatinine and glutamine. 
 
3.4. Recovery 
Real urine matrices (n=3) were spiked with known concentrations of sarcosine 
standards, all of which fell within the linear range of the technique. The spiked 
concentrations were low (5 ppb), middle (50 ppb), and high (500 ppb). The averages of the 
recoveries for each level were determined to be 111.7% ± 3.7% (RSD 3.3%), 90.8% ± 
1.1% (RSD 1.2%), and 90.1% ± 1.6% (RSD 1.8%), respectively, for the low, middle, and 
high injections. In the case of the low concentrations, a positive interference exists, which 
may be linked to marginal degradation of D,L-alanine by sarcosine oxidase and other 
chemical species or to positive modulation of sarcosine oxidase. Nevertheless, this level of 
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precision is sufficient for biological matrices like that of urine, and is primarily attributed 
to the high dilution (500 fold) of the samples. It is noted, however, that with the high 
dilution comes a loss in accuracy. Nevertheless, as shown by the recovery data, this 
uncertainty is reasonable, and the technique is considered analytically valid. 
 
3.5. Real Urine Analysis 
Real urine samples taken from healthy subjects (n=15) and prostate cancer-positive 
patients (n=20) were analyzed by the enzymatic technique. Samples were diluted 500 times 
with ultra-pure water in order to fall within the linear range as well as to minimize matrix 
effects including pH differences. These sample sets were run in triplicate to provide 
sufficient statistical validation. Standard solutions containing 50 ppb sarcosine, 50 ppb 15N 
isotope-labeled glutamine, and 50 ppb D,L-alanine standard samples were evenly dispersed 
throughout the sample as a quality control measure. The calibrated sarcosine 
concentrations were corrected for dilution to provide the final urinary sarcosine 
concentration. 
 
The experimental results suggest that the enzymatic approach (average urinary 
sarcosine concentration = 13.67 ppm) has a superior separation compared with the 
incomplete separation achieved by the optimized HPLC/MS/MS method alone (average 
urinary sarcosine concentration = 35.69 ppm). Indeed, the optimized HPLC/MS/MS 
method without enzymatic treatment failed to separate sarcosine and alanine due to their 
similar retention times in reversed-phase columns as expected. Assuming then, that the 
non-enzymatic method represented 100% of the sarcosine-alanine mixture, it can be 
deduced by the comparison of the two methods that average urinary sarcosine comprises 
approximately 40% of the sarcosine-alanine mixture. This concept may be extrapolated to 
concurrently estimate the amount of urinary D,L-alanine. This idea has not been 
extensively addressed in this study, however,  
 
With sufficient separation, then, accurate comparisons between normal and prostate 
cancer-positive urine samples can be made using liquid chromatography with tandem mass 
spectrometry for sarcosine as a potential marker using this technique. Since analyte 
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concentrations can vary greatly among samples due to number of reasons, including dietary 
intake, genetic disposition, fluid intake and retention, among other factors, sarcosine 
concentrations were normalized to creatinine concentrations analyzed by HPLC/MS/MS 
[16, 17]. Indeed, creatinine is often used as a urinary normalization factor due to its high 
concentrations in urine samples. In this way, it is representative of the overall solute 
concentration of urine. Creatinine was analyzed simultaneously with sarcosine and its 
internal standard, 15N isotope-labeled glutamine. 
 
This study reports a negligible difference (p = 0.115, two-tailed t-test) of urinary 
sarcosine concentrations between normal and prostate cancer-positive urine samples 
(Figure 3). Despite this, the validation of sarcosine as a prostate cancer biomarker was not 
the intent of this study. Indeed, a more detailed clinical study with more control over the 
cancer patients and healthy subjects would be required to afford more conclusive findings. 
Nevertheless, this method provides an accurate analytical platform for the analysis of 
sarcosine in urine and other biological samples as an alternative to HPLC/MS/MS analysis 
utilizing derivatization. Moreover, the sarcosine-alanine isomers are but one of many 
metabolic isomers that have presented difficulties to HPLC/MS/MS techniques. Others 
include amino acid isomers, such as leucine and isoleucine, as well as isomeric fatty acids 
and oligopeptides, all of which possess selective enzymes. With non-invasive diagnostic 
techniques increasingly being developed, demand for high-throughput analyses that can 
discern among interferences is critical. In this way, the study more broadly demonstrates 
the novel application of selective enzymes to isomeric interferences using high-throughput 





Figure 3. Comparison of urinary sarcosine concentrations adjusted to urinary creatinine 





As an alternative solution to derivatization for the separation of sarcosine and D,L-
alanine under HPLC/MS/MS analysis, a simple, enzymatic method has been developed 
and validated in this study. The premise of the technique rests on the fact that selective 
enzymatic elimination from an isomeric pair that traditionally generates a merged peak on 
reversed-phase HPLC/MS/MS will result in a marked decrease in apparent concentration 
proportional to the original amount of the eliminated species. Sarcosine oxidase was used 
as the selective enzyme in this study, and was shown to be selective for sarcosine in the 
presence of D,L-alanine. The difference in calibrated sarcosine concentrations, before and 
after enzymatic treatment, when normalized to the percent degraded, yielded the original 
concentration of sarcosine (R2=0.9999) within the linear range of 1 ppb – 1ppm. The 
method is simple, sensitive (MDL is 1 ppb), and shows a good reproducibility (RSD = 
1.8% for sarcosine standards in synthetic urine). It is comparable with current fluorimetric 
studies, but offers a more robust solution as a potential screening technique through the 
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simultaneous analysis of other analytes. In short, this study presents the coupling of high-
throughput HPLC/MS/MS with the selectivity of enzymes to form an analytical platform 
for the broad analysis of biological samples including metabolic isomers.  
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Recent preliminary studies have implicated urinary pteridines as candidate 
biomarkers in a growing number of malignancies including breast cancer. While the 
development of capillary electrophoresis – laser induced fluorescence (CE-LIF), high 
performance liquid chromatography (HPLC), and liquid chromatography – mass 
spectroscopy (LC-MS) pteridine urinalyses among others have helped to enable these 
findings, limitations including poor pteridine specificity, asynchronous or non-existent 
renal dilution normalization, and a lack of information regarding adduct formation in mass 
spectrometry techniques utilizing electrospray ionization (ESI) have prevented application 
of these techniques to a larger clinical setting. In this study, a simple, rapid, specific, and 
sensitive high-performance liquid chromatography – tandem mass spectrometry (HPLC-
MS/MS) method has been developed and optimized for simultaneous detection of six 
pteridines previously implicated in breast cancer and creatinine as a renal dilution factor in 
urine. In addition, this study reports cationic adduct formation of urinary pteridines under 
ESI-positive ionization for the first time. This newly developed technique separates and 
detects the following six urinary pteridines: 6-biopterin, 6-hydroxymethylpterin, d-
neopterin, pterin, isoxanthopterin, and xanthopterin, and as well as creatinine. The method 
detection limits for the pteridines are between 0.025 and 0.5 µg/L and 0.15 µg/L for 
creatinine. The method was also validated by spiked recoveries (81-105%), reproducibility 
(RSD: 1-6%), and application to 25 real urine samples from benign and malignant breast 
cancer samples through a double-blind study. The proposed technique was finally 
compared directly with a previously reported CE-LIF technique, concluding that additional 
or alternative renal dilution factors are needed for proper investigation of urinary pteridines 
as breast cancer biomarkers.  
 
KEY WORDS 





Improvements in early cancer detection techniques for breast cancer, including 
clinical breast examination (CBE), mammography, ultrasonography (US), and magnetic 
resonance imaging (MRI), have contributed to an approximately 25% increase in incidence 
detection rates in the United States since the 1970s.1 Despite the increased awareness, 
confident diagnosis is non-ideal, instead relying on a combination of the above techniques. 
For example, routine CBEs, which are considerably more cost-effective than 
mammography as preliminary assessments of malignancy, are characteristically poor 
indicators of malignancy, with positive predictive values and diagnostic sensitivities 
reported at 1-10% and 25-60%, respectively.2-6 Hence, the practical value of CBEs is often 
questioned since CBEs fail to improve mortality rates as many cases go undetected until 
later stages and high false positive rates lead to additional anxiety, cost, and the possible 
need for invasive techniques. 
 
Mammography as a preliminary assessment for malignancy offers significantly 
improved diagnostic sensitivity over CBE with reported sensitivities ranging from 63% to 
98%.7-9 Such values can be deceptive, however, since mammographic sensitivity decreases 
to 30-48% in cases of dense and heterogeneously dense breasts, which have been shown to 
have up to a fivefold increased risk of cancer compared with fatty breasts.10-12 Generally 
large interradiologist variability further obscures accurate cancer detection rates in imaging 
techniques like mammography.13 While US and MRI have been found to be more sensitive 
than mammography alone in cases of invasive cancer, only the combination of CBE, 
mammography, and confirmational MRI has been reported to have nearly 100% diagnostic 
sensitivity.12 Thus, while confident breast cancer detection can be achieved with available 
techniques, the development of a simple and rapid biomarker-based analytical technique 
with comparable diagnostic sensitivity would be vastly superior to the relatively complex 
and uneconomical combination of analyses currently used. One possible biomarker-based 




Urinary pteridines are an emerging class of metabolites that may be monitored non-
invasively and are increasingly being preliminarily implicated in a number of 
malignancies, including breast cancer.14 Pteridines as biomarkers are not without 
challenges, however. Despite the diversity of the pteridine family, with such wide 
implications, the possibility of urinary pteridines serving as ambiguous indicators of 
malignancy must be considered. Thus, adequately large panels need to be examined with 
special attention placed on ratios of the individual pteridines toward specific malignancies. 
Pteridine urinalysis in particular has overcome significant analytical challenges over the 
past decade enabling the recent flurry of studies investigating pteridines as potential and 
novel biomarkers.15-21 Examples of typical pteridine urinalysis difficulties include: 
thermally and photocatalytically labile compounds, poor solubilities in common solvents, 
the presence of three oxidation species, and relatively low urinary clearance. Nevertheless, 
capillary electrophoresis – laser induced fluorescence (CE-LIF) has emerged as a capable 
analytical platform to quantify urinary pteridines.15, 17, 19 Indeed, the minimal sample 
preparation required by CE-LIF urinalysis and its high cost-effectiveness compared with 
more advanced chromatographic techniques are certainly appealing advantages. However, 
current CE-LIF techniques are limited by two fundamental problems: (1) the inability to 
simultaneously quantify non-fluorescent creatinine as a renal dilution factor, and (2) the 
platform is inherently non-specific and consequently subject to relatively high interference 
levels from the complicated matrices in real urine samples. 
 
High-performance liquid chromatography – tandem mass spectrometry (HPLC-
MS/MS) presents an alternative to CE-LIF that can sufficiently address these two 
problems. Indeed, the high-throughput nature of HPLC-MS/MS is better suited for the 
identification and validation of urinary pteridines as indicators of malignancy while CE-
LIF may represent the most sensible and economic choice only after such potential 
confirmations. These considerations are not novel, either, as a couple of HPLC and LC-
MS/MS techniques for selected pteridines have recently been developed.18, 22 Nevertheless, 
these studies have thus far been limited in scope by either considering a narrow panel of 
urinary pteridines, failing to examine possible adduct formation in ESI-MS/MS techniques, 
or incorporating either impractical  asynchronous or no corrections for renal dilution. By 
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considering these limitations, in this study, an optimized HPLC-MS/MS has been 
developed to separate and quantify six pteridines and creatinine (Figure 1) simultaneously 
in urine samples as an alternative technique to a CE-LIF technique previously used to 
implicate urinary pteridines in breast cancer.15 Since this previous CE-LIF technique 
reported positive correlations between urinary pteridines in positive and negative breast 
cancer samples, rather than corroborate these findings, this study further examined the 






Figure 1. Chemical structures of eight urinary pteridines (fully oxidized) and creatinine: 
(a) pterin, (b) 6-hydroxymethylpterin, (c) pterin-6-carboxylic acid, (d) d-neopterin, (e) 6-




2.1. Chemicals and Materials 
Isoxanthopterin, pterin, D-neopterin, xanthopterin, 6-biopterin, pterin-6-carboxylic 
acid, ammonium oxalate, ammonium hydroxide, and sodium hydroxide were purchased 
from Sigma-Aldrich (St.Louis, USA). 6,7-Dimethylpterin and 6-hydroxymethylpterin 
were obtained from Schircks Laboratory (Jona, Switzerland). Potassium iodide and iodine 
were purchased from Fisher Scientific (New Jersey, USA). Synthetic urine was obtained 
from CST Technologies Inc. (New York, USA). Ultrapure water was generated by a Milli-
Q Advantage® A10 and Millipore Elix® water purification system. 
 
2.2. Instrumentation 
A Luna phenyl-hexyl column (3.0 μm, 3.0×150 mm, Phenomenex, USA) and a 
Shimadzu UFLC system (Columbia, MD) comprised of a degasser (DGU-30A3), two 
pumps (LC-20 AD XR), an autosampler (SIL-20AC XR) and a column oven (CTO-20A) 
were used for the separation of the urinary pteridines. HPLC was performed at 25°C under 
a flow rate of 0.3 mL/min using a gradient system with the mobile phase consisting of A: 
0.1% formic acid in water and B: 0.2% formic acid in acetonitrile. The gradient program 
was characterized by an initial 2 minute pre-equilibrium of 20% A followed by a linear 
increase to 37% A in 5.5 minutes. Run-to-run time was 7.5 minutes with a sample injection 
volume of 10 μL. 
 
An API 4000Q trap MS/MS system (Applied Biosystems, Foster City, CA) was 
used for the quantification of urinary pteridines. All ions were monitored in scheduled 
multiple-reaction monitoring (MRM) mode with ESI-positive ionization. Optimized flow 
injection parameters include: ion spray voltage: 5500V; curtain gas: 14 psi; collision gas: 
6 psi; GS1: 35 psi; GS2: 35 psi; and source temperature: 425°C. 
 
2.3. Standard Preparation 
Approximately 2 mg of each pteridine and creatinine was accurately weighed and 
dissolved in 15 mL of ultrapure water and 500 µL of 1 M ammonium hydroxide. Upon 
complete dissolution by sonication and vortexing, all components were added together with 
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enough ultrapure water and 500 µL of oxidizing solution (4:2% w/v potassium iodide to 
iodine in ultra-pure water) to generate a stock solution of 10 mg/L of each component. 
Calibration standards were prepared from the stock solution by serial dilution in ultra-pure 
water and enough synthetic urine to generate a 0.5% solution of synthetic urine to mimic a 
200-fold dilution in real sample analysis.  
 
2.4. Urine Samples and Preparation 
Real urine samples (N=25) were provided by Mercy Hospital (Springfield, MO) by 
consenting women (age range: 25-80) referred to the Mercy Hospital Breast Cancer 
Treatment Center as a double-blind study. Pathologies (benign or malignant) were 
independently determined by Mercy Hospital through a combination of CBE, 
mammography, US, MRI, and biopsy methods. 
 
Real urine samples were stored in a freezer at a temperature of -80°C. Upon fully 
thawing the samples to room temperature, a 100 µl aliquot of urine sample was placed in 
a yellow centrifuge tube containing 850 µL ultrapure water, 40 µl of oxidizing solution, 
and 10 µl of 2.0 M ammonium hydroxide. The sample was then thoroughly mixed and was 
incubated for 30 minutes at 4°C followed by centrifugation at 5000 rpm (2571 g) for 20 
min at 4°C. Upon centrifugation and filtration with a 0.22 µm membrane, a 10-fold dilution 
was made by adding 100 µL of the filtrate to 870 µL of ultra-pure water and 30 µL of 440 
mg/L ammonium oxalate, giving a final dilution factor of 100. 
 
3. RESULTS AND DISCUSSION 
3.1. Oxidation Pre-treatment 
 Most pteridine urinalyses reported thus far have incorporated an oxidation pre-
treatment step with the rationale being that the fully oxidized species are substantially more 
stable than the reduced dihydro- and tetrahydro-pterin species and that the fully oxidized 
species also affords the strongest fluorescence response in CE-LIF techniques.17, 23 While 
a variety of oxidizing agents have been investigated, including tri-iodide ions via potassium 
iodide-iodine solutions, permanganate, and manganese oxide, potassium iodide-iodine was 
chosen in order to represent an easier adaptation of the model CE-LIF technique. Since 
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previous studies had concluded that a 1:2 proportion of 4%:2% (w/v) potassium iodide-
iodine solution to urine was sufficient to fully oxidize all pteridines, this study maintained 
these oxidation conditions. To further consider adverse reactions with the tri-iodide ions, 
untreated and treated pteridine standards (which were shown to be 95-99% oxidized as 
labeled) were examined via direct infusion. The presence of tri-iodide ions did not 
significantly alter pteridine response under these oxidation conditions.  
 
3.2. MS/MS Optimization 
ESI-positive ionization with 0.1% formic acid yielded the highest ionization 
efficiencies for all oxidized pteridines and creatinine. Formic acid content above 0.2% 
suppressed pteridine ionization for xanthopterin, isoxanthopterin, 6-biopterin, and pterin-
6-carboxlyic acid. The adduct formation potentials of the oxidized pteridines and creatinine 
were then examined under various conditions via direct infusion into the MS/MS unit at a 
concentration of 100 µg/L prepared in 0.1% formic acid in ultra-pure water. Q1 ions were 
monitored under Multiple Channel Analyzer (MCA) mode with a flow rate of 0.2 mL/hour. 
The scan range was set from 5 m/z below the expected molecular ion to 200 m/z above to 
monitor singly charged ions as no doubly charged ions were preliminarily observed. 
Dissolution with sodium hydroxide afforded significant sodium, [M+Na]+, and in some 
cases disodium, [M-H+2Na]+, and tri-sodium, [M-2H+3Na]+, adducts in 6,7-
dimethylpterin, d-neopterin, 6-hydroxymethylpterin, pterin, and pterin-6-carboxylic acid. 
Sodium adducts in these standards comprised over 60% of the total signal, and in the case 
of fully unsubstituted pterin, 83% of the total signal, thereby affecting pteridine detection 
sensitivities by splitting the signal among various adducts. In contrast, dissolution with 
ammonium hydroxide favored the protonated adduct, [M-H]+, in all pteridines but 
xanthopterin and pterin-6-carboxylic acid with resulting ammonium adducts, [M+NH3]
+ 
and [M-H+2NH4]
+, representing only 32% of total xanthopterin signal and 31% of the total 
pterin-6-carboxylic acid signal, respectively. The Q1 scans for pterin dissolved in sodium 
hydroxide and ammonium hydroxide were shown in Figure 2 to demonstrate the formation 
of sodium adduct ions of pteridines. In addition, a significant creatinine dimer (48% of 
total signal) was found at 227 m/z. Because real urine has significant sodium and 
ammonium cation populations, all adducts with relative abundances of over 30% for each 
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respective compound were considered as quantitative precursor ions. MS/MS ions pairs 
were then systematically optimized with direct infusion and flow injection analysis for all 
quantification and confirmation pairs including all major adducts (sodium and ammonia) 
for the eight fully oxidized pteridines and creatinine. The optimized MS/MS parameters 





Figure 2. Q1 scans of 100 µg/L pterin in 0.1% formic acid in ultra-pure water dissolved 




Table 1. Optimized MS/MS conditions of 8 urinary pteridines, creatinine, and their 
common adducts. 










Creatinine 114.034/44.000 56 33 6 
 
114.034/86.000 56 19 14 
Creatinine Dimer 227.503/113.900 1 21 4 
6,7-Dimethylpterin 192.534/165.300 96 31 10 
 
192.534/147.000 96 31 12 
6,7-Dimethylpterin+Na 213.999/196.200 101 19 12 
 
213.999/86.300 101 27 14 
6-Biopterin 238.423/220.300 31 21 14 
 
238.423/178.200 31 29 10 
D-Neopterin 254.156/206.200 51 27 12 
 
254.156/190.200 51 31 12 
D-Neopterin-Na 276.088/216.200 81 27 14 
 
276.088/234.100 81 27 24 
6-Hydroxymethylpterin 194.293/176.300 31 23 14 
 
194.293/106.100 31 39 10 
6-Hydroxymethylpterin+Na 216.210/204.000 86 25 12 
 
216.210/199.100 86 15 26 
Pterin 164.431/119.000 76 31 8 
 
164.431/91.900 76 41 4 
Pterin-Na 185.891/114.100 71 35 8 
 
185.891/86.200 71 45 16 
Isoxanthopterin 180.113/135.400 76 33 10 
 
180.113/163.100 76 27 10 
Xanthopterin 180.113/135.400 76 33 10 
 
180.113/163.100 76 27 10 
Xanthopterin+NH3 196.115/168.500 91 23 10 
 
196.115/112.200 91 35 6 
Xanthopterin—H+2NH4 213.754/141.200 66 21 8 
 
213.754/141.200 66 31 6 
Pterin-6-carboxylic acid 208.110/190.100 66 19 12 
 
208.110/180.300 66 23 10 
Pterin-6-carboxylic acid+Na 229.787/186.300 61 25 18 
 
229.787/212.200 61 17 14 
Pterin-6-carboxylic acid+NH3 225.084/208.100 36 17 14 
 




3.3. Adduct Reduction 
Although adduct speciation was analytically considered by ultimately summing the 
calibrated concentrations, sodium scavenging additives were considered as an additional 
safe-measure in real urine samples where high sodium and relatively low pteridine levels 
may obfuscate pteridine detection through adduct formation. Indeed, this concern was 
substantiated by monitoring adduct formation in 100 µg/L fully oxidized pteridine 
standards dissolved with ammonium hydroxide and prepared in 0.5% synthetic urine 
(representing a 200-fold dilution of real urine), which afforded sodium adduct formation 
comparable to pteridine dissolution with sodium hydroxide. Thus, in real urine samples, 
active measures to minimize sodium adduct formation must be taken for ideal pteridine 
detection. 
 
While desalting and trap columns may be used to remove free sodium cations, these 
techniques are indiscriminate and alter the oxidative environment by also removing the tri-
iodide ions, thereby possibly and more detrimentally affecting pteridine detection. 
Therefore, in this study, in situ sodium scavenging additives including ascorbic acid, oxalic 
acid, and ammonium oxalate were examined based on their previously reported cationic 
adduct reduction in MALDI techniques.24 The sodium adduct reduction capabilities of the 
three compounds were evaluated by direct infusion of 100 µg/L fully oxidized pteridine 
standards prepared in 0.5% synthetic urine and spiked with 10 mg/L additive under MCA 
scan mode and a 200 m/z scanning window. In comparison to the control that contained no 
additives, combined sodium and ammonia adducts for all eight pteridines were decreased 
53% by ammonium oxalate, 37% by ascorbic acid, and oxalic acid instead promoted 
ammonia adduct formation without significantly affecting sodium adduct formation to 
yield an overall 10% increase in total adduct formation. In addition to cationic adduct 
reduction, the mild reducing agents, ascorbic acid and oxalic acid, also afforded minor 
reduction (3-12%) of the quantitation ions for xanthopterin, isoxanthopterin, and 6-
biopterin. More importantly, the sodium scavenging capabilities of ammonium oxalate 
seem to be accentuated in real urine samples, up to 99.4% in some samples. Indeed, the 
MRM transitions for sodium and ammonia adducts in some real samples were entirely 
undetected. While this phenomenon was not thoroughly investigated, the authors presume 
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this is caused by the association of free sodium and ammonia with excess organic matter 
and the highly charged, filtered and precipitated proteins. Excess ammonium oxalate was 
therefore added during the final dilution of real urine samples to counteract adverse cationic 
adduct formation. The final concentration of ammonium oxalate used (13 mg/L ≈ 0.1 mM) 
was found to afford the maximum adduct reduction with minimal pteridine ion suppression 
in 0.5% synthetic urine. 
 
3.4. UFLC Optimization 
 The structural isomers, xanthopterin and isoxanthopterin, must be 
chromatographically resolved for quantitation with MS/MS. A Phenomenex Luna phenyl-
hexyl column was found to sufficiently separate the two isomers under a wide range of 
liquid chromatographic conditions including flow rate (0.15-0.40 mL/min) and mobile 
phase constitution. (0.0-0.2% formic acid in water, acetonitrile, and methanol). In 
comparison, the previously utilized LUNA amine column provided inferior resolution 
under the conditions described above.22 Upon column selection, chromatographic 
conditions were systematically optimized for all eight pteridines and creatinine (see 
Experimental for optimized conditions). The resulting chromatogram, including separation 





Figure 3. Overlaid extracted ion chromatograms (XIC) of eight urinary pteridines, 
creatinine, primary adducts, and confirmation pairs with nominal concentrations of 100 
µg/L under the optimized UFLC-MS/MS conditions. 
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3.5. Method Performance 
Under the optimized HPLC-MS/MS conditions, calibration curves for all pteridines 
and creatinine were constructed to demonstrate linearity under an appropriate analytical 
range. Because some pteridines exhibit significant adduct formation in 0.5% synthetic 
urine, even after treatment with ammonium oxalate, and fragmentation efficiencies were 
furthermore widely distributed among the various adducts, calibration curves were 
produced from standards by monitoring MRM transitions alongside an accompanying Q1 
scan. The Q1 scan allowed for absolute concentration determination by considering the 
signal proportionality among the various adducts for each respective pteridine. For 
example, a nominal 100 µg/L pteridine standard with a 20% monosodium adduct formation 
potential represented 80 µg/L [M+H]+ and 20 µg/L [M+Na]+, from which appropriate 
calibration curves may be produced. The desired calibration range was set to 1-1000 µg/L 
based on previous studies indicating that the monitored pteridines should fall within this 
range after a 200-fold dilution.15, 17 As shown in Table 2, all compounds were highly linear 
with linear regression coefficients above 0.9998 under the selected analytical range. 
Moreover, the method was found to be highly sensitive with detection limits ranging from 
0.025 to 0.5 µg/L. These sensitivities are comparable to the model CE-LIF technique and 
marginally better than previously reported HPLC and LC-MS/MS techniques. Because 
urinary creatinine concentrations are on average 1000-fold higher than that of pteridines, 
creatinine analysis varied from that of pteridines. Creatinine levels in 200-fold diluted urine 
range from 500 to 5000 µg/L. At these levels, creatinine ionization saturation produced a 
sigmoid calibration curve, requiring the construction of a non-traditional calibration curve 
in order to simultaneously quantify it with pteridines. Linearization was achieved by 
doubly inverting creatinine concentrations and detector response (cps), providing a new 
linear regression coefficient of 0.9972 for this elevated range. This approach, in addition 
to pteridine analysis, was validated through spiked recoveries in real urine samples (Table 
3). The data in Tables 2 and 3 clearly demonstrate that the method is highly sensitive and 
reproducible for all eight pteridines and creatinine in real urine samples. Finally, this 


































































































































































































































































































































































































































































































































































































































































































































Table 3. Summarized results of triplicate recoveries (%) of three varying concentrations of 
eight urinary pteridines and creatinine in a spiked real urine sample. 
 
 
Low (1 µg/L) Medium (10 µg/L) High (100 µg/L) 
Compound Recovery  RSD  Recovery  RSD  Recovery  RSD  
†Creatinine 95.4 2.4 97.1 3.0 101.1 1.8 
D-Neopterin 102.4 4.2 97.4 2.3 96.4 2.1 
6-Biopterin 97.6 3.0 104.7 3.2 102.3 2.7 
Xanthopterin 81.3 4.2 91.4 2.7 93.4 2.5 
6-Hydroxymethylpterin 103.0 2.1 99.2 2.3 98.6 1.6 
Pterin 97.8 2.7 96.5 2.4 93.1 2.2 
Isoxanthopterin 104.5 4.5 100.3 3.8 102.8 4.0 
6,7-Dimethylpterin 89.4 3.6 89.7 2.4 93.7 1.8 
Pterin-6-carboxylic acid 84.1 5.7 91.3 5.5 93.4 5.3 
 
†Creatinine spiked recoveries were made at 500, 1000, and 3000 µg/L in to better 































































































































































































































































































































































































































































































































































































































































































3.6. Real Urine Analysis 
The newly developed HPLC-MS/MS method was ultimately validated in 25 real 
urine samples provided by Mercy Hospital (Springfield, MO) through a double-blind 
study. The sample set consisted of 13 benign breast cancer samples and 12 malignant breast 
cancer samples, with pathologies determined independently by Mercy Hospital. At 200-
fold dilution, six of the eight pteridines were detected with 6,7-dimethylpterin and pterin-
6-carboxylic acid remaining undetected except for in concentrated specimens (N=6). At 
100-fold dilution, the compounds were detected in 16 of the samples. Lower dilution folds 
resulted in significant ion suppression caused from ion saturation. This phenomenon is 
especially evident for creatinine which experienced complete saturation near 10 µg/L. 
Therefore, 100-fold dilutions were considered as the absolute lowest dilution factor in order 
to simultaneously quantify the pteridines and creatinine. Moreover, without further sample 
preparation or the addition of a desalting or trap column, lower dilution factors risked the 
longevity of the column and the mass spectrometer. Other studies have also reported low 
urinary concentrations for these two pteridines, although the authors expected to detect 
these two compounds at a 200-fold dilution based on previously reported ranges and the 
supporting spiked recovery data.15 The apparent inability to monitor these two pteridines 
in urine is currently pending further investigation. Hence, the proposed technique may not 
be valid for 6,7-dimethylpterin and pterin-6-carboxylic under the conditions described 
herein. Nevertheless, the remaining six pteridine and creatinine concentrations were found 
in similar ranges to those previously reported. These encountered pteridine ranges have 
been summarized in Table 3. 
 
Despite being a method development study, we further examined the potential 
ability of urinary pteridines to discern benign from malignant breast cancer samples. This 
limited real sample study, designed solely to validate the presented method, should not be 
considered conclusive; rather, more detailed clinical trials are needed to confirm urinary 
pteridines as useful breast cancer biomarkers. Pathological correlations were calculated 
with Minitab Statistical Software by rejecting or accepting the null hypothesis that mean 
pteridine levels in malignant breast cancer samples are lower than or equal to those from 
benign specimens. Interestingly, the HPLC-MS/MS technique failed to show any 
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pathological correlations with any of the creatinine-normalized pteridines. These findings 
were validated by analyzing the same 25 samples with the model CE-LIF technique. As 
shown in Table 5, neither technique afforded positive pathological correlations with any 
of the eight pteridines. Thus, urinary pteridines may not be able to differentiate benign and 
malignant breast cancers. Since only an age range for the samples analyzed herein were 
provided through the double blind study, it possible that the control (benign) population 
differed significantly from the positive (malignant) population. While baseline urinary 
pteridine levels are currently unknown in large populations, urinary creatinine levels are 
known to be age- and gender-dependent where levels are substantially elevated in younger 
individuals.25, 26 Moreover, urinary creatinine by itself may not be an appropriate 
normalization factor for breast cancer since breast cancer has been reported to adversely 
affect both creatinine production and clearance.27, 28 To at least preliminarily address this 
issue, pathological correlations for unnormalized urinary pteridine levels were determined 
(Table 5). Although neglecting creatinine afforded no statistically significant correlations, 
nearly all correlations improved with the HPLC-MS/MS technique, while sparse 
improvements were seen with the CE-LIF technique, supporting this conjecture to some 
extent. 
 
Table 5. Pathological correlations (P-values) of eight creatinine-normalized and 




Pteridine Normalized Unnormalized Normalized Unnormalized 
6-Biopterin 0.604 0.608 0.732 0.728 
Pterin 0.638 0.275 0.546 0.549 
Neopterin 0.529 0.413 0.47 0.845 
Xanthopterin 0.274 0.149 0.759 0.931 
Pterin-6-carboxylic Acid N/A N/A 0.995 0.73 
6,7-Dimethylpterin N/A N/A 0.725 0.474 
6-Hydroxymethylpterin 0.837 0.11 0.636 0.755 





Moreover, direct comparison of the two techniques revealed that xanthopterin and 
isoxanthopterin concentrations determined by the CE-LIF technique were on average 5- 
and 30-fold higher, respectively, than those reported by the proposed HPLC-MS/MS 
technique. Based on the high quality method validation data for the proposed HPLC-
MS/MS technique and the inherently non-specific nature of CE-LIF, it is possible that these 
concentration discrepancies arise from co-eluting interferences or different oxidation states 
of pteridines in the CE-LIF approach. This phenomenon is under further investigation. 
Nevertheless, the new method may be used to determine urinary pteridines and creatinine 
simultaneously for biomedical studies, in which the pteridines need to be quantified. 
 
4. CONCLUSION 
A simple, rapid, specific, and sensitive HPLC-MS/MS method was developed for 
simultaneous analysis of six urinary pteridines and creatinine, which has not been 
previously reported to the best of our knowledge, especially toward application of breast 
cancer detection. Additionally, cationic adduct formation for urinary pteridines analyzed 
with ESI-positive ionization have been reported for the first time. The HPLC-MS/MS 
platform allows for greatly enhanced run times and increased specificity over previously 
reported CE-LIF approaches. The method was validated through evaluation of spiked 
recoveries, reproducibility (represented by RSD), MDLs, and application in 25 real urine 
samples from breast cancer positive and negative samples. Results from the real samples 
have finally led to the conclusion that improved validation studies with sufficient statistical 
power and the utilization of an alternative renal dilution factor to creatinine are needed for 
clinical confirmation of urinary pteridines as breast cancer biomarkers. Finally, the 
disclosed technique may be applied to other diagnostic studies in addition to breast cancer. 
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Background: Urinary biomarkers, such as pteridines, require normalization with 
respect to an individual’s hydration status and time since last urination. Conventional 
creatinine-based corrections are affected by a multitude of patient factors whereas urine 
specific gravity (USG) is a bulk specimen property that better resists those same factors. 
In this study, we examined the performance of traditional creatinine adjustments relative 
to USG to six urinary pteridines in aggressive and benign breast cancers in addition to high 
grade bladder cancers. 
Methods: 6-Biopterin, neopterin, pterin, 6-hydroxymethylpterin, isoxanthopterin, 
xanthopterin, and creatinine were analyzed in 66 urine specimens with a previously 
developed liquid chromatography – tandem mass spectrometry technique. Creatinine and 
USG performance was evaluated with non-parametric Mann-Whitney hypothesis testing. 
Results: USG and creatinine were moderately correlated (r = 0.857) with deviations 
occurring in dilute and concentrated specimens. In 48 aggressive and benign breast cancers 
and 16 bladder cancer and healthy specimens, normalization by USG significantly 
outperformed creatinine adjustments which marginally outperformed uncorrected 
pteridines in predicting pathological status. In addition, isoxanthopterin and xanthopterin 
were significantly higher in pathological specimens when normalized by USG. 
Conclusion: USG, as a bulk property, can provide better performance over creatinine-
based normalizations for urinary pteridines in cancer detection applications. 
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The past five years have witnessed a renewed interest in urinary pteridines as 
noninvasive, metabolic biomarkers for early cancer detection [1]. Recent advances aimed 
at improving pteridine urinalysis have overcome many of the early challenges facing 
pteridine research including molecular speciation and physiologically low urinary 
concentrations [2-6]. Equipped with powerful, new analytical techniques, exploratory 
studies continue to associate elevated pteridine levels with cancer, although a biological 
premise for these associations remains unclear [7-9]. Despite these encouraging 
preliminary findings, pteridine urinalyses have not yet matured to a level acceptable for 
comprehensive clinical assessment. Particularly, urinary biomarkers like pteridines must 
be adjusted to reflect an individual’s hydration level and time since last urination [10]. 
While many pteridine studies employ creatinine-based adjustments, one study recently 
questioned the validity of normalizing urinary pteridines to creatinine after reporting that 
pteridines could not distinguish benign and aggressive breast cancers [2]. 
 
Creatinine is an endogenous byproduct of muscle activity produced with 
supposedly little day-to-day variation in a given individual [11]. In addition, serum 
creatinine is constantly cleared from the bloodstream by the kidneys, leading many to 
consider creatinine as an acceptable measure of renal dilution [12]. This has resulted in the 
common practice of reporting urinary analytes as a ratio of the analyte to creatinine (mol 
analyte / mol creatinine). There is growing evidence, however, that creatinine excretion is 
not consistent, following repeated challenges to creatinine’s usefulness as a normalization 
factor [13-15]. In particular, creatinine has been linked to: age, race, sex, and gender [16-
18]; physical activity and muscle mass [19]; diet [20-22]; normal physiological functions 
including menstrual cycles [23]; and an increasing number of pathological conditions 
including diabetes and breast cancer [24, 25]. Hence, creatinine may not be an appropriate 
renal dilution factor for certain sample populations. 
 
Urine specific gravity (USG) is the dimensionless ratio between the density of a 
urine specimen and that of pure water under given conditions. As a bulk property that is 
representative of the entire urine specimen, USG is presumably less affected by the same 
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individual factors that influence creatinine [26]. Importantly, the urine density which 
provides a useful measure of total urine concentration (g/L), is based not only on the 
number of solute particles, but also on their molecular mass. Thus, abnormal urinary 
constituents such as protein and glucose, in addition to physiological albumin, sulfates, 
phosphates, and other heavy species can erroneously inflate USG [27, 28]. Conversely, low 
density ketones, which are excreted under states of dehydration, starvation, or high fat 
metabolism common to diabetic patients suffering from ketoacidosis, can deflate USG 
values [29, 30]. Unlike creatinine, however, USG may be easily corrected with routine 
clinical urinalyses for many of these factors [31].Moreover, USG can withstand multiple 
freeze/thaw cycles and long-term storage at -20°C or colder [32, 33]. Consequently, USG 
has been extensively used as an alternative renal dilution factor to creatinine in primarily 
toxicological applications [34-36]. In contrast USG corrections have currently found 
limited utility in clinical settings, presumably from a lack of relevant performance 
evaluations [10, 37]. 
 
Methods employing USG normalizations have generally adopted the correction 
protocol proposed by Levine and Fahy [38]: 




where Ccorrected is the adjusted analyte concentration, Craw is the uncorrected analyte 
concentration, USGreference is a reference USG for a given population, and USGexperimental is 
the experimentally determined USG. A USGreference value of 1.020 is typically applied to 
U.S. populations, although minor variations can be made to account for differing salts and 
ingested fluids [35, 38]. 
 
To the best of our knowledge, the performance of USG corrections relative to 
creatinine has not been thoroughly studied in candidate biomarkers for cancer, and 
specifically, urinary pteridines. In this study, breast cancer was identified as a useful 
paradigm for performance evaluations based on the recent conflicting reports concerning 
the ability of urinary pteridines to distinguish benign and aggressive breast cancers in 
sample populations possibly inappropriate for creatinine normalization [2, 7]. Creatinine 
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and USG adjustments of urinary pteridines in benign and aggressive breast cancers were 
therefore compared to evaluate their performance in this double-blind study. We further 
applied the study to a small scale specificity study involving bladder cancers to demonstrate 
the utility of USG normalized pteridines beyond breast cancer. 
 
2. MATERIALS AND METHODS 
2.1. Samples and specimens 
Fifty women 35-85 years of age (mean age: 61 years; standard deviation: 13 years) 
were recruited by the Mercy Hospital Breast Cancer Treatment Center in Springfield, 
Missouri [2]. All participants provided written consent, and the collection was approved 
by the Institutional Review Board at Mercy Hospital in Springfield, Missouri. No monetary 
compensation was provided. All participants had been recently referred to the Breast 
Cancer Treatment Center following positive indications by routine clinical breast 
examinations. Urine specimens were collected early, before 10:00 a.m., but did not 
necessarily constitute first morning voids. New specimens were stored up to two weeks in 
a freezer at -20°C at Mercy Hospital. Urine specimens were shipped weekly by frozen 
ground freight whereby they were transferred to a -80°C freezer until thawing, aliquoting, 
centrifugation, and assaying one to three months later. Between sample collection and final 
pteridine assays, samples underwent 2-3 freeze-thaw cycles. No dietary restrictions were 
placed on the participants prior to sample collection. Pathologies were independently 
determined by Mercy Hospital pathologists using a combination of clinical breast 
examinations, mammography, ultrasound and MRI imaging, and biopsy methods [2]. 
Anonymous pathological reports including diagnoses were disclosed in a double-blind 
manner at the end of the study. 
 
Sixteen additional specimens from men and women 26-70 years of age (mean age: 
52 years; standard deviation: 14 years) were collected in spring 2010 by the Rolla Urology 
Clinic for the bladder cancer component of the study [7]. All participants provided written 
consent, and the collection was approved by the Institutional Review Board at Missouri 
University of Science and Technology. No monetary compensation was provided. Four 
men and women had untreated, high grade bladder cancers that were diagnosed within the 
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past five years. Twelve more specimens were collected from healthy, age-matched men 
and women. Urine specimens were thawed immediately, aliquoted, and centrifuged at 5000 
rpm (2571 g) at 4°C for 20 minutes. Centrifuged aliquots were immediately stored at -80°C 
for three years. Between sample collection and final pteridine assays, samples underwent 
2-3 freeze-thaw cycles. 
 
2.2. Chemicals and materials 
Isoxanthopterin, pterin, D-neopterin, xanthopterin, 6-biopterin, ammonium 
oxalate, and ammonium hydroxide were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). 6-Hydroxymethylpterin was obtained from Schircks Laboratories (Jona, 
Switzerland). Potassium iodide and iodine were purchased from Fisher Scientific (New 
Jersey, USA). Synthetic urine was obtained from CST Technologies Incorporated (New 
York, USA). Ultrapure water was generated by a Milli-Q Advantage® A10 and Millipore 
Elix® water purification system. 
 
2.3. Assays 
The pteridine assay that was used has been described elsewhere [2]. Briefly, a liquid 
chromatography – tandem mass spectrometry (LC-MS/MS) technique was used to separate 
and quantify urinary pteridines. Separation was achieved with a Phenomenex Luna phenyl-
hexyl column (3.0µm, 3.0 x 150 mm) and a Shimadzu UFLC system (Columbia, MD, 
USA) comprised of a degasser (DGU-30A3), two pumps (LC-20 AD XR), an autosampler 
(SIL-20AC XR), and a column oven (CTO-20A) operating under HPLC conditions. An 
API 4000Q trap MS/MS system from Applied Biosystems (Foster City, CA, USA) 
quantified urinary pteridines under scheduled multiple-reaction monitoring (MRM) mode 
with ESI-positive ionization. Pteridines were quantified over a linear range of 
approximately 0.25 µg/L to 1000 µg/L. Spiked recoveries in real urine samples ranged 
from 81% to 105% with relative standard deviations (RSDs) between 1% and 6% [2]. Urine 
specimens were centrifuged at 5000 rpm (2571 g) at 4°C for 20 minutes and pre-treated 
with 2M ammonium hydroxide and a 4:2% w/v potassium iodide to iodine solution in order 
to promote fully oxidized pteridines. Ammonium oxalate was used as a sodium adduct 
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suppressor at a final concentration of 10 µg/L. Urine specimens were diluted a total of 200-
fold prior to analysis. All samples were run as true triplicates. 
 
Creatinine was quantified simultaneously with pteridines by the same LC-MS/MS 
technique using a non-linear calibration curve [2]. The non-linear calibration curve 
produced spiked recoveries ranging from 95.4% to 101.1% and RSDs between 1.8% and 
3.0% for creatinine concentrations between 500 µg/L and 5,000 µg/L. Overly concentrated 
specimens in which creatinine was unquantifiable by the non-linear calibration curve were 
diluted 2000-fold and reanalyzed. 
 
Because USG is most accurately determined refractometrically [31], a Carl Zeiss 
Abbe refractometer. (No. 51865) was used for USG quantification. Prior to analysis, 
thawed, centrifuged urine specimens were equilibrated at 25°C for 20 minutes. Refractive 
indices were converted to USG values via a Reichert total solids refractometer conversion 
table. Ultra-pure water and synthetic urine of known specific gravity were additionally 
used as quality control standards. The USG assay had inter- and intra-assay CVs of 0.18% 
and 0.07%, respectively. USG normalizations followed Levine-Fahy protocol using a 
reference value of 1.020. 
 
2.4. Statistical analysis 
Final pteridine concentrations were reported in molar units. Creatinine-corrected 
pteridines were expressed as mol pteridine/mol creatinine while USG-corrected pteridines 
remained in molar units. Minitab 16 Statistical Software was used to perform all statistical 
analyses. Pearson correlations were used to describe the relationship between USG and 
creatinine. Regular outliers found in aggressive cancers in this study (normality P-value = 
0.001) and previous findings suggested a Student’s t-Test, which assumes a normal 
distribution, would erroneously inflate statistical significance [2, 7]. Therefore, non-
parametric, one-tailed Mann-Whitney hypothesis testing that offers improved efficiency 
for non-normal distributions was used to evaluate mean differences among normalized 
pteridines and pathologies at a 5% significance level (P-value < 0.05). Finally, two overly 
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dilute specimens in which pteridines were unquantifiable were excluded from statistical 
analysis. 
 
3. RESULTS AND DISCUSSION 
 Spot urine samples, like those taken during clinical tests, come from a patient of 
unknown hydration status and void time. Analytes of interest must therefore be adjusted to 
consider the dilution-concentration of the urine specimen. In this study, we examined the 
performance of traditional creatinine adjustments relative to USG. A direct comparison 
between urinary creatinine and USG from 48 urine specimens in the breast cancer study 
was made in Figure 1. The Pearson correlation (r = 0.857, P-value = 0.0000, SE = 0.0058 
USG) indicated a moderately strong relationship between urinary creatinine and USG, in 
agreement with previous findings [34]. Moreover, as a primary component of urine that is 
presumably constantly excreted, creatinine was expected to model USG in a linear fashion. 
Significant deviations were nevertheless observed in overly concentrated (creatinine > 250 
mg/dL) and overly dilute (creatinine < 50 mg/dL) specimens. Similarly, it has become 
common practice, particularly in toxicological applications, to reject overly dilute 
(creatinine < 50 mg/dL, USG < 1.010) and overly concentrated (creatinine > 300 mg/dL, 
USG > 1.030) urine specimens [10, 13, 35]. However, these conventional creatinine and 
USG requirements may be too restrictive for clinical practice; as shown in Figure 1, 26% 
of our specimens had unacceptable creatinine levels and 42% failed to meet these USG 
requirements. Such a considerable number of low urinary creatinine and USG specimens 
in this study may be explained by a recent finding that women 50 years or older have 
unusually low urinary creatinine and USG [35]. In addition, such sample discarding is 
impractical in a clinical setting and creates additional economic and emotional burden on 
the patient by requiring another specimen provided at a later date. For these reasons, some 
studies have proposed relaxed concentration-dilution requirements down to 10 mg/dL and 
1.002 for the minimum acceptable creatinine and USG levels, respectively [34]. In contrast 
this study excluded samples with unquantifiable pteridines rather than based on creatinine 
and USG values resulting in the exclusion of only two urine specimens. Finally, it is 
important to note that we did not correct USG to conditions including glucosuria, 
proteinuria, and ketonuria. In addition, study participants were not screened for diabetes. 
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Thus, these USG-based results may be further optimized in future studies by considering 





Figure 1. Relationship between USG and creatinine in benign (n = 27) and aggressive 




USG and creatinine normalization performance were evaluated by statistical 
hypothesis testing that assumed mean pteridine levels were higher in aggressive cancers 
based on earlier clinical studies [7]. P-values from non-parametric Mann-Whitney mean 
difference tests for each pteridine in aggressive and benign breast cancers were 
summarized in Table 1. Summed P-values for all six pteridines were provided for simple 
comparisons among normalization methods, although each pteridine must be considered 






























Table 1. P-values from non-parametric Mann-Whitney one-tailed mean difference tests 
between aggressive breast cancer (n = 21) and benign breast cancer (n = 27) urine 
specimens.  
Normalization Method Uncorrected Creatinine USG 
6-Biopterin 0.4787 0.4111 0.3776 
Pterin 0.2094 0.1277 0.1968 
Neopterin 0.5000† 0.5000† 0.3935 
Xanthopterin 0.4736 0.3956 0.0090 
6-Hydroxymethylpterin 0.1799 0.1586 0.0767 
Isoxanthopterin 0.1651 0.1417 0.0011 
Summed P-values 2.0067 1.7347 1.0547 
 
 
† Uncorrected and creatinine adjusted mean neopterin values in aggressive cancers 
were less than those in benign samples. 
 
Interestingly, creatinine normalization (summed P-value = 1.7347) provided only 
a marginal 13.6% improvement over uncorrected pteridines (summed P-value = 2.0067). 
In addition, no pteridines adjusted by creatinine were found to have significantly different 
(P-value < 0.05) mean levels between benign and aggressive breast cancers, rendering any 
clinical utility useless. These results corroborated similar findings published in a recent 
study evaluating pteridines adjusted to creatinine in benign and aggressive breast cancers 
[2]. In comparison USG normalization (summed P-value = 1.0547) yielded an overall 
47.4% improvement in pathologically correlating pteridines over uncorrected pteridines 
and outperformed creatinine by a factor of 3.5. Statistical mean differences for all six 
pteridines except pterin increased with USG normalization, which is reflected by its 
significantly lowered summed P-value. Isoxanthopterin (P-value = 0.0011) and 
xanthopterin (P-value = 0.0090) had significantly elevated levels in aggressive breast 
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cancers compared with benign breast cancers. In addition, 6-hydroxymethylpterin, which 
was unquantifiable in 22% of samples, also demonstrated some ability to differentiate 
benign and aggressive breast cancers, although the difference in 6-hydroxymethylpterin 
values was not statistically significant (P-value = 0.0767). Neopterin, which had lower 
uncorrected mean values in aggressive breast cancers than in benign, highlights the need 
for urine concentration-dilution normalization. Mean neopterin levels became marginally 
biased toward aggressive cancers when normalized with USG. Basic statistical information 
for USG normalized pteridines from the breast cancer study was summarized in Table 2. 
 
Table 2. Basic statistical summaries for six urinary pteridines normalized to USG as well 




(n = 21) 
Mean Benign 





6-Biopterin (M) 1.55E-05 1.00E-05 5.62E-10 1.17E-10 
Pterin (M) 2.89E-06 1.99E-06 1.64E-11 6.86E-12 
Neopterin (M) 1.42E-05 9.65E-06 4.28E-10 8.70E-11 
Xanthopterin (M) 9.05E-06 5.62E-06 7.40E-11 1.31E-11 
6-Hydroxymethylpterin 
(M) 
4.73E-06 3.37E-06 6.16E-11 4.07E-11 
Isoxanthopterin (M) 3.55E-06 1.03E-06 3.25E-11 8.43E-13 
Creatinine (mg/dL) 99.3 122.2 52.4 94.0 
USG 1.012 1.017 0.009 0.013 
 
The implications of xanthopterin and isoxanthopterin in aggressive breast cancers 
in this study prompted further investigation of their potential clinical utility. Boxplots 
detailing the pathological differences observed in this study for xanthopterin and 
isoxanthopterin were shown in Figures 2 and 3, respectively. As seen in Figure 2, 
xanthopterin values associated with aggressive breast cancers were defined as several 
significantly elevated outliers with a majority of values similar to benign breast cancers. 
Hence, xanthopterin may not serve as a particularly reliable standalone biomarker for 
discerning aggressive and benign breast cancers. In contrast isoxanthopterin values from 
aggressive breast cancers were visibly elevated indicating isoxanthopterin may have 
superior predictive power which is reflected by its lower P-value. Where previous pteridine 
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studies have focused on individual pteridine diagnostic utilities, we additionally coupled 
xanthopterin and isoxanthopterin to produce a bivariate indicator of aggressive breast 
cancers with enhanced diagnostic utility. A corresponding scatterplot of this approach has 
been provided in Figure 4. A remarkably clear distinction between benign and aggressive 
breast cancers was observed with the bivariate approach in comparison with those 





Figure 2. Boxplot of USG normalized xanthopterin levels in aggressive (n = 21) and benign 

































Figure 3. Boxplot of USG normalized isoxanthopterin levels in aggressive (n = 21) and 




Applying arbitrary thresholds at 5 µM xanthopterin and 1.5 µM isoxanthopterin, 
this bivariate approach afforded 87.5% diagnostic sensitivity, 70% specificity, 70% 
positive predictive value, and 87.5% negative predictive value in discerning aggressive 
from benign breast cancers. While the individual implications of xanthopterin and 
isoxanthopterin were supported by numerous other implications of xanthopterin and 
isoxanthopterin in a variety of pathological conditions, to the best of our knowledge, 
similar bivariate approaches have not been considered before for pteridines [4-7]. In 
addition, the isoxanthopterin and xanthopterin results from this study differed significantly 
from an earlier study using capillary electrophoresis – laser-induced fluorescence (CE-LIF) 
that also implicated urinary isoxanthopterin and xanthopterin in breast cancers [7]. While 
it been suggested that the CE-LIF technique may have co-eluting interferences for 































concentrations compared with LC-MS/MS methodologies, it is also important to note the 
differences in normalization methods and sample exclusion protocol between this study 
and that study [2]. Importantly, the CE-LIF study utilized healthy controls that were not 
gender- and age-matched. As Carrieri and co-workers have demonstrated, creatinine varies 
considerably more with age and gender than does USG [35]. These considerations 
alongside new reports indicating that creatinine is affected by menstrual cycles and breast 
cancer suggest that creatinine may not be an appropriate normalization factor for urinary 
breast cancer biomarkers [10, 23-25]. While benign and aggressive breast cancers in this 
study were gender- and age-matched, a clinically wide range of ages were encountered 
which merited additional correlation studies. Pearson correlations were made for USG, 
creatinine, xanthopterin, and isoxanthopterin with respect to patient age. Urinary 
xanthopterin (r = 0.048, P-value = 0.754) and isoxanthopterin (r = -0.113, P-value = 0.500) 
clearance were largely age-independent. In contrast, creatinine (r = -0.321, P-value = 
0.026) was moderately correlated with age with a relationship similar to that reported by 
Rowe and colleagues [39]. Interestingly, USG (r = -0.185, P-value = 0.224) was also 
weakly correlated with age but did not conflict with larger USG studies. In addition, this 
study had a significant bias toward women over 50 years of age (mean age = 61 years), 
which represents a subpopulation in which USG has not been sufficiently studied. 
Nevertheless, the relatively age-independent nature of xanthopterin, isoxanthopterin, and 
USG in comparison with creatinine provided a useful interpretation of the observed 
normalization performance parameters. Because xanthopterin and isoxanthopterin has now 
been shown to not vary with age within these demographics, their normalization by age-
dependent creatinine was reasonably inappropriate. Although these findings were highly 
encouraging, it should be stressed that a biological premise for pteridines like xanthopterin 
and isoxanthopterin in cancer has not been firmly established. More importantly, the study 
results indicated that USG normalization may provide superior performance to creatinine-







Figure 4. Scatterplot of urinary xanthopterin and isoxanthopterin in 48 benign and 




Finally, the applicability of USG normalization of urinary pteridines was 
considered through a small-scale bladder cancer study. The results of that study were 
summarized in Table 3 in the form of P-values. Similar to breast cancers, USG 
normalization afforded optimal P-values (summed P-value = 0.9109) compared with 
creatinine normalization (summed P-value = 1.8224) which again provided only a marginal 
improvement over uncorrected pteridines (summed P-value = 1.9714). Isoxanthopterin (P-
value = 0.0105) and xanthopterin (P-value = 0.0220) were again implicated as potentially 
useful biomarkers. It should be noted that 6-hydroxymethyl pterin was strongly 
uncorrelated with pathology whereas pterin showed some ability, although not statistically 
significant (P-value = 0.0736). Hence, 6-hydroxymethylpterin and pterin may be useful in 
discerning breast and bladder cancers, although further study is required. As a final note, 
the bladder cancer study, which was comprised of four untreated, high grade bladder cancer 
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specimens and 12 normal, healthy specimens, lacked sufficient statistical power to form 
any conclusions. For this reason, basic statistical information from this study has not been 
provided and the study is purely demonstrative. A more robust sample set was not pursued 
based on a lack of appropriate urine specimens. Nevertheless, the preliminary results from 
this comparison study again suggest that USG normalization of urinary pteridines may be 
more efficient than creatinine adjustments. 
 
Table 3. P-values from non-parametric Mann-Whitney one-tailed mean difference tests 




Uncorrected Creatinine USG 
6-Biopterin 0.4274 0.3784 0.2463 
Pterin 0.2144 0.4485 0.0736 
Neopterin 0.3797 0.2683 0.1285 
Xanthopterin 0.2011 0.1400 0.0220 
6-
Hydroxymethylpterin 
0.4844 0.3422 0.4300 
Isoxanthopterin 0.2644 0.2450 0.0105 
Summed P-values 1.9714 1.8224 0.9109 
 
4. CONCLUSION 
 In this study, we compared the performance of USG and creatinine normalizations 
of six urinary pteridines in discerning aggressive from benign breast cancers in 50 gender- 
and age-matched urine specimens. The basis of the study was premised on reports that 
commonly used creatinine normalizations may be inappropriate for clinical biomarkers due 
to its influence by a variety of patient factors whereas USG may be a more tolerant urine 
concentration-dilution indicator. Urinary creatinine was found to be well correlated with 
USG with deviations occurring in overly dilute and overly concentrated specimens. In 
addition, creatinine was found to be moderately correlated with patient age while USG, 
xanthopterin, and isoxanthopterin were reported to be relatively age-independent. This age 
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dependence was observed in a clinical performance comparison where USG-adjusted 
pteridines significantly outperformed creatinine-adjusted pteridines which only marginally 
outperformed uncorrected pteridines in discerning aggressive from benign breast cancers. 
In addition, isoxanthopterin and xanthopterin were reported to be significantly elevated in 
aggressive cancers when normalized by USG in comparison to creatinine. Moreover, these 
pathological correlations were enhanced by coupling xanthopterin and isoxanthopterin to 
form a bivariate indicator of cancer aggression with remarkable diagnostic sensitivity and 
specificity. These trends were also replicated in a similar small scale study involving 
bladder cancers. Hence, these findings indicated that USG normalization offers improved 
performance for clinical biomarkers and particularly urinary pteridines. In addition, these 
results strongly recommend that biomarker studies consider sample population 
demographics in order to choose the most appropriate normalization factor. Finally, larger 
studies are required to confirm the conclusions made by this study.  
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Pteridines are a diverse family of endogenous metabolites that may serve as useful 
diagnostic biomarkers for disease. While many preparative and analytical techniques have 
been described for analysis of selected pteridines in biological fluids, broad intracellular 
pteridine detection remains a significant analytical challenge. In this study, a novel, specific 
and sensitive extraction and high performance liquid chromatography – quadrupole time-
of-flight – mass spectrometry (HPLC-QTOF MS) method was developed to 
simultaneously quantify seven intracellular pteridines and monitor 18 additional, naturally-
occurring intracellular pteridines. The newly developed method was validated through 
evaluation of spiked recoveries (84.5% - 109.4%), reproducibility (2.1% – 5.4% RSD), 
method detection limits (0.1 – 3.0 µg/L) and limits of quantitation (0.1 – 1 µg/L), and 
finally application to non-small cell lung cancer A549 cells. Twenty-three pteridine 
derivatives were successfully detected fromcell lysates with an average RSD of 12% 
among culture replicates. Quantified intracellular pteridine levels ranged from 1 to 1000 
nM in good agreement with previous studies. Finally, this technique may be applied to 
cellular studies to generate new biological hypotheses concerning pteridine physiological 
and pathological functions as well as to discovery new pteridine-based biomarkers. 
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Pteridines are endogenous metabolites that function broadly in the human body as 
cofactors and intermediates for an array of metabolic pathways. Reported associations 
between pteridine levels and actively proliferating cells have prompted efforts to evaluate 
pteridine derivatives as novel indicators of disease and especially cancer [1]. Consequently 
the clinical significance of a handful of pteridine derivatives has been established over the 
past several decades [1-3]. Neopterin in particular has been comprehensively studied 
leading to an improved understanding of its pathomechanistic production and related 
diagnostic utility. Briefly, neopterin production has been linked to the stimulation of human 
monocytes by T-lymphocytes- and natural killer cell-derived cytokines and is related to a 
variety of pathological conditions such as infection, cancer, autoimmune diseases and 
rejected organ transplants [4-7]. Similarly, the cytokine-induced synthesis of 
tetrahydrobiopterin (BH4), a cofactor for nitric oxide synthase that is further related to 
vascular dysfunctions, has also been widely reported [8-10]. Hence, some pteridine 
derivatives like neopterin and BH4 appear to reflect activated immune systems in response 
to disease and associated inflammation. While such pteridine biomarkers fail to constitute 
classical tumor markers, other pteridine derivatives like xanthopterin, isoxanthopterin, 
oncopterin, pterin-6-carboxylic acid, 6-biopterin, among others have been widely 
speculated as candidate cancer biomarkers with pathomechanistic production thought to be 
related to perturbed cancer cell metabolisms. However, the lack of rigorous clinical 
validation and a poor understanding of how these pteridine derivatives specifically relate 
to cancer suggest further study is urgently required [1, 3, 11]. Moreover, with a large 
number of pteridine derivatives relatively unstudied and multiple, previously studied 
pteridine derivatives already having reported diagnostic value, the inclusion of broader 
pteridine panels in new analytical methods is urgently needed. These serious issues facing 
general pteridine research and efforts to establish pteridine derivatives as useful biomarkers 
for disease have arisen in part from complex bioanalytical and clinical challenges related 





Pteridine analysis in biological fluids has progressed significantly in the past 
several years. These method development studies have met varied challenges ranging from 
physiochemical properties and sample preparation issues to clinical considerations and 
limited pteridine profiling. Physiochemical complications include trace concentrations in 
biological fluids, pteridine derivatives with multiple oxidation states, and species labile to 
heat, light, and auto-oxidation [11, 12]. For these reasons, various oxidative pre-treatments 
have often been utilized by a wide range of techniques and sample matrices to oxidize any 
residual reduced pteridine derivatives to facilitate the analysis of more stable and more 
fluorescent, oxidized forms [13-19]. The resulting destruction of biologically useful 
information related to the reduced pteridine derivatives by these oxidative pre-treatments 
has prompted recent efforts to develop new techniques capable of simultaneously 
determining pteridines in their native oxidation states[20-22]. This trend toward total, 
native pteridine detection has become increasingly important as efforts to clinically 
validate pteridines continue to expand. In addition, the role of creatinine as an appropriate 
normalization factor in noninvasive urine-based strategies has been recently questioned for 
applications involving certain populations [14]. In response, urine specific gravity has been 
proposed as a more tolerant indicator of urine concentration-dilution for pteridine-based 
discrimination of benign and aggressive breast cancers [23]. Finally, new methods continue 
to improve detection limits and overcome these and other bioanalytical challenges 
following the rapid development of multiple, sensitive and specific pteridine detection 
techniques utilizing a variety of platforms including capillary electrophoresis – laser-
induced fluorescence (CE-LIF) [19], high-performance liquid chromatography – 
fluorescence detection (HPLC-FD) [13, 15, 22, 24], high-performance liquid 
chromatography – mass spectrometry (HPLC-MS) [25], high-performance liquid 
chromatography – tandem mass spectrometry (HPLC-MS/MS) [14], and synchronous 
fluorescence spectroscopy [26]. These techniques have expanded beyond urinary pteridine 
detection [13, 14, 19, 24-26] to include serum [15] and cerebrospinal fluid [22] analyses as 
well, although these additional matrices remain relatively underdeveloped. 
 
In comparison, intracellular pteridinic profiling, central to both elucidating 
pathomechanistic production of pteridine derivatives and discovering new, clinically useful 
  
89 
pteridine biomarkers, remains remarkably underdeveloped. Current techniques have been 
generally limited to analysis of biopterin and neopterin derivatives using a combination of 
HPLC-ED, HPLC-FD and ELISA methods with the exception of a recent HPLC-MS/MS 
technique for biopterin derivatives [20, 27-29]. Specific analytical difficulties such as polar 
metabolite extraction, interference minimization, and instrument compatibility especially 
with mass spectrometry, have complicated efforts to further intracellular pteridinic 
profiling. For example, while fluorescence-based techniques, such as capillary 
electrophoresis – laser-induced fluorescence (CE-LIF) and liquid chromatography – 
fluorescence detection (LC-FD), have remained popular for pteridine detection due to their 
high sensitivities and effective separations, such techniques require chemical standards for 
compound confirmation and are particularly sensitive to fluorescent interferences and UV-
absorbing material. Similarly, conventional quadrupole tandem mass spectrometry 
techniques (e.g. LC-MS/MS) offer competitive sensitivities without the need for complete 
separation, but lack the high mass resolution currently to reliably semi-quantitatively 
monitor additional pteridine derivatives without the use of often expensive and otherwise 
difficult-to-obtain chemical standards. In comparison, high resolution, high-performance 
liquid chromatography – quadrupole time-of-flight mass spectrometry (HPLC-QTOF MS) 
provides adequate sensitivity, greatly improved selectivity, and the ability to perform 
MS/MS experiments in combination with comprehensive database integration to provide a 
platform suitable for both quantitative and semi-quantitative profiling of a robust pteridine 
panel. 
In this study, a combination pteridine extraction and high resolution HPLC-QTOF 
MS detection method was developed for the quantitative determination of seven selected 
pteridines (Figure 1) and the semi-quantitative analysis of 18 additional pteridines to 
profile a complete panel of 25 pteridines in cell lysate matrices (Figure 2). Basic 
information for the 25 selected pteridine derivatives have been provided in Table 1. The 
validated method was finally applied to non-small cell lung cancer A549 cells to 







Figure 1. Chemical structures of seven quantitatively measured cellular pteridine 
derivatives: (1) pterin, (2) xanthopterin, (3) isoxanthopterin, (4) d-neopterin, (5) 6,7-




Figure 2. General schematic of the newly developed extraction and quantitative techniques 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2. MATERIALS AND METHODS 
2.1. Chemicals and Materials 
Isoxanthopterin, pterin, D-neopterin, xanthopterin, 6,7-dimethylpterin, and 
dithiothreitol were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). 6-Biopterin, 
pterin-6-carboxylic acid, ammonium hydroxide, formic acid, and ascorbic acid were 
purchased from J&K Scientific, LTD (Beijing, China). Trypsin and Dulbecco’s Modified 




A Venusil XBP phenyl-hexyl column (5.0 μm, 4.6×150 mm, Bonna-Agela 
Technologies Inc., USA) and an Agilent LC 1200 HPLC system (Santa Clara, California, 
USA) comprised of a degasser (G1322A), a binary pump (G1312B), an autosampler 
(G1367D), an autosampler thermostat controller (G1330B), and a column oven (G1316B) 
were used for the separation of the selected cellular pteridines. Separation was carried out 
at 25 °C with a flow rate of 0.25 mL/min using mobile phase that had the following 
composition, A: 0.1% (v/v) formic acid in water and B: 0.1% (v/v) formic acid in 
acetonitrile. A gradient program was used to enhance separation that initialized at 50% B 
followed by a linear decrease to 20% B at 3 minutes followed by a linear increase to 80% 
B at 8 minutes. This composition was held for the remainder of the run. Run-to-run time 
was 25 minutes with a sample injection volume of 5 μL. 
 
An Agilent 6530 high resolution QTOF mass spectrometer with positive-ion ESI 
was used to detect and quantify the selected pteridines. The QTOF mass spectrometer was 
operated under untargeted MS/MS mode for characterization and semi-quantitative 
analysis of selected pteridines lacking standard reagents. Optimized operational parameters 
included: gas temperature: 325 °C; drying gas: 6 L N2/min; nebulizer pressure: 30 psig; 
sheath gas temperature: 350 °C; sheath gas flow: 7.5 L N2/min; ESI voltage: +3500 V; TOF 




2.3. Standard Preparation 
Approximately 4 mg of each pteridine standard was accurately weighed to 0.01 mg 
precision and dissolved in a 0.1% (w/v) dithiothreitol (DTT) solution comprised of 9.8 mL 
ultrapure water and 200 µL 2 M ammonium hydroxide. Ultrasonication and vortexing were 
used together to facilitate the dissolution process. A stock mixture containing 10 mg/L of 
each pteridine standard was prepared daily and maintained at 4 °C under dark conditions. 
Calibration standards were prepared from the stock mixture by serial dilution in a 0.1% 
(w/v) DTT solution prepared from ultrapure water. 
 
2.4. Cell Cultures and Preparation 
A549 adenocarcinoma human alveolar basal epithelial cells were obtained from the 
American Type Culture Collection (Manassas, Virginia, USA). Cells were suspended in 
DMEM with 10% fetal bovine serum (FBS). Cells were cultivated in 10 cm Petri dishes in 
a controlled incubator maintained at 37 °C and 5% carbon dioxide under dark conditions. 
Cells were harvested by incubating at 37 °C and 5% carbon dioxide with 1 mL trypsin 
solution and immediately counted with a hemocytometer. After centrifuging the 
trypsinized cells at 200 g for 5 minutes at 4 °C, the trypsin supernatant was carefully 
aspirated and the cell pellets were washed twice with ultrapure water. The cells were then 
resuspended in 500 µL chilled ultrapure water containing 0.1% DTT followed by manual 
homogenization to lyse cellular membranes. The homogenized cells were then further 
snap-frozen with liquid nitrogen for 1 minute and allowed to gradually thaw to 4 °C. A 500 
µL addition of cold (-20 °C) methanol containing 0.1% DTT and 10 mM ammonium 
hydroxide was made to the thawed lysate and the extract was allowed to incubate for 10 
minutes on ice. Insoluble portions were subsequently removed by centrifugation at 20,000 
g for 20 minutes at 4 °C. A 500 µL aliquot of the undiluted supernatant was transferred to 
a 1.5 mL vial and placed in a dark, thermostated (4 °C) autosampler. A 5 µL aliquot was 




3. RESULTS AND DISCUSSION 
3.1. Pteridine Extraction 
 Similar to pteridine analysis, intracellular pteridine extraction is complicated by the 
unique physiochemical properties of pteridines, specifically poor solubility in many 
aqueous and organic solvents, trace biological concentrations, and high polarity. While 
pteridine extraction from insect tissue and animal irises using basic buffers followed by 
fluorimetric detection has been widely reported, pteridine extraction protocol for either 
mammalian cells or MS-compatible detection has remained limited [30-32]. Fismen et al 
reported biopterin derivative extraction from cell lysates using a combination of 
trichloroacetic acid, acetic acid, and EDTA, but did not consider other extraction solvents 
or other pteridine derivatives [20]. Therefore, previously reported comparisons made 
among common metabolite extraction techniques for similarly polar nucleotide-derived 
compounds and amino acids were used to develop candidate pteridine extraction 
techniques [33]. The selected extraction solvents included 100% cold (-20 °C) methanol, 
50% cold (-20 °C) aqueous methanol, and hot (60 °C) water, all of which contained 0.1% 
DTT to prevent auto-oxidation of reduced pteridine species [13] and 5 mM ammonium 
hydroxide [14] to improve pteridine solubility. Systematic comparison of DTT 
concentrations on a variety of reduced pteridines has previously demonstrated 0.1% DTT 
effectively maintains reduced pteridine stability in complex biological matrices [13]. It 
should be noted that 50% aqueous acetonitrile was not examined due to pteridine solubility 
concerns. A standard extraction volume of 1000 µL was used, although this parameter 
remains to be optimized for given cell counts. It was noted that extraction volumes larger 
than 5000 µL for approximately 1•107 A549 cells resulted in non-detection of some 
pteridine derivatives. In addition, cryogenic cell lysis through liquid nitrogen exposure 
significantly improved pteridine extraction over manual homogenization alone which was 
indicative of more complete lysis. Normalized extraction efficiencies were determined by 
normalizing the extracted concentrations of the seven, quantitatively monitored pteridines 
to the highest performing extraction solvent. 
 
 Pure organic solvent (100% cold methanol) failed to appreciably extract pteridines 
with an average extraction efficiency of 41%. The resulting poor extraction efficiency may 
  
95 
be attributed to the limited solubility of polar pteridines in cold, pure organic solvent. 
Pteridine extraction by hot water provided 122% extraction efficiency, but was 
characterized by high inter-experimental variability and markedly decreased reduced 
pteridine derivatives. These data indicate hot water extractions may promote the non-
specific oxidation of reduced pteridine derivatives to more oxidized forms. Meanwhile, 
50% cold methanol afforded optimal extraction efficiencies without significantly affecting 
reduced pteridine species, although it remains unclear to what extent these oxidation 
processes may have occurred. These extraction comparisons supported similar findings for 
the extraction of polar nucleotide-derived compounds and amino acids [33]. In addition, 5 
mM ammonium hydroxide significantly improved pteridine extraction for all extraction 
solvents studied. Oxidative influence on reduced pteridine derivatives by ammonium 
hydroxide was not appreciably observed in the presence of 0.1% DTT. Higher ammonium 
hydroxide concentrations posed MS compatibility concerns and often resulted in the 
formation of a viscous precipitate after centrifugation that rendered removal of the 
supernatant difficult and resulted in decreased pteridine levels. This phenomenon has been 
reported with similar potassium hydroxide-assisted extractions [33]. Finally, a wider range 
of inorganic solvents may further improve extraction efficiencies, but are not compatible 
with HPLC-QTOF MS analysis. 
 
3.2. MS/MS Optimization 
Seven, quantitatively monitored pteridines were mass optimized with respect to 
their precursor and two most abundant product ions. Quantitative analysis of these seven 
pteridines implemented a 20 ppm symmetric expansion about these optimal masses to 
provide high-resolution extracted ion chromatograms for each pteridine derivative. 
Previous work has reported optimal positive-ion ESI using 0.1% (v/v) formic acid in 
aqueous and organic mobile phases [14, 25]. Therefore, 1000 µg/L pteridine standards 
were prepared in 0.1% (v/v) aqueous formic acid and injected into the high resolution 
QTOF mass spectrometer via direct infusion at a rate of 0.3 mL/hour. Ions were monitored 
under full scan mode between 150 m/z and 300 m/z for one minute to determine the crude 
average ion mass. The pteridine standard was reexamined under Selected Ion Monitoring 
(SIM) scan mode for one minute centered on the crude average ion mass with a 200 ppm 
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symmetric expansion. The new centroid mass from the SIM scan was used as the 
experimentally optimized precursor ion mass. To optimize product ion masses, targeted 
MS/MS acquisition was used on the infused standard centered on the optimized precursor 
ion mass with a 20 ppm symmetric expansion and a collision energy of 20 eV which was 
preliminarily found to afford the optimal product ion intensities. MS/MS spectra were 
acquired for one minute, and the average masses for the two most abundant product ions 
were used as the optimized product ion masses for confirmation purposes. The precursor 
and production ion masses determined were similar to those reported by studies using lower 
mass resolution instruments [14]. Notably, primarily [M+H]+ ions were observed with 
negligible formation of ammonium adducts, [M+NH3]
+ and [M-H+2NH4]
+, in xanthopterin 
and pterin-6-carboxlyic acid. These differences may be attributed to different positive-ion 
ESI conditions, such as a lower capillary voltage (3500 V vs 4500 V) and significantly 
higher gas flow rates. Hence, under the given MS/MS conditions, the assumption that 
similar pteridine derivatives will form [M+H]+ appeared reasonable. The optimized 
MS/MS parameters were summarized in Table 2. 
 
3.3. HPLC Optimization 
 The separation of the seven, quantitatively monitored pteridines was based 
on chromatographic conditions described in our previous work with some notable 
modifications [14]. In this study, a larger Venusil XBP phenyl-hexyl (5.0 μm, 4.6×150 
mm) column, in comparison with a Phenomenex Luna phenyl-hexyl (3.0 μm, 3.0×150 mm) 
column, was selected to separate the seven pteridines based on column availability. 
Resulting differences in retention time, retention order, and peak shape were noted in 
comparison with the previously described method. Therefore, the separation was evaluated 
and optimized under a range of flow rates from 0.10 mL/min to 0.40 mL/min with a variety 
of mobile phase compositions (0.0-0.2% formic acid in water, methanol, and acetonitrile). 
Briefly, it was observed that initially high aqueous mobile phase (>50%) compositions 
resulted in loss of retention and the occurrence of significant peak tailing while very high 
organic compositions (>80%) resulted in complete retention. The resulting optimized 












































































































































































































































































































































































































































































































































































































A representative chromatogram, including separation of the structural isomers, 
xanthopterin and isoxanthopterin, was shown in Figure 3. In addition, significant 
equilibriation volumes were required for reproducible separations involving real cell 
lysates, necessitating longer 25 minute run-to-run times. Peak resolution also decreased as 
a result of the larger column, indicating that smaller HPLC and UPLC columns with more 
efficient packing may further improve method separation. Nevertheless, it is clear from 
Figure 3 that the quantitatively measured, structural isomers xanthopterin and 
isoxanthopterin remained completely resolved. Moreover, matrix interference concerns 
were further minimized through high resolution QTOF MS and MS/MS monitoring with 





Figure 3. Overlaid extracted ion chromatograms (EIC) of seven quantitatively monitored 




3.4. Method Performance 
Method performance parameters for the seven quantitatively monitored pteridine 
derivatives were determined in similar extraction solvent matrices without the presence of 
cell lysate material which presented matrix reproducibility challenges. Hence, possible 
matrix effects were not present for this component of the study, but were quantitatively 
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evaluated later in the real cell study. Under the optimized HPLC-QTOF MS conditions, 
calibration curves for all seven quantitatively monitored pteridines were constructed to 
demonstrate linearity under a broad analytical range. As shown in Table 2, all seven 
pteridines performed linearly over multiple orders of magnitude with linear regression 
coefficients (R2) above 0.9985. Moreover, the method was found to be highly sensitive 
with method detection limits ranging from 0.1 to 3 µg/L and limits of quantitation ranging 
from 0.1 to 10 µg/L. These detection limits were comparable to previously reported 
pteridine detection limits with fluorescence detectors and mass spectrometry techniques. 
In addition, spiked recoveries were performed at low (10 µg/L), medium (100 µg/L) and 
high (1,000 µg/L) concentrations to determine technique precision and reproducibility. The 
data in Table 3 demonstrated high recovery accuracies ranging from 94.5% to 109.4% with 
deviations ranging from 1.2 to 5.4% RSD. These figures of merit indicated the quantitative 
HPLC-QTOF MS technique is both accurate and precise as well as comparable to other 
pteridine analyses developed for biological fluid analysis. 
 
Table 3. Triplicate spiked recovery results of seven selected pteridines at three varying 
concentrations. 
  
Low (10 µg/L) Medium (100 µg/L) High (1000 µg/L) 
Compound Recovery RSD Recovery RSD Recovery RSD 
D-Neopterin  109.4 4.0 105.4 3.5 102.9 2.8 
6-Biopterin  104.5 3.8 105.1 3.2 101.7 2.4 
Xanthopterin  94.7 3.4 102.4 4.4 97.8 2.7 
Pterin  98.7 2.1 95.1 3.0 95.6 3.4 
Isoxanthopterin  100.2 3.7 102.1 4.3 103 3.9 
6,7-Dimethylpterin  105.7 5.4 103.2 5.2 97.8 4.2 
Pterin-6-carboxylic 
acid  
94.5 4.2 95.7 3.4 95.9 4.7 
 




3.5. Application to Real Cell Cultures 
 The newly developed extraction and HPLC-QTOF MS methods were applied to 
real cell cultures to demonstrate method validation and feasibility. A549 adenocarcinomic 
human alveolar basal epithelial cells were selected as a useful model due to their 
widespread occurrence in biomedical research, consistent cell growth and size, and relative 
ease of culturing. Biological and analytical triplicate cell cultures were examined to provide 
quantitative figures of merit for the combined extraction and quantitative techniques. 
Summarized results have been shown in Table 4. Under the optimized conditions, all 25 
selected pteridine derivatives except oncopterin (expected 295.15131 m/z) were detected. 
The presence of an unidentified system peak centered at 294.13091 m/z with significant 
[A+1] and [A+2] isotopic ions obfuscated possible oncopterin signals. Moreover, all seven 
quantitatively monitored pteridines were quantifiable from the cell lysate except neopterin 
and isoxanthopterin which was generally detected but unquantifiable with an average 
signal-to-noise ratio (SNR) of 2.1. Among the semi-quantitatively monitored pteridine 
derivatives, 12 were identified by the elution of a single peak at the expected precursor ion 
using a 20 ppm symmetric expansion as well as confirmation by MS/MS fragmentation 
and comparison with MS/MS spectra provided in the Human Metabolome Database. 
Multiple elution peaks and lacking relevant MS/MS fragmentation spectra complicated the 
confirmation of six additional pteridine derivatives. For these compounds, all elution peaks 
for a respective precursor ion were monitored for the purpose of this study. The inability 
to confidently confirm these particular pteridine derivatives with MS/MS spectra reflects 
the often poorly studied nature of many of these compounds within broader mass 
spectrometry applications. Further study of these compounds is therefore urgently required. 
Combined technique reproducibility among the pteridine derivatives was nevertheless 
generally good with an average RSD of 12%. Accuracy limitations related to the cell 
hemocytometer and incomplete trypsin solution removal during the extraction process may 
further improve technique reproducibility and accuracy. Nevertheless, these data indicated 
the newly developed technique was suitable and useful for broad intracellular pteridine 













Oncopterin N/A N/A N/A - 
Pterin-6-carboxylic Acid 8.61 6280 22.32 111 
6-Hydroxymethylpterin 8.64 66838 19.76 - 
6-Hydroxylumazineb 8.66 67828 1.98 - 
6-Formylpterin1 8.75 21702 5.06 - 
Monapterind 8.87 14224 4.92 - 
7,8-Dihydroneopterin1 8.92 39599 13.31 - 
7-Hydroxylumazineb 8.95 52077 19.81 - 
Lumazine1 9.00 21733 1.03 - 
Sepiapterinc 9.05 23446 30.68 - 
6-Formylpterin-21 9.41 5410 68.29 - 
Neopterind 9.42 4199 6.92 <MDL 
7,8-Dihydroneopterin-21 9.62 361 17.61 - 
Isoxanthopterina 9.76 4426 24.27 <MDL 
5,6,7,8-Tetrahydroneopterin 9.78 2050489 5.27 - 
6-Biopterinc 9.87 20780 4.69 379 
Biolumazine 9.98 2928486 9.56 - 
5,6,7,8-Tetrahydrobiopterin 9.99 195769 10.82 - 
7,8-Dihydrobiopterin 10.00 7386079 8.92 - 
7,8-Dihydropterin 10.10 20807 8.45 - 
6-Methylpterin1 10.22 2599 79.85 - 
Xanthopterina 10.22 8371 3.25 475 
7,8-Dihydroxanthopterin1 10.25 84546 14.99 - 
Pterin 10.27 13786 13.85 280 
6-Formylpterin-31 10.27 82467 8.81 - 
Lumazine-21 10.28 7098 27.79 - 
6,7-Dimethylpterin 10.96 4107 15.36 106 
5,6,7,8-Tetrahydropterin1 11.39 8844 8.15 - 
6-Methylpterin-21 11.54 19914 4.67 - 
6,7-Dimethyltetrahydropterin1 13.32 44649 17.46 - 
6-Methylpterin-31 13.42 12646 14.59 - 
5,6,7,8-Tetrahydropterin-21 13.49 55897 22.62 - 
7,8-Dihydroneopterin-31 13.49 16328 9.61 - 
6,7-Dimethyltetrahydropterin-21 14.92 211973 7.67 - 
7,8-Dihydroxanthpterin-21 19.43 1607940 27.08 - 
a-dThese pteridines are structural isomers with equivalent precursor ion exact masses. 
1The identities of these compounds were not confirmed after database lookup. 
2All values are presented as a percentage determined from analytical triplicates. 
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 In addition, the intracellular concentrations of the seven quantitatively monitored 
pteridine derivatives were determined. Molar concentrations within the 1 mL extract were 
converted to moles pteridine derivative and normalized by the estimated number of cells 
determined by the manual hemocytometer to yield average moles pteridine per cell. An 
average A549 cytosolic volume of 1204 µm3 was finally used to determine average molar 
pteridine concentrations per cell.[34] Selected intracellular pteridine concentrations ranged 
from 1 nM to 1000 nM. Limited data concerning absolute intracellular pteridine 
concentrations rendered literature comparisons difficult. Total biopterin has been reported 
in hepatocytes using HPLC-FD near 9.0 µM with BH4 comprising nearly 8.6 µM and 
dihydrobiopterin (BH2) comprising the remaining 0.4 µM [35]. Fismen et al reported 
similar BH4 values in HUVEC cells with an HPLC-MS/MS technique while also reporting 
negligible BH2 and biopterin content [20]. The BH4, BH2, and biopterin levels reported 
herein appeared to be in agreement with these previous studies. For example, while this 
study successfully detected biopterin from the cell lysates, the reported levels were beneath 
the detection limits reported by these previous studies. Similarly, BH2 and BH4 were also 
reported herein with vastly higher peak areas than biopterin, although the semi-quantitative 
nature of their analysis and their co-elution under the given conditions limited further 
comparisons. While co-elution and differences in ionization efficiencies may limit the 
extent of this observation, there is some evidence of non-specific oxidation of BH4 to BH2 
based on reportedly higher BH2 peak areas in this study. EDTA may therefore serve as a 
useful addition to the extraction solvent to chelate free metal ions to improve reduced 
pteridine derivative quantitative analyses [20, 36]. In addition to biopterin, reported 
intracellular xanthopterin levels compared well with previously reported xanthopterin 
levels in red blood cells [37]. With respect to neopterin, Werner and colleagues also 
reported undetectable neopterin levels in A549 cells using HPLC-FD and oxidative 
treatment [29]. Curiously, fully reduced 5,6,7,8-tetrahydroneopterin generated a significant 
peak, although its occurrence merits further study. The abundant prevalence of biolumazine 
was also unexpected and is most likely a result of its co-elution with BH2 and BH4. The 
general agreement between the intracellular pteridine levels reported in this study and 
others supported the accuracy and precision of the newly developed extraction and 
quantitation techniques. Moreover, the intracellular pteridine detection method described 
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herein provides several distinct advantages over previous techniques. First, these data 
indicate significantly broadened application potential by enabling quantitative analysis of 
reduced and oxidized pteridine derivatives. This marks a substantial improvement over 
previous intracellular pteridine techniques that typically examine no more than three 
pteridine derivatives. This technique may therefore be applied to multiple cell lines to 
generate novel pteridine profiles to generate new biological hypotheses and to discover 
new pteridine-based biomarkers for pathological conditions. In addition to quantitatively 
monitoring selected pteridine derivatives in perturbed metabolic pathways, additional 
pteridine derivatives may now be semi-quantitatively monitored without the need for 
expensive and difficult-to-obtain chemical standards. Second, the utilization of a chemical 
stabilizer through DTT absolves the need for oxidative pre-treatments that may destroy 
useful reduced pteridine derivative information as well as minimizes the introduction of 
procedural artifacts that may lead to inaccurate measurements. Finally, the authors note 
that this component of the study did not aim to generate any biological hypotheses 
concerning pteridine derivatives in pathological conditions. 
 
4. CONCLUSIONS 
A novel, specific, and sensitive extraction and HPLC-QTOF MS method was 
developed for simultaneous analysis of seven intracellular pteridines with the ability to 
semi-quantitatively monitor 18 additional, naturally-occurring pteridines which has not 
been previously reported to the best of our knowledge. Additionally, multiple extraction 
solvents and conditions were evaluated to provide an optimized pteridine extraction 
protocol from cell lysates. Method validation through evaluation of spiked recoveries, 
reproducibility (represented by RSD), MDLs, and application in A549 cell cultures 
indicated the newly developed method was suitable for the detection of various pteridine 
derivatives in endothelial cells with high precision and accuracy. This technique has 
significantly advanced intracellular pteridine detection by substantially expanding the 
number of pteridine derivatives that may be simultaneously detected, either quantitatively 
or semi-quantitatively. Finally, this technique may be applied to cellular studies to generate 
new biological hypotheses concerning pteridine physiological and pathological functions 
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Background: Urinary metallomics is presented here as a new “omics” approach that aims 
to facilitate personalized cancer screening and prevention by improving our understanding 
of urinary metals in disease. 
Methods: Twenty-two urinary metals were examined with inductively-coupled plasma – 
mass spectrometry in 138 women newly diagnosed with breast cancer and benign 
conditions. Urinary metals from spot urine samples were adjusted to renal dilution using 
urine specific gravity. 
Results: Two urinary metals, copper (P-value = 0.036) and lead (P-value = 0.003), were 
significantly elevated in the urine of breast cancer patients. A multivariate model that 
comprised copper, lead, and patient age afforded encouraging discriminatory power (AUC: 
0.728, P-value < 0.0005), while univariate models of copper (61.7% sensitivity, 50.0% 
specificity) and lead (76.6% sensitivity, 51.2% specificity) at optimized cutoff thresholds 
compared favorably with other breast cancer diagnostic modalities such as mammography. 
Correlations found among various metals suggested potential geographic and dietary 
influences on the urine metallome that warrant further investigation.  
Conclusions: In summary, this proof-of-concept work introduces urinary metallomics as 
a noninvasive, potentially transformative “omics” approach to early cancer detection. 
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Metallomics is an emerging field concerned with the comprehensive analysis of 
metal and metalloid species within a biological system [1, 2]. The extensive and essential 
roles of metal and metalloids in pathophysiology lend suitability to metallomics as a novel 
approach to disease detection and monitoring. For example, metalloproteins represent 
approximately one third of the known proteome and have wide-ranging roles in 
biologically important processes such as oxygen and electron transport, biosynthesis and 
biodegradation, and hydrolysis of amides and esters, and others [3]. Metalloprotein 
dysregulation is frequently associated with pathological status, such as metallothionein 
overexpression in certain invasive ductal breast cancers [4-6]. Moreover, metal ions are 
presumed to be highly regulated [7, 8] owing to their critical roles in maintaining cellular 
redox status and regulating protein expression [9-11]. A comprehensive understanding of 
metal content, speciation, localization and function under various pathophysiological 
conditions is therefore becoming increasingly important in understanding disease 
mechanisms and discovering novel diagnostic, prognostic, and therapeutic targets. 
The role of metallomics in understanding breast cancer has led to novel insights 
into metal functionality in breast cancer carcinogenesis and metastasis. For example, 
copper hyperaccumulation in cancer cells is required for angiogenesis and tumor growth 
[12]. Similarly, dysregulated copper transport leads to oxidative stress and perturbed cell 
signaling pathways via the copper transport protein CTR1 while copper transport protein 
CTR2 expression has been linked to breast cancer prognosis and cisplatin drug resistance 
[13]. Intracellular copper additionally stimulates breast cancer metastasis via redox 
regulation such as inducing reactive oxygen species generation in cellular structures 
associated with cell motility [14]. Consequently, novel chemotherapy sensitizers that 
function as redox modulators via copper(II) chelation have emerged [15]. Similarly, 
intracellular zinc is physiologically highly regulated in order to maintain cellular redox 
status [16], but becomes deregulated in breast tumors. Metallothioneins, antioxidant 
proteins with high binding affinities for essential metals like copper and zinc, are also 
poorly regulated in invasive ductal carcinomas [17], resulting in increased free cytosolic 
zinc and copper ions [18]. Zinc importer protein overexpression and zinc 
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hyperaccumulation have similarly been well documented in heterogeneous breast cancers 
[18-22]. For these reasons, researchers have explored the utility of copper and zinc as 
diagnostic biomarkers for breast cancer, such as low serum zinc [23] and high serum Zn/Cu 
serum ratios [24]. Furthermore, divalent transition metals including copper, cobalt, lead, 
mercury, tin, and chromium have been shown to activate estrogen receptor-α and 
consequently cell proliferation [25]. Other metals, like lead, have been associated with 
selenium antagonism, which minimizes the anti-carcinogenic effect of selenium, leading 
to higher risk for developing breast cancer [26]. Together, these pathophysiological 
metallomic changes provide a new molecular modality for earlier detection of aggressive 
breast cancer. 
Comprehensive metallomic screening techniques essential to discovering new 
clinically useful metallomic biomarkers have become popular following advances in 
advanced analytical techniques that have enabled researchers to study otherwise trace 
metals in biologically relevant matrices. Inductively-coupled plasma – mass spectrometry 
(ICP-MS) in particular has emerged as a powerful platform based on its unparalleled 
sensitivity and throughput. Recent efforts have already used this approach to implicate high 
lead, uranium [27] in addition to antimony and cadmium [28] in hair samples of breast 
cancer patients. Urinary cadmium, another selenium antagonist, has recently been 
proposed as a noninvasive indicator of breast cancer through multiplicative interactions 
with selenium [29]. However, application of metallomics to urinalysis remains 
underdeveloped, despite its distinct advantages that include reduced sample preparation 
and noninvasive detection modality. While concentration ranges of many urinary metals in 
healthy populations have been widely reported, other trace elements and concentration 
ranges in clinically relevant populations, such as women with newly diagnosed breast 
cancer or with suspected breast cancer, have yet to be described or critically reviewed. This 
study therefore examined 22 urinary metals using ICP-MS in a proof-of-concept study 
involving 138 women with newly diagnosed breast cancer and benign conditions in order 





2. MATERIALS AND METHODS 
2.1. Patients and specimens 
A total of 138 women 33-84 years of age were recruited to provide urine specimens 
for this proof-of-concept study and other studies at the Mercy Breast Center - Springfield 
(Springfield, Missouri) between July 2013 and December 2014. Study protocol was 
approved by the Mercy Medical Research Institute Institutional Review Board (IRB) and 
participants were required to provide informed consent. Inclusion criteria for participants 
included new referrals to the Mercy Breast Center - Springfield following possible 
indication for breast cancer that required further biopsy and immunohistochemical 
characterization. Exclusion criteria included individuals with a previous history of cancer 
and/or any known comorbidities. All women resided in the Southwest Missouri region 
which is a predominate lead and zinc mining area. Additional demographic, metal 
exposure, and patient health information were not collected owing tothe retrospective 
nature of this study. Spot urine specimens comprising first morning and second morning 
voids were collected for the study and immediately stored at -20°C for 1-6 days at Mercy 
Breast Center – Springfield followed by shipment to Missouri University of Science and 
Technology via next-day frozen ground freight for analysis. Urine aliquots were stored at 
-80°C and underwent 2-4 freeze/thaw cycles prior to analysis which occurred 1-6 months 
after specimen collection. Urinary metals were shown to be freeze/thaw resistant with 
minimal metal adsorption on container walls after five freeze/thaw cycles across six 
months storage at -80°C. Patient diagnoses were independently determined by qualified 
Mercy Breast Center – Springfield staff using a combination of ultrasound-guided core 
biopsies and pathological stains. The study was conducted in a double-blind manner. Data 
and resources including patient urine specimens, pathological reports, and metallomic 
results were anonymized with numerical identifiers. 
 
2.2. ICP-MS Urinary Metal Assay 
Twenty-two urinary metals including vanadium (V), chromium (Cr), manganese 
(Mn), cobalt (Co), nickel (Ni), copper (Cu), zinc (Zn), gallium (Ga), arsenic (As), selenium 
(Se), rubidium (Rb), strontium (Sr), molybdenum (Mo), silver (Ag), cadmium (Cd), tin 
(Sn), antimony (Sb), cesium (Cs), barium (Ba), tellurium (Tl), lead (Pb), and uranium (U) 
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were quantified using a previously described ICP-MS technique with several significant 
modifications [30]. Briefly, 2 mL urine specimen aliquots were equilibrated to room 
temperature and diluted fivefold with 1% Optima grade nitric acid (Fisher Scientific Inc, 
#A467-1) and internal metal standards 45Sc, 89Y, and 159Tb (PerkinElmer Inc, N9303834) 
in nitric acid pretreated sample tubes. Two calibration standard mixtures (PerkinElmer Inc, 
N9300233 and N9301721) comprising the 22 metals were used for instrument calibration. 
Samples were injected into a NexION 350D ICP-MS (PerkinElmer Inc) using an 
autosampler and peristaltic pumps. The ICP-MS was operated in kinetic energy 
discrimination (KED) mode using ultra-high purity helium with a flow rate of 3.9 mL/min 
for As and Se, and 4.7 mL/min for other metals to minimize polyatomic interferences that 
may arise in complex urine matrices. Quantitation isotopes included 51V, 52Cr, 55Mn, 59Co, 
60Ni, 63Cu, 66Zn, 69Ga, 75As, 77Se, 85Rb, 88Sr, 97Mo, 107Ag, 111Cd, 118Sn, 121Sb, 133Cs, 137Ba, 
205Tl, 208Pb, and 238U, while confirmation isotopes included 53Cr, 62Ni, 65Cu, 68Zn, 82Se, 
86Sr, 95Mo, 110Cd, 117Sn, 123Sb, 135Ba, 203Tl, 206Pb, and 235U. ICP-MS operational parameters 
included: RF power, 1600 W; plasma gas flow, 18 L/min; auxiliary gas flow, 1.20 L/min; 
and nebulizer gas flow: 1.06-1.08 L/min. Urinary metal concentrations were adjusted by 
internal standard responses and dilution. 
 
Urinary metals were quantified over an element dependent linear range from 0.01 
µg/L to 100 µg/L using matrix-matched calibration standards. Matrix-matched calibration 
standards were prepared using fivefold synthetic urine (CST Technologies Inc, UriSub®) 
to mimic the high salt content and formation of polyatomic interferences in real urine 
specimens. A freeze-dried reference urine standard (UTAK Laboratories Inc, Product 
#12110) with certified metal concentrations was also used as an indicator of trueness. 
Duplicated samples and spiked recoveries of urine specimens were additionally used to 
measure reproducibility and accuracy of the technique. Method accuracy ranged from 87% 
to 127% at biologically relevant concentrations (Table 1) while intra- and inter-run 
reproducibility were calculated as 1-7% and 2-12% relative standard deviation, 
respectively. Metal concentrations measured below the limit of quantitation (LOQ) were 












































































































































































































































































































































































































































































































































































































































































































































































































































































2.3. Urine specific gravity assay 
Urinary metals were adjusted for patient hydration-dilution status using urine 
specific gravity (USG). Conventional creatinine normalizations were excluded since 
urinary creatinine varies with age [31], diet [32], physical activity [33], and presence of 
breast cancer [34]. USG was measured using a temperature-corrected Reichert TS 400 
clinical refractometer. Bulk urine specimens were allowed to equilibrate to room 
temperature followed by analysis of a 200 µL aliquot. Ultra-pure water (USG = 1.000) and 
synthetic urine (USG = 1.022) of known specific gravity were used as reference standards. 
USG was measured with inter- and intra-assay RSDs of 0.12% and 0.04%, respectively. 
Biomarker concentrations were adjusted to USG using the Levine-Fahy equation and a 
reference USG of 1.020: 




where Ccorrected is the adjusted analyte concentration, Craw is the uncorrected analyte 
concentration, USGreference is a reference USG for a given population, and USGexperimental is 
the measured USG. 
 
2.4. Statistical analyses 
Anderson-Darling normality tests indicated non-normal distributions for all 22 
urinary metals (Anderson-Darling > 3.5, P < 0.005), while log10 transformation failed to 
approximate the normal curve (Anderson-Darling > 3.0, P < 0.005). For this reason, 
nonparametric analyses were performed on untransformed USG-adjusted metal 
concentrations and the covariates USG and patient age. Mann-Whitney U analyses were 
used to compare women newly diagnosed with breast cancer and benign conditions. 
Kruskal-Wallis and Dunn’s multiple comparisons tests were used to compare urinary metal 
concentrations across individual carcinoma types and grades. Correlations among different 
urinary metals and clinicopathological factors were measured with Pearson correlations. 
Logistic regression analyses were used to generate classification models, compute odds-
ratios, and construct receiver-operating characteristic (ROC) curves for metals that were 
found to be associated with breast cancer. Odds-ratios were computed using interquartile 
range (IQR) increments for each covariate. The ROC curves evaluated the potential of each 
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classification model to distinguish invasive breast cancer across all thresholds and were 
constructed by plotting sensitivity vs. 1-specificity. Statistical uncertainty was quantified 




3.1. Patient Population 
One hundred thirty-eight urine specimens were collected among which seven were 
excluded for being overly dilute or concentrated, defined as having a USG value below 
1.003 or above 1.030, respectively. These cutoff thresholds were selected based on the 
diminished ability of USG to accurately model patient hydration-dilution status beyond 
these points [35]. The remaining 131 eligible patients were classified as 79 (60%) women 
diagnosed with benign fibroadenomas, fibrocystic changes, benign papillomas, and stromal 
fibrosis, and 52 (40%) women with newly diagnosed breast carcinomas. Carcinomas were 
further characterized as comprising 12 ductal carcinomas in situ (DCIS), 38 invasive ductal 




Figure 1. Patient enrollment flowchart including excluded specimens. 
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Low-grade DCIS cases (n = 5) were considered pre-invasive, indolent disease [36], 
which resulted in their classification as a benign condition. The retrospective nature of this 
study, whereby samples were originally collected for a different purpose, precluded the 
inclusion of healthy, age-matched controls. As a proof-of-concept study, the benign cases, 
which lacked known comorbidities, previous history of cancer, and had pathologically 
confirmed absence of breast cancer were used as approximate controls. However, future 
studies should include healthy control populations since urinary metals may associate with 
benign conditions of the breast. 
 
3.2. Association of Urinary Metals with Breast Cancer 
Urinary metal concentrations encountered in the two patient groups were 
summarized in Table 2. All 22 urinary metals were reliably detected by the ICP-MS 
analysis with the exceptions of V, Mn, Ag, and U. Trace levels of Cr and Ga were also 
unquantifiable (signal-to-noise < 10) in a majority of samples. Notably, the heavy metals 
Cu (P-value = 0.036) and Pb (P-value = 0.003) were significantly elevated in the women 
with newly diagnosed breast cancer. Weak associations from Cd (P-value = 0.163) in 
addition to non-significant increases in Zn, Ba, and Rb were also observed. Patient age was 
additionally considered a disease correlate (P < 0.0005) with means (SD) of 64.7 (10.9) 
years in the breast cancer group and 56.7 (11.8) years in the benign group. Patient age was 
not found to correlate with any of the urinary metals, which indicated that patient age was 
not a confounding factor for the observed relationships between metals and breast cancer. 
USG was not associated with presence of breast cancer and had a pooled mean (SD) of 
1.013 (0.001). 
 
Logistic regression models were used to evaluate the clinical performance of 
various classification models in distinguishing invasive breast cancer. Univariate models 
were independently developed for Cu (odds-ratio increment = 4.48 µg/L) and Pb (odds-
ratio increment = 0.368 µg/L) owing to their significant elevation in breast cancer patients. 
Both Cu (odds-ratio: 1.77, 95% CI: 1.15-2.72, P-value = 0.008) and Pb (odds-ratio: 1.65, 
95% CI: 1.14-2.40, P-value = 0.005) were found to be significant factors for having breast 
cancer. A multivariate model that comprised Cu, Pb, and patient age (odds-ratio increment 
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= 19 years) was additionally constructed where Cu (odds-ratio: 1.52, 95% CI: 0.95-2.43, 
P-value = 0.079) and Pb (odds-ratio: 1.46, 95% CI: 0.97 – 2.18, P-value = 0.064) did not 
significantly contribute to the regression line which was dominated by patient age (odds-
ratio: 2.77, 95% CI: 1.44-5.32, P-value < 0.0005). 
 
Table 2. Comparison of USG-adjusted urinary metal levels in women with benign 









51V 0.45 <LOQ <LOQ N/A 
52Cr 0.35 0.175 (0.175-0.580)c 0.175 (0.175-0.424)c 0.541 
55Mn 1.60 <LOQ <LOQ N/A 
59Co 0.05 0.316 (0.235-0.439) 0.254 (0.191-0.431) 0.405 
60Ni 0.45 1.28 (0.99-2.75) 1.54 (0.99-2.39) 0.730 
63Cu 0.70 9.35 (7.43-13.61) 8.47 (6.92-10.46) 0.036 
66Zn 1.45 447 (286-757) 386 (263-664) 0.272 
69Ga 0.95 0.475 (0.475-1.152)c 0.475 (0.475-1.047)c 0.310 
75As 0.55 4.15 (2.94-6.34) 4.28 (2.74-6.44) 0.981 
77Se 1.50 36.66 (29.07-53.26) 38.92 (29.64-49.10) 0.726 
85Rb 0.20 1318 (1104-1747) 1239 (958-1819) 0.330 
88Sr 1.30 123.43 (84.27-162.41) 123.00 (80.45-167.46) 0.814 
97Mo 1.75 38.43 (26.43-56.69) 42.33 (29.85-70.92) 0.420 
107Ag 0.10 <LOQ <LOQ N/A 
111Cd 0.15 0.669 (0.440-1.262) 0.611 (0.472 – 0.885) 0.163 
118Sn 0.10 0.482 (0.191-1.475) 0.469 (0.137-1.005) 0.467 
121Sb 0.15 0.163 (0.075-0.234) 0.075 (0.075-0.210) 0.348 
133Cs 0.05 6.01 (5.25-8.57) 6.58 (4.56-9.00) 0.950 
137Ba 1.70 2.82 (0.85-4.71) 2.19 (0.85-3.38) 0.205 
205Tl 0.01 0.165 (0.131-0.223) 0.175 (0.129-0.256) 0.781 
208Pb 0.05 0.578 (0.395-0.876) 0.388 (0.260-0.597) 0.003 
238U 0.01 <LOQ <LOQ N/A 
a LOQs and urinary concentrations were adjusted by a 5-fold dilution factor. 
 
b P-values represent group comparisons between women newly diagnosed with breast 
cancer and benign conditions using nonparametric Mann-Whitney U analyses. 
 
c Unquantifiable levels of Cr, Ga, Sb, and Ba in some samples were taken as LOQ/2.. 
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 ROC analysis suggested clinical performance of individual models was ordered as 
follows: Cu < Pb < Patient Age < Multivariate Model (Fig. 2). Specifically, Cu poorly 
distinguished invasive breast carcinomas across all thresholds (AUC: 0.611, 95% CI: 
0.510-0.712, P-value = 0.035) while Pb demonstrated slightly improved discriminatory 
power (AUC: 0.659, 95% CI: 0.562-0.756, P-value = 0.003). Although patient age 
possessed marginally better discriminatory power (AUC: 0.685, 95% CI: 0.593 – 0.778, P-
value < 0.0005), the combined multivariate model provided optimal results (AUC: 0.728, 
95% CI: 0.641-0.816, P-value < 0.0005). The univariate Cu and Pb models both had 19.2% 
sensitivity (95% CI: 9.2%-33.3%) and 91.2% specificity (95% CI: 83.6%-96.6%) while 
the multivariate model afforded 36.2% sensitivity (95% CI: 22.7%-51.5%) and 88.1% 
specificity (95% CI: 79.2%-94.1%). While characteristic performance permits objective 
classification model ranking, clinical applicability is better assessed at optimal cutoff 
thresholds. To this end, Cu had 61.7% sensitivity (95% CI: 46.4%-75.5%) and 50.0% 
specificity (95% CI: 38.9%-61.1%) using a cutoff of 8.50 µg/L, while Pb had 76.6% 
sensitivity (95% CI: 62.0%-87.7%) and 51.2% specificity (95% CI: 40.0%-62.3%) using 




Figure 2. ROC data comparing incremental increases in diagnostic performance for the 
univariate models of Cu and Pb and the multivariate model comprising Cu, Pb, and patient 
age in women newly diagnosed with breast cancer (n=47) and benign conditions (n=84). 
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3.3. Correlations among urinary metals and clinicopathological factors 
It was also of interest to identify potential correlations among different urinary 
metals to better understand exposure routes and possible pathophysiological mechanisms. 
Significant correlations (|Pearson r| > 0.3, P-value < 0.05) among different urinary metals 
were summarized in Table 3. Notably, twice as many correlations were noted in breast 
cancer patients compared with women with benign conditions, although this finding may 
result from the limited sample size of the breast cancer group. Among the benign condition 
group, interactions among Ba, Sr, and Ga were the strongest. Moderate correlations 
included those between Cu with Ni, Zn, and Cs in addition to those among trace essential 
metal Se with Zn and Cu, and heavy metal Sn with Co and Zn. The correlations from the 
breast cancer subgroup were markedly different from those observed in the benign 
condition group, although strong interactions among Ba, Sr, and Ga were similarly 
observed. Urinary Cd was correlated with several heavy metals including As, Zn, Sb, Tl, 
Rb, and Cu. The heavy metal Cr was also found to be correlated with Sn, Ni, Se, and Sb. 
Urinary Pb was correlated with Se, Ni, and Zn. Correlations among USG, patient age, Cu, 
and Pb also suggested Pb was weakly correlated with both USG (r = 0.201, P-value = 
0.021) and age (r = 0.178, P-value = 0.042). 
 
Prognostic immunohistochemical factors including progesterone receptor status, 
estrogen receptor status, Her-2/neu, and Ki67 cell proliferation marker for the 45 invasive 
breast cancers were compared with the 22 urinary metals to identify possible prognostic 
capabilities. Urinary As was found to have a weak inverse relationship with progesterone 
receptor status (r = -0.294, P-value = 0.023) and Her-2/neu (r = 0.362, P-value = 0.028). 
Other correlations included Sr and estrogen receptor status (r = 0.340, P-value = 0.037), 
Mo and Her-2/neu (r = -0.350, P-value = 0.034), and Cd and estrogen receptor status (r = 
-0.334, P-value = 0.04). Urinary Pb correlated moderately with estrogen receptor status (r 
= -0.441, P-value = 0.006), progesterone receptor status (r = -0.315, P-value = 0.044), and 





Table 3. Significant correlations among USG-adjusted urinary metals. 
 








Sn-Zn 0.305 0.005 Zn-Cu 0.304 0.038 
Sn-Co 0.307 0.004 Cd-As 0.318 0.029 
Mo-Se 0.307 0.005 Zn-Ni 0.323 0.027 
Cs-Sr 0.307 0.004 Cd-Zn 0.325 0.026 
Cs-Rb 0.333 0.002 Pb-Se 0.327 0.025 
Se-Cu 0.347 0.001 Sn-Cr 0.337 0.020 
Se-Zn 0.365 0.001 Sb-Cu 0.357 0.014 
Sb-Mo 0.381 <0.0005 Cs-Rb 0.359 0.014 
Cu-Ni 0.427 <0.0005 Sn-Cu 0.360 0.013 
Tl-Sr 0.433 <0.0005 Ni-Cr 0.371 0.010 
Cs-Cu 0.470 <0.0005 Mo-Sr 0.384 0.008 
Zn-Cu 0.506 <0.0005 Mo-Se 0.391 0.007 
Sr-Ga 0.543 <0.0005 Ba-Se 0.394 0.006 
Ba-Sr 0.666 <0.0005 Ni-Cu 0.415 0.004 
Ba-Ga 0.874 <0.0005 Pb-Ni 0.415 0.004 
   
Sr-Ga 0.419 0.03 
   
Se-Cr 0.422 0.003 
   
Sb-Cd 0.431 0.002 
   
Cs-Co 0.433 0.002 
   
Pb-Zn 0.443 0.002 
   
Sb-Ni 0.457 0.001 
   
Tl-Cd 0.462 0.001 
   
Sn-Ni 0.510 <0.0005 
   
Sb-Cr 0.528 <0.0005 
   
Se-Zn 0.551 <0.0005 
   
Cd-Rb 0.581 <0.0005 
   
Ba-Sr 0.652 <0.0005 
   
Cd-Cu 0.656 <0.0005 




Finally, the correlation between Pb and Cu with cancer progression was explored 
using Kruskal-Wallis analyses and Dunn’s multiple comparisons tests. The highly limited 
sample size of the DCIS subgroups warrant cautious interpretation of their results. Urinary 
Pb levels were arranged in the following order: Benign Condition < Grade 3 DCIS < Grade 
1 DCIS < Grade 2 DCIS < Grade 1 IDC ≤ Grade 2 IDC < Grade 3 IDC. The difference 
between Grade 3 IDC and benign conditions was most significant (Dunn’s multiple 
comparisons P-value = 0.0006). Similarly, urinary Pb was weakly correlated with cancer 
grade using cancer grade as a continuous variable (r = 0.265, P-value = 0.002). No 
significant differences among cancer grades were noted for urinary Cu, which was ranked 
in the following order: Benign conditions < Grade 2 DCIS < Grade 1 DCIS < Grade 1 IDC 
< Grade 3 DCIS < Grade 2 IDC < Grade 3 IDC. Weak correlations between urinary Cu 
and continuous variable cancer grade (r = 0.254, P-value = 0.003) were similarly noted. 
 
4. DISCUSSION 
We investigated 22 urinary metals in women newly diagnosed with breast cancer 
and benign conditions in a proof-of-concept study to determine whether urinary 
metallomics may serve as a useful platform for biomarker discovery. In this study, two 
metals, copper and lead, were encountered at significantly elevated levels in the urine of 
breast cancer patients. This finding is consistent with a growing body of literature 
concerned with in vivo metallomics of breast cancer tissue. For example, copper 
hyperaccumulation occurs in breast carcinomas [12] through dysregulated copper transport 
proteins [13]. Importantly, the association of urinary copper with high-grade breast cancers 
in particular appeared to reflect copper-based mechanisms related to cancer motility in 
metastatic breast carcinomas [15]. Elevated urinary lead concentrations were similarly 
more pronounced in high-grade breast carcinomas. Environmental lead exposure, a salient 
consideration for our study population, is associated with risk for developing breast cancer 
while recent work has suggested that lead functions as a selenium antagonist that 
competitively binds selenium [26]. The significant indirect correlation between lead and 
selenium in breast cancer patients observed in this study appears to support this proposed 
mechanism. While urinary cadmium weakly associated with breast cancer, no 
multiplicative interactions with selenium were observed (r = -0.02, P-value = 0.82) as 
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previously cited, presumably due to substantial differences in environmental cadmium 
exposure between our study population and that of Wei [29]. Although univariate 
classification models for copper and lead demonstrated limitations in breast cancer 
diagnostics, the multivariate model that included patient age performed remarkably well. 
The clinical performance of copper and particularly lead at optimized cutoff thresholds 
compared favorably with other breast cancer diagnostic modalities such as clinical breast 
examinations and mammography [37]. This diagnostic performance appears promising 
given the inexpensive and noninvasive character of urinary metal screening. However, the 
authors acknowledge the limited sample size of this study and point out that larger clinical 
studies are required to validate these preliminary findings. 
Moreover, our results suggest that diagnostic performance may be further improved 
through enhanced understanding of metal and metalloid exposure routes. For example, 
numerous correlations among various metals in this study provided pertinent information 
regarding common exposure routes that include dietary intake, residential exposure, 
occupational exposure, and more broadly, environmental exposure. For instance, barium, 
strontium, and gallium, which together represented the strongest metal-metal correlations, 
are typically co-present in ore-bearing rock. The interaction between nickel and copper 
among other interactions may be similarly attributed to shared geochemical distribution 
[38]. Although this study was not designed to evaluate the influence of local mineralogy 
on urinary metal epidemiology, we feel it necessary to mention that geochemical 
distributions likely represent a major determinant of biometal concentrations. Supporting 
this claim is a comparison of previously reported urinary metal concentrations in baseline 
populations and those reported from our southwest Missouri cohort which demonstrates 
that while many essential metals obtained primarily from dietary exposure were in good 
agreement [39, 40], trace and toxic metals like cadmium varied considerably [29]. 
Differences arising from unique local geochemistry will additionally be influenced by 
environmental regulations. For example, the similar urinary lead values reported in our 
study population compared with other reported industrialized country populations likely 
reflects lead removal from drinking water. Further investigations into local geochemical 
distributions and metallomic correlations will be needed to qualify these considerations. 
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Finally some correlations, such as those between copper, zinc, and nickel, may additionally 
reflect dietary supplement use and other dietary fortifications. Hence, characterization of 
the exposure routes to urinary metals of interest is critical to advancing urinary metal 
molecular pathological epidemiology.  
Finally, the correlations between urinary metals and clinicopathological factors 
provided new insights into disease mechanisms and clinical applicability of urinary metals 
in breast cancer patients. Notably, both copper and lead correlated weakly with cancer 
progression and peaked in high-grade IDC patients. This observation suggests copper and 
lead may have applicability in the detection of early stage breast cancer, an observation 
that merits further investigation. The ability to detect early stage breast cancer is especially 
critical given the potential to reduce tumor upstaging and improve patient mortality. 
Finally, several metals and particularly lead were shown to have potential use in 
prognostics. Because prognostic capability was not directly quantified, future studies 
should aim to quantitatively assess urinary metals for their ability to predict breast cancer 
outcome. Such a finding would render urinary metals a valuable supplementary technique 
for current immunohistochemical techniques. 
 
5. CONCLUSIONS 
In conclusion, this proof-of-concept study introduces urinary metallomics as a 
noninvasive platform for biomarker discovery and clinical translational research. This 
work provides new insights into the epidemiology of urinary metals in suspected breast 
cancer cases. Specifically, this work highlights the potential of urinary copper and lead as 
noninvasive diagnostic breast cancer biomarkers in addition to an array of urinary metals 
with prognostic capabilities. Future studies should aim to improve understanding of the 
relationship between urinary metals and source exposure, to measure the prognostic 
capability of individual metals in prospective clinical studies, and to evaluate copper and 
lead applicability to early stage breast cancer detection. 
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Renewed interest in pteridine molecular pathology has generated new details on the 
emerging clinical significance of urinary pteridines as putative disease biomarkers. Central 
to these efforts is the need to understand the sources and extent of their non-
epidemiological variation. In response, this study was designed to characterize two primary 
sources of urinary pteridine variance: daily variation and the effect of dietary folate. Daily 
variation was studied by collecting urine specimens (n = 81) three times daily for three 
days. The effect of dietary folate was investigated in a treatment study in which urine 
specimens (n = 168) were collected daily during a control week and a treatment week 
during which participants received dietary folate supplements. Measurements of six 
urinary pteridines were made using high-performance liquid chromatography – tandem 
mass spectrometry. Coefficients of variation were calculated to grossly characterize daily 
variance between and within subjects, while nearest neighbor non-parametric analyses 
were used to identify diurnal patterns and measure dietary folate effects. This study 
confirms that pteridines respond to circadian rhythms with urinary levels that typically 
peak in the morning. Similarly this research corroborates previous findings that dietary 
folate affects pteridines in a pathway dependent manner that likely impacts endogenous 
neopterin and biopterin biosynthesis. Together with preliminary associations between 
urinary pteridine levels and different activities, the findings of this study have been used to 
gain new insights into the pteridine biosynthetic pathway and the impact of pteridine 
variation on molecular epidemiology studies. 
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The discovery of fluorescent pteridine derivatives in urine premised new analytical 
methodologies for their quantitation and simultaneously renewed interest in understanding 
their roles in human health and disease (Stea et al. 1978). Briefly, pteridine derivatives 
constitute an extensive class of metabolites that are primarily involved in the biosynthetic 
and biodegradation pathways of vitamins and cofactors (Kośliński et al. 2011). Many 
pteridines additionally function as regulatory cofactors, such as tetrahydrobiopterin in 
aromatic acid biosynthesis and endothelial vasodilation (Thony et al. 2000; Gross and Levi 
1992) and neopterin as an agent of cellular immune response (Huber et al. 1983; 
Reibnegger et al. 1987). Recent studies have provided new mechanistic insights into the 
roles of these compounds in broader pathophysiological contexts. From these studies, it 
has become increasingly clear that the unique physicochemical properties of pteridines, 
such as their remarkable capacity to generate reactive oxygen species (Lorente et al. 2011; 
Thomas et al. 2003; Cabrerizo et al. 2004; Petroselli et al. 2006) and even photosensitize 
biologically important biomolecules including DNA (Denofrio et al. 2009; Serrano et al. 
2015; Serrano et al. 2012), folic acid (Dántola et al. 2010), and tryptophan (Thomas et al. 
2013), carry intriguing biological implications. For these reasons, the photosensitizing 
aromatic pteridines derived from folic acid such as 6-carboxypterin, 6-formylpterin, 6-
hydroxymethylpterin (Fukushima and Shiota 1974) and their downstream derivatives like 
xanthopterin and isoxanthopterin have recently come under intense investigation as 
putative cancer biomarkers (Ma and Burton 2013). These pteridine biomarker development 
efforts have primarily focused on the use of noninvasively monitored urinary pteridine 
panels following promising indications from early molecular epidemiological studies 
which have implicated these compounds in an assortment of malignancies, including lung 
and colon cancers (Gamagedara et al. 2011), bladder cancer (Han et al. 1999; Kośliński et 
al. 2014), breast cancer (Gamagedara et al. 2011; Burton et al. 2013, 2014), digestive tract 
cancers (Konishi et al. 1999), and brain tumors (Manjula et al. 1993). 
 
One of the key challenges facing pteridine biomarker development is the 
determination of their non-epidemiological variation and the individual factors that 
influence endogenous pteridine biosynthesis. Daily variation of urinary pteridine levels, 
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which includes both diurnal fluctuations in response to circadian rhythms and day-to-day 
variance related to microscale changes to feeding and physical activities, is particularly 
salient in the context of urinary pteridine screening where spot urine specimen collection 
times have varied widely across studies and the differences between pathological and 
physiological urinary pteridine levels are often marginally significant (Burton et al. 2014; 
Gamagedara et al. 2011). Biological variation, such as genetic heterogeneity, disease 
status, environmental factors, as well as long-term lifestyle and dietary factors, has further 
complicated efforts to characterize pteridine metabolism and molecular epidemiology. 
While certain biological factors such as disease type and progression can be controlled in 
well-designed clinical studies, other undetermined factors remain. Dietary folate in 
particular has been suggested to function as a key source of biological variation (Burton et 
al. 2014) owing to wide discrepancies in total daily folate intake and vitamin 
supplementation across different demographic characteristics (Bailey et al. 2010). Finally, 
analytical variance related to measurement imprecision is generally marginal with well-
validated methods in the modern analytical laboratory with the advent of advanced 
analytical techniques like tandem mass spectrometry. In this way, daily variation and the 
effect of dietary folate on pteridines pose the greatest uncertainty to our understanding of 
pteridine metabolism and molecular pathological epidemiology. 
 
Therefore, the purpose of this study was to measure the primary sources of non-
epidemiological pteridine variation: daily variation and dietary folate. Six urinary 
pteridines, namely neopterin, 6-biopterin, pterin, 6-carboxypterin, xanthopterin, and 
isoxanthopterin, were selected owing to their previously reported clinical significance to 
disease detection and diagnosis (Gamagedara et al. 2011; Burton et al. 2014). Daily 
variation was measured by collecting spot urine specimens at defined time points across 
several days. Meanwhile, the effect of dietary folate was measured in a treatment study in 
which baseline pteridine levels were determined from individuals during a control week 
followed by a treatment week during which participants received daily folate supplements. 
Daily urine specimens were collected at reproducible times during the folate study. To the 
best of our knowledge, systematic investigations into the non-epidemiological sources of 
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pteridine variation are generally lacking. The findings of this study in relation to pteridine 
metabolism and its broader pathophysiological implications are discussed. 
 
2. MATERIALS AND METHODS 
2.1. Study population 
A total of 30 individuals were locally recruited at Missouri University of Science 
and Technology (Rolla, MO) to participate in this study between April and June 2015. 
Selection criteria included healthy adults without known or suspected medical conditions, 
no prior history of cancer, were not actively taking folate supplements, and were not 
currently pregnant or planning to become pregnant during the study duration. Participants 
were additionally asked to complete a questionnaire which evaluated current vitamin and 
supplement use, currently used medications, self-assessed physical activity levels, and 
participant height and weight. Study protocol was approved by the Missouri University of 
Science and Technology Institutional Review Board (IRB) and informed consent was 
obtained from all participants. Demographic composition included 50% females, 46.7% 
Asian Americans, 40.0% Caucasians, 6.7% African Americans, and 6.6% Asian Indians. 
The mean (SD) age of the participants was 27.3 (11.1) years. The mean weight (SD) of the 
study population was 159 (26) lbs. 
 
2.2. Daily variation study 
Nine individuals were recruited for the specific purpose of quantifying both the 
within-day and between-day variation of urinary pteridines. Midstream spot urine 
specimens were collected from these individuals thrice daily consisting of (1) second 
morning voids collected between 8 a.m. and 10 a.m., (2) mid-afternoon voids collected 
between 12 p.m. and 2 p.m., and (3) evening voids collected between 6 p.m. and 8 p.m. for 
a total of three days. At each collection, participants were asked to complete a daily log 
that detailed feeding activity and self-assessed physical activity levels since the previous 
collection point. Urine specimens (20-60 mL) were collected in sterile biological specimen 
containers and immediately stored at -80°C for approximately one month after collection. 




2.3. Dietary folate effect study 
Twenty-one individuals were recruited to study the effect of dietary folate on 
urinary pteridine levels. This phase of the study was additionally designed to extend the 
results of the diurnal variation experiment by measuring between-day variation across a 
larger sample size for a longer period of time. In this experiment, participants were 
instructed to provide a single midstream spot urine specimen at reproducible times daily 
for two weeks (Monday – Friday). The first week served as a control to establish baseline 
urinary pteridine levels for each individual. During the second week, participants were 
given one 400 µg (100% recommended daily value) folate supplement. Urine specimens 
were similarly collected in sterile biological containers and immediately frozen at -80°C 
for approximately one month prior to analysis. Data from participants who missed two or 
more collection points were excluded from analysis. A total of 168 urine specimens were 
collected for this component of the study. 
 
2.4. Urinary pteridine assay 
Six urinary pteridines including xanthopterin (CAS #119-44-8), isoxanthopterin 
(CAS #529-69-1), neopterin (CAS #2009-64-5), 6-biopterin (CAS #22150-76-1), pterin 
(CAS #218-799-1), and 6-carboxypterin (CAS #948-60-7) were separated and quantified 
by a high-performance liquid chromatography – tandem mass spectrometry (HPLC-
MS/MS) technique that has been described previously (Burton et al. 2013). Briefly, urine 
specimens underwent an oxidative pretreatment to oxidize residual reduced pterin species 
by treating a 100 µL aliquot of thawed urine prepared in 850 µL of ultra-pure water with 
40 µL of 4:2% w/v potassium iodide-iodine solution (I3
-) and 10 µL of 2 M ammonium 
hydroxide for 30 minutes at 4°C under dark conditions. Following incubation, the treated 
samples were centrifuged at 3000 g at 4°C for 20 minutes to remove bulk sediment. 
Centrifuged samples were filtered with a 0.22 µm nylon membrane filter and diluted 20-
fold in ultra-pure water. Ammonium oxalate was prepared at a final concentration of 10 





Urinary pteridines were separated using a Phenomenex Luna phenyl-hexyl column 
(3.0µm, 3.0 × 150 mm) and a Shimadzu UFLC system (Columbia, MD, USA) comprised 
of a degasser (DGU-30A3), two pumps (LC-20 AD XR), a temperature controlled 
autosampler (SIL-20AC XR), and a column oven (CTO-20A). Urinary pteridines were 
quantified using an AB Sciex 4000 QTrap MS/MS system (Foster City, CA, USA) that 
was operated under ESI-positive ionization and scheduled multiple-reaction monitoring 
(MRM) scan modes. The six urinary pteridines were quantified over a linear range from 
0.10 µg/L to 100 µg/L with representative spiked recoveries that ranged from 80% to 112% 
and analytical reproducibility that ranged between 2.3% and 6.8% relative standard 
deviation (RSD). Urine specimens that afforded urinary pteridine levels under the 
corresponding detection limits were assigned a concentration of one half the limit of 
quantitation (LOQ/2). 
 
2.5. Urine specific gravity adjustment 
Urinalysis requires adjustments to reflect patient hydration-dilution status and time 
since last urination. Urine specific gravity (USG) was used for this purpose since 
conventionally used urinary creatinine is dependent on muscle mass and related individual 
characteristics (Burton et al. 2014). USG was measured refractometrically using a 
temperature-corrected Reichert TS 400 clinical refractometer since this method remains 
the most accurate (Miller et al. 2004). Freshly thawed urine specimens were allowed to 
equilibrate to room temperature (21-25°) whereby a 200 µL aliquot was analyzed with the 
refractometer. Freeze-thaw cycles were preliminarily shown to have no impact on USG 
(Online Resource 1). Urine specific gravity was measured with inter- and intra-assay 
RSDs of 0.12% and 0.04%, respectively. Urinary pteridine levels were adjusted to USG 
using the Levine-Fahy equation and a reference USG of 1.020: 




where Ccorrected is the adjusted analyte concentration, Craw is the uncorrected analyte 
concentration, USGreference is a reference USG for a given population, and USGexperimental is 




2.6. Statistical analysis 
2.6.1. Data processing 
Urinary pteridine levels were normalized to USG to compensate for differences in 
individual hydration status and time since last urination. Overly dilute and concentrated 
urine specimens, defined as having a USG value less than 1.003 or greater than 1.030, 
respectively (Bush 2008; Alessio et al. 1985), were excluded from statistical analysis (n = 
3). Similarly, urinary pteridine concentrations that fell below their respective limits of 
quantitation (n = 6), which have been defined elsewhere (Burton et al. 2013), were taken 
as one half their limit of quantitation. Anderson-Darling goodness-of-fit tests indicated 
pteridine distributions with substantial right skew (skew range: +0.97 – 1.88) that were 
most accurately modeled as lognormal distributions. Although log-transformations have 
been previously employed to normalize metabolite concentrations (Thompson et al. 2012), 
such an approach is problematic for the study of metabolite variation. Namely, 
transformation processes distort coefficients of variation, which serve as a primary measure 
in the daily variation component of the study. Secondly, the nearest neighbor ratio analyses 
performed in this study would lose intrinsic meaning following a log-transformation since 
this process inadvertently reduces resulting ratios to unity. Finally, the paired differences 
and ratios that formed the bases of most statistical analyses in this study were acceptably 
symmetric about 0 and 1, respectively (Anderson-Darling < 0.5, P-value > 0.05) for all six 
pteridines. For these reasons, data were not transformed. 
 
2.6.2. Statistical methods 
Coefficients of variation (%CVs) were determined from untransformed data using 
the method of moments defined as σ/?̅? where σ is the sample standard deviation and ?̅? is 
the sample mean. Our study design permitted determination of two types of daily variation: 
(a) within-day and (b) between-day. Within-day variation was calculated as the mean %CV 
determined for each day for each pteridine for each individual. Between-day variation was 
calculated as the mean %CV for each corresponding time point (e.g. mornings, afternoons, 
evenings) across three days for each pteridine for each individual. The averages and %CVs 
of the individual daily variations were calculated as the within-individual and between-
individual variance, respectively. 
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Nearest neighbor ratio nonparametric analysis was used to quantify diurnal patterns 
by taking the ratios of each successive time point for each pteridine for each individual. 
Ratios for major time points (e.g. morning, afternoon, and evening) were combined and 
subjected to a Signed Rank test with the null hypothesis that the overall ratio was equivalent 
to unity. The paired ratios of the case week to the control week in the folate study were 
similarly analyzed with a Signed Rank test. Paired equivalence tests were used to confirm 
equivalence where appropriate. Pearson correlations were performed to quantify the 
correlation between urinary pteridine values amongst one another and self-reported 
parameters of feeding and physical activity. Mann-Whitney U group comparison tests were 
used to measure the differences between unpaired data sets. A P-value below 0.05 was 
considered statistically significant, except in cases of multiple comparisons wherein 
Bonferroni corrections were made. 
 
2.6.3. Sample size and statistical power 
 This study aimed to quantify the daily variation and effect of dietary folate on six 
urinary pteridines. The sample size for the Signed Rank tests for determining these two 
types of variation was determined to be 67 using a statistical power of 80%, a 5% Type I 
error rate, a minimum effect size of 0.15, and a standard deviation of 0.40. This standard 
deviation estimate was premised on the variation of serum acylcarnitines, which may 
similarly be considered secondary metabolites (Thompson et al. 2012), as well as 
derivations of previously reported clinical investigations of urinary pteridine levels (Burton 
et al. 2014). The observed sample sizes, 81 and 168, for the daily variation and folate 
experiments, respectively, enabled formative conclusions to be drawn from these analyses, 
although the generalizability of these findings may be extended with larger sample sizes. 
 
3. RESULTS 
3.1. Daily variation 
Daily variation of urinary pteridines was assessed on within-day and between-day 
bases for a period of three days with three measurements taken each day at defined times 
for a total of nine measurements per individual (Table 1). Briefly, the encountered 
pteridine ranges reported in this study population (range: 43 nM 6-carboxypterin – 3,326 
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nM neopterin) were comparable to previous accounts, although considerably lower than 
previously reported levels in certain cancer patient populations (Gamagedara et al. 2011; 
Burton et al. 2013, 2014). Gamagedara and co-workers noted comparable epidemiological 
differences in their case-control study that examined a demographically similar control 
population and a substantially older case population (Gamagedara et al. 2011). 
 
Within-day variation was studied to determine whether urinary pteridine 
concentrations respond to circadian rhythms. Within-subject variance was approximately 
35% for all urinary pteridines with the exception of 6-carboxypterin which had 
substantially higher variance measured at 72.5%. High urinary 6-carboxypterin variance 
was generally observed across the study population as reflected by its lower 36.6% 
between-subject variance. The between-subject variance for the other urinary pteridines 
remained at ~35%. While these measures of variance provide a characterization of the total 
daily and biological variation, they provide little insight into the individual factors that 
comprise pteridine variation, such as diurnal trends in relation to circadian rhythms. To this 
end, nearest neighbor ratios were determined for each successive time point for each 
individual and composited to provide a generalized characterization of daily urinary 
pteridine clearance trends (Table 2). Specifically, 6-biopterin, pterin, neopterin, and 
isoxanthopterin levels in urine were significantly elevated in the morning (Signed Rank P-
values < 0.05). Nonsignificant increases (Signed Rank P-values = 0.073) were also 
observed in xanthopterin and 6-carboxypterin. Morning pteridine levels were generally 
maintained throughout the afternoon (paired equivalence test P-values < 0.05) for all 
urinary pteridines except 6-carboxypterin, followed by substantial decreases in the evening 
(Signed Rank P-values < 0.05 for 6-biopterin, pterin, neopterin, and isoxanthopterin; P-






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Between-day variation was additionally studied to provide supplemental 
information about the individual sources of pteridine variation. For example, urinary pterin 
variance was consistently higher when measured between subjects than within subjects. A 
comparison of the within-day and between-day variances of urinary pterin on an individual 
basis revealed that the two measures were strongly correlated (Pearson r = 0.806, P-value 
= 0.029) and were considered equivalent within a 30% margin of difference (paired 
equivalence test P-values (lower bound, upper bound) = 0.026, 0.036) for each individual. 
The isomers xanthopterin and isoxanthopterin exhibited similar behavior. Specifically, 
comparisons between the within-day and between-day variances for xanthopterin were 
considered insignificant (Pearson r = 0.706, P-value = 0.076) and statistically equivalent 
within a 30% margin of difference (paired equivalence P-values = 0.010, 0.046), while 
those of isoxanthopterin displayed a slightly weaker correlation (Pearson r = 0.657, P-value 
= 0.109) and were not considered equivalent within a 30% margin of difference (paired 
equivalence P-values = 0.067, 0.029). 
 
Total daily variation was studied by combining the nine samples collected for each 
pteridine from each individual over the three day period. Representative time series for 
xanthopterin and isoxanthopterin are shown in Fig. 1. Nearest neighbor ratios were 
tabulated for each individual and then composited to produce a generalized characterization 
of urinary pteridine fluctuations with respect to each successive time point (Table 3). This 
analytical approach taken together with the self-assessed descriptions of feeding and 
physical activities prior to each time point was used to elucidate distinct sources of 
pteridine variance. Specifically, individuals who had eaten calorific meals prior to 
overnight fasting had significantly lower 6-biopterin levels compared with individuals who 
had eaten smaller dinners (Mann-Whitney P-value = 0.004). High-intensity physical 
activities that included extended walking (>30 minutes), resistance training, and prolonged 
gardening tended to increase urinary neopterin levels (Mann-Whitney P-value = 0.027) up 
to several hours after the activity occurred, an observation that has been reported elsewhere 
(Sprenger et al. 1992). Exposure to sunlight was also found to substantially attenuate 
urinary 6-carboxypterin levels (Mann-Whitney P-value < 0.001) by up to one order of 
magnitude. Finally, some urine specimens appeared as elevated outliers in comparison with 
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the other urine specimens collected from the same individual. Reproducible times for these 
outlier events (e.g. evenings) on an individual basis suggested these events may coincide 





Figure 1. Representative time series for urinary xanthopterin and isoxanthopterin from nine 















































































































































































































































































































































































































































































































































































































3.2. Dietary folate 
Dietary folate has been suggested to serve as a key source of variation of urinary 
pteridine derivatives owing to its implicit role in the pteridine biosynthetic pathway as a 
major entry point for aromatic pteridine biosynthesis and the wide epidemiological 
discrepancies in total daily folate intake. Herein baseline urinary pteridine levels were 
established during a control week which generated between-day variations that were 
comparable to those shown in Table 1 (2-sample equivalence test P-value = 0.024 for 10% 
margin of difference). Urinary pteridines were subsequently measured during the case 
week in which study participants were provided one folate supplement at the total daily 
recommended value (400 µg). The mean weekly pteridine values for each individual for 
each pteridine were compared by taking the ratio of the case week to the control week. 
Signed Rank analyses were performed to determine the effect of folate intake on urinary 
pteridine levels (Table 4).  
 
Table 4. Effect of dietary folate supplementation on six urinary pteridine levels. 
 
Pteridine % Change‡ P-Value 
6-Biopterin -31 <0.0001 
Pterin +27 <0.001 
Neopterin -16 0.031 
Xanthopterin -32 0.021 
6-Carboxypterin +11 0.021 
Isoxanthopterin -5 1.000 
 
‡Data are presented as the percent change between mean urinary pteridine levels between 
a control week in which no folate supplementation was given and a case week in which 
folate supplementation was provided at a level of 400 µg/day. P-values were calculated 





Clinical interest in pteridine derivatives as investigative cancer biomarkers has 
prompted efforts to study the functionality and biological significance of pteridines in 
human health and disease. Central to these efforts is the need to understand the sources and 
extent of their non-epidemiological variation. As metabolites, pteridines are subject to 
myriad factors capable of effecting their natural variation, which include but are not limited 
to circadian rhythms, genetic heterogeneity, disease status, environmental factors, diet and 
physical activity. This study was therefore designed to measure the extent of urinary 
pteridine variation with respect to daily variation and dietary folate intake, and to lesser 
extents, diet and physical activity, which together represent the largest sources of variation. 
In doing so, new insights have been gained regarding pteridine metabolism and its 
complicated and intersecting biosynthetic pathways. 
 
The daily variation of urinary pteridines was approximately 35% RSD for both 
within-day and between-day periods for most pteridines. The extent of this daily variability 
is comparable to other metabolites, even highly regulated serum amino acids and 
acylcarnitines (Thompson et al. 2012). The clinical significance of this daily variability 
should be considered minimal, since pathological epidemiological differences between 
healthy individuals and cases typically exceed the daily variability described here. For 
example, Burton and co-workers demonstrated that mean urinary isoxanthopterin levels 
from breast cancer patients are 350% higher than those of healthy women (Burton et al. 
2014). However, pteridine biomarkers with lesser effect sizes will be more acutely affected 
by daily variability. For this reason, clinical studies aiming to quantify pteridine biomarker 
performance in spot urine samples should collect at consistent time periods. Furthermore, 
urinary pteridine variation in this study exhibited diurnal patterns that likely reflected 
circadian rhythms that modulate metabolism. These patterns were generally characterized 
as peaking in the morning followed by a reduction in urinary pteridine levels later in the 
evening. These patterns corroborated similar findings that have been described for urinary 
neopterin, which has been more extensively studied as an inflammatory marker (Garcia‐
Gonzalez et al. 2006; Auzéby et al. 1988). These patterns support the hypothesis that 
melatonin plays a regulatory role in endogenous pteridine biosynthesis (Jang et al. 2000). 
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Specifically, guanosine triphosphate (GTP) is a major entry to the pteridine biosynthetic 
pathway and leads to the production of reduced pteridine derivatives, like 
tetrahydrobiopterin and dihydroneopterin, that give rise to 6-biopterin and neopterin 
(Huber et al. 1984). Jang and co-workers have demonstrated that melatonin modulates 
biopterin and neopterin biosynthesis by inhibiting GTP cyclohydrolase I, the initial enzyme 
in the GTP pteridine biosynthetic pathway, and downregulating its gene expression (Jang 
et al. 2000). Biopterin derivatives have also been shown to modulate neurotransmitters like 
melatonin as enzymatic cofactors to tryptophan hydroxylase, suggesting a possible 
feedback mechanism (Makoto et al. 1994; Wang et al. 2002). The present study supports 
the hypothesis that melatonin regulates endogenous pteridine biosynthesis given the 
sensitivity of GTP-derived pteridines, 6-biopterin, neopterin, and pterin, to circadian 
rhythms. 
 
 In contrast, folate-derived pteridines were not significantly affected by circadian 
rhythms in this study. This observation may be attributed to the distinctive biochemistry of 
folic acid degradation and resulting pteridine interconversion. Specifically, folic acid 
degradation yields 6-formylpterin that is subsequently oxidized to 6-carboxypterin, which 
in turn may be further converted to pterin (Off et al. 2005). Xanthine dehydrogenase 
catalyzes the formation of xanthopterin and isoxanthopterin from 7,8-dihydropterin and 
pterin, respectively (Blau et al. 1996). It has been recognized that folic acid degradation is 
accelerated in the presence of UV radiation (Off et al. 2005). Consequently, elevated levels 
of folate-derived pteridines have been measured in the skin of patients suffering from 
vitiligo, a depigmentation disorder (Schallreuter et al. 2001). This understanding of the 
folic acid photodegradation supports the observation that urinary 6-carboxypterin levels 
were elevated in study participants who received significant sunlight exposure, although 
this study was not designed to measure that effect. More importantly, the relative 
contributions of the GTP and folic acid entry points to shared downstream pteridine 
derivatives, such as pterin, isoxanthopterin, and xanthopterin, remains poorly understood. 
Given current understanding of the folic acid degradation pathway and the lack of diurnal 
behavior observed in the present study, these findings suggest that the folic acid entry point 
may be the dominant pathway for the formation 6-carboxypterin, xanthopterin, and 
  
149 
isoxanthopterin. This hypothesis is explored further in the dietary folate supplementation 
study. 
 
 The effect of dietary folate supplementation elicited varied responses in a 
seemingly pathway dependent manner. Specifically, neopterin, biopterin, and xanthopterin 
were appreciably downregulated while 6-carboxypterin and pterin were upregulated and 
no significant change was observed in isoxanthopterin. Downregulation of the primary 
GTP pteridines suggests a possible competitive interaction between the GTP and folic acid 
entry points in the pteridine biosynthetic pathway. This novel observation provides for the 
first time evidence that folic acid can modulate endogenous neopterin and biopterin 
biosynthesis. The biological significance of neopterin and biopterin derivatives in human 
and health and disease suggest that folate modulation may have important clinical 
implications. Moreover, these interactions provide new insights into the relative 
contributions of GTP and folic acid on pteridine production as well as into the crosstalk 
between the two metabolic entry points. For example, the non-specific formation of pterin 
from ubiquitous pteridines can occur via non-enzymatic side chain cleavage (Kośliński et 
al. 2011; Cañada-Cañada et al. 2009). Similarly, 7,8-dihydropteridines, including 7,8-
dihydrofolate, preferentially oxidize to 7,8-dihydroxanthopterin which is subsequently 
oxidized to xanthopterin (Oliveros et al. 2010). The resulting crossover interactions 
between the two metabolic entry points has complicated the interpretation of pterin and its 
downstream pteridines in clinical epidemiological studies. The present work clearly 
demonstrates that folate supplementation augmented urinary levels of 6-carboxypterin and 
pterin, suggesting that folate catabolism is a major source of pterin biosynthesis. A 27% 
change in urinary pterin levels corresponds to approximately 20 µg folic acid when a 
typical 250 mL urine void is assumed. This contribution of folic acid to an individual 
pteridine within a spot urine sample is significant given that folic acid is primarily excreted 
in the form of its major metabolites, p-aminobenzoylglutamate (pABG) and the acetamide 
derivative of p-aminobenzoylglutamate (apABG), the latter of which lacking biological 
activity with excretion rates up to 20-fold higher than that of folic acid (Álvarez-Sánchez 
et al. 2010; Niesser et al. 2013). Moreover, the insignificant effect of dietary folate 
supplementation on isoxanthopterin suggests that alternatives mechanisms for 
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isoxanthopterin biosynthesis possibly involving xanthine dehydrogenase appear likely 
(Blau et al. 1996). Finally, decreases in xanthopterin levels suggest that urinary 
xanthopterin is primarily driven from the GTP entry point through the nonspecific 
oxidation of reduced GTP pteridine derivatives. With this new information, we have 
proposed a pteridine biosynthetic pathway that for the first time comprehensively bridges 
the GTP and folic acid entry points (Fig. 2). Further in vitro work will be needed to confirm 





Figure 2. Simplified schematic of the proposed pteridine biosynthetic pathway. Pteridine 




 Finally, there were several limitations to the present study that may be improved 
upon to gain more conclusive findings. Namely, a limited number of measurements (n = 
81), representing three samples collected daily for three days from nine individuals was 
taken to study the daily variation of urinary pteridines. Larger sample sizes and a greater 
number of time points may extend the generalizability of these findings across different 
patient populations and timespans, which may provide additional insights into the finer 
patterns in urinary pteridine variation. Similarly, this study was not designed to measure 
the effect of specific physical activities, environmental factors, and diet on urinary 
pteridine variation which represent useful directions on which to extend these findings. 
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Self-reporting of disease status additionally has intrinsic limitations, as was evidenced by 
the development of a bladder infection in one of the study participants which resulted in 
their immediate exclusion from the study. Finally, long-term studies of dietary folate 
supplementation would benefit from the secondary half-life of folic acid that occurs after 
approximately 100 days that is associated with the decay of existing body folate pools. 
Together these areas provide new research directions based on the findings of this study 
for future studies aiming to study pteridine metabolism and urinary excretion. 
 
5. CONCLUDING REMARKS 
In summary, this study aimed to quantify the daily variation and effect of dietary 
folate on urinary pteridine levels. Urinary pteridines were confirmed to exhibit diurnal 
patterns in response to circadian rhythms marked by rising levels in the morning that 
decrease later in the evening. Dietary folate was similarly demonstrated to have a 
pronounced effect on urinary pteridine levels in a pathway dependent manner. This 
pathway dependence suggests dietary folate may modulate endogenous neopterin and 
biopterin biosynthesis. A number of secondary associations between urinary pteridine 
levels and various feeding and physical activities were additionally made. Together these 
newly quantified sources of variation have provided new insights into the pteridine 
biosynthetic pathway and their broader effects on human metabolism, health, and disease. 
Better understanding of pteridine metabolism through these findings will enable more 
accurate interpretation of pteridine molecular pathological epidemiology and elucidate an 
obscure branch of metabolism with wide-reaching physiological implications. 
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Pteridines have evoked considerable interest from the scientific community owing 
to their prominent roles in human health and disease. The availability of analytical 
methodologies suitable for comprehensive pteridine profiling, termed here as 
“pterinomics”, has been limited by inconsistent sample preparation and the exclusion of 
lesser studied pteridine derivatives. In response, the present study describes a new 
pterinomics workflow using a high-performance liquid chromatography – tandem mass 
spectrometry (HPLC-MS/MS) methodology for the simultaneous analysis of 15 pteridine 
derivatives including five structural isomers, marking the largest quantitative pteridine 
panel that has been studied to-date. The validated method possessed excellent sensitivity 
with method detection limits (0.025 µg L-1 to 0.5 µg L-1) that were comparable or superior 
to existing techniques. Spiked recovery studies demonstrated the technique was both 
accurate (88-112%) and precise (RSD: 0-6%). A comparative study of commonly used 
oxidative pretreatments, including triiodide, permanganate, and manganese dioxide, 
revealed that the oxidative mechanisms were inefficient, complex, and concentration 
dependent. Finally, 50 clinical urine specimens were examined with the new technique 
wherein 10 pteridine derivatives were quantified and population ranges have been given. 
This technique can be used to examine pteridine molecular epidemiology and biochemistry 
to support related research applications, and may further be readily extended to include 
additional pteridine derivatives and biological matrices for specific applications. 
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Pteridines have evoked interest from the scientific community since their successful 
isolation from butterfly wings by Hopkins in 1889 [1]. The structural elucidation of their 
pyrazine [2,3-D]pyrimidine ring system that followed in the early 1940s prompted 
tremendous efforts to catalogue their biological and chemical diversity that continue to this 
day [2-4]. From these studies have emerged an extensive and complex family of 
metabolites related to the biosynthesis and biodegradation of vitamins and cofactors [5]. 
The key finding that 5,6,7,8-tetrahydrobiopterin is an obligatory cofactor for aromatic 
amino acid hydroxylases [6, 7] and nitric oxide synthase [8, 9], as well as the cytokine-
inducible biosynthesis of neopterin [10, 11], has furthered research into the function of 
pteridine derivatives in human health and disease. In recent years, these efforts have 
expanded to include the aromatic pteridines derived from folic acid catabolism [12], 
including 6-formylpterin, 6-carboxypterin, 6-hydroxymethylpterin, pterin, and 
isoxanthopterin [13]. Aromatic pteridines, and to lesser extents their semi-reduced and 
reduced counterparts, have remarkable photocatalytic and oxidoreductive properties, 
including a considerable capacity to generate reactive oxygen species [14-17] and even 
photosensitize important biomolecules including DNA [18-20], folic acid [21], and 
tryptophan [22], which has led researchers to postulate that pteridines may actively 
participate in molecular pathology [13]. Similarly, the overexpression of the endocytic 
folate receptor α in solid epithelial tumors [23-25] has presented a novel pathomechanistic 
premise for the clinical observation of elevated levels of folate-derived pteridines in the 
urine of patients suffering from lung and colon cancers [26], bladder cancer [27, 28], breast 
cancer [26, 29, 30], digestive tract cancers [31], and brain tumors [32]. 
 
However, current understanding on the biochemistry and molecular pathology of 
mammalian pteridines remains fragmented [33]. As Rembold and Gyure presciently 
remarked over forty years ago, analytical limitations related to the general instability and 
trace levels of biogenic pteridines have precluded detailed studies of the prevalence and 
role of many lesser known derivatives [13, 34]. More recent efforts have seen an attempt 
to develop robust analytical methodologies using advanced instrumental platforms and 
oxidative pretreatments to enable sensitive detection of biologically significant pteridine 
  
160 
derivatives. To this end, a multitude of competent analytical techniques have emerged over 
the past several years using an array of sensitive instrumental platforms including capillary 
electrophoresis – laser-induced fluorescence (CE-LIF) [35], high-performance liquid 
chromatography – fluorescence detection (HPLC-FD) [28, 36-40], high-performance 
liquid chromatography – mass spectrometry (HPLC-MS) [41], high-performance liquid 
chromatography – tandem mass spectrometry (HPLC-MS/MS) [29, 42-44], hydrophilic 
interaction chromatography – tandem mass spectrometry (HILIC-MS/MS) [45], and 
synchronous fluorescence spectroscopy [46, 47], which have been summarized in Table 1. 
 
Nevertheless, the availability of analytical methods suitable for comprehensive 
pteridine analysis, termed here as “pterinomics”, has been limited by several notable 
factors. First, fragmented understanding of the pteridine biosynthetic pathway alongside 
the tendency to select pteridine derivatives with previously established biological 
significance have generally limited the inclusion of lesser known derivatives in new 
analytical techniques. The interconversion of 6-substituted pteridines to 7-substituted 
isomers via biochemical processes that are unrelated to classical pteridine biosynthetic 
pathways presents an additional class of pteridine derivatives with probable biological 
significance that have otherwise received little attention thus far [48, 49]. Secondly, the 
problematic practice of using a variety of oxidative and anti-oxidative pretreatments, as 
recently reviewed by Tomšíková and co-workers [50], has led to inconclusive or 
inconsistent findings. Although a number of oxidative pretreatments have been proposed 
and optimized for selected pteridine derivatives, comparative studies of oxidative 
efficiency and byproduct formation for a wide panel of pteridine derivatives are lacking. 
An alternative strategy to oxidative pretreatments has more recently focused on the 
investigation of pteridine derivatives in their native oxidative states [40-42, 51], although 
the relative abundance and interconversion of semi-reduced and reduced pteridine 
derivatives in biological fluids, and particularly urine, remains disputed [36, 52-54]. For 
these reasons, new methods are urgently needed to study expanded pteridine panels, 
including structural isomers, alongside improved knowledge on the effectiveness of 













PTE, XAN, ISO, NEO, 6-BIO, 6-CAP, 
6,7-DMP, 6-HMP 
Alkaline I3- 20 
Gibbons et al 
(2009)[35] 
HPLC-FD PTE, NEO, 6-BIO, XAN, ISO None 16 
De Llanos et al 
(2011)[39] 
HPLC-FD 
PTE, XAN, ISO, NEO, 6-BIO, 7-BIO, 
MNP, 6-CAP, 6-HMP, LUM, 6-
HLUM, 7-HLUM, BLUM 
Alkaline I3- and 
KMnO4 
39 
De Llanos et al 
(2011)[39] 
HPLC-FD PTE, NEO, 6-BIO; XAN, ISO None 16 




PTE, ISO, 6-BIO, 7-BIO, NEO, MNP Acidic MnO2 19 
Allegri et al 
(2012)[44] 
HPLC-MS 
PTE, XAN, ISO, NEO, MNP, NH2, 6-
BIO, BH2, 6-HMP, 6-MP, 6-CAP 
None 30 




PTE, XAN, ISO, NEO, 6-BIO, 6-CAP, 
6,7-DMP, 6-HMP 
Alkaline I3- 7.5 
Burton et al 
(2013)[29] 
HPLC-FD 6-BIO, BH2, BH4, NEO, NH2 None 16 
Guibal et al 
(2014)[38] 
HPLC-FD 
PTE, XAN, ISO, NEO, 6-BIO, 6-CAP, 
6,7-DMP, 6-HMP 
Alkaline I3- and 
KMnO4 
25 
Kośliński et al 
(2014)[28] 
HPLC-FD 
PTE, XAN, ISO, NEO, MNP, 6-BIO, 
7-BIO, 6-CAP, 6-HMP 
Acidic I3- 29 




Quantitative: PTE, XAN, ISO, NEO, 
6-BIO, 6-CAP, 6,7-DMP, 6-HMP 
None 25 




PTE, XAN, XH2, NEO, NH2, 6-HMP, 
6-HMDP, 6-FOP, 6-CAP 
Mn2O5 8 





PTE, XAN, XH2, ISO, NEO, MNP, 6-
BIO, SEP, 6-CAP, 6,7-DMP, 6-MP, 6-
HMP, LUM, 6-HLUM, 7-HLUM 
None 7 -- 
1 PTE: Pterin; XAN: Xanthopterin; ISO: Isoxanthopterin; NEO: Neopterin; 6-BIO: 6-Biopterin; 6-CAP: 6-
Carboxypterin; 6,7-DMP: 6,7-Dimethylpterin; 6-HMP: 6-Hydroxmethylpterin; 7-BIO: 7-Biopterin; MNP: 
Monapterin; LUM: Lumazine; 6-HLUM: 6-Hydroxylumazine; 7-HLUM: 7-Hydroxylumazine; BLUM: 
Biolumazine; NH2: 7,8-Dihydroneopterin; BH2: 7,8-Dihydrobiopterin; 6-MP: 6-Methylpterin; BH4: 
Tetrahydrobiopterin; XH2: 7,8-Dihydroxanthopterin; PH2: Dihydropterin; PH4: Tetrahydropterin; 6,7-
Dimethyltetrahydrobiopterin; NH4: Tetrahydroneopterin; 6-HMDP: 6-Hydroxymethyldihydropterin; 6-
FOP: 6-Formylpterin; SEP: Sepiapterin; 
2 Run time includes pre- and post-equilibration and cleaning procedures. 
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In the present study, we described a new workflow for the quantitative analysis of 
15 pteridine derivatives in urine using a novel HPLC-MS/MS methodology. The pteridines 
investigated in this study were selected primarily as folate-derived pteridines with cancer 
biomarker applications [55] and include five structural isomers, multiple lesser known 
derivatives, and two semi-reduced compounds (Figure 1). However, the analytical 
workflow has been designed with extensibility to additional pteridine derivatives and 
biological matrices for specific applications. This new technique was subsequently used to 
systematically study the in-source oxidation, interconversion, and efficiency of several 
commonly used oxidative pretreatments in an attempt to standardize pteridine sample 
preparation. The resulting standardized technique was used to profile pteridine derivatives 





Figure 1. Chemical structures of: (1) pterin, (2) xanthopterin, (3) isoxanthopterin, (4) 7,8-
dihydroxanthopterin, (5) 6-carboxypterin, (6) 6-hydroxymethylpterin, (7) 6,7-
dimethylpterin, (8) 6-methylpterin, (9) neopterin, (10) L-monapterin, (11) 6-biopterin, (12) 
sepiapterin, (13) lumazine, (14) 6-hydroxylumazine, and (15) 7-hydroxylumazine. 
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2. MATERIALS AND METHODS 
2.1. Chemicals and Materials 
Pterin, xanthopterin, 7,8-dihydroxanthopterin, isoxanthopterin, 6-biopterin, 
sepiapterin, neopterin, monapterin, 6-carboxypterin, 6-hydroxymethylpterin, 6,7-
dimethylpterin, 6-methylpterin, lumazine, 6-hydroxylumazine, 7-hydroxylumazine, 6-
formylpterin, leucopterin, and folic acid were purchased from Schircks Laboratory (Jona, 
Switzerland). LC-MS grade ammonium hydroxide and formic acid were purchased from 
Fisher Scientific (New Jersey, USA). Potassium iodide, iodine, ascorbic acid, and 
dithiothreitol were purchased from Sigma-Aldrich (St. Louis, USA). Synthetic urine was 
obtained from CST Technologies Inc. (New York, USA). Ultrapure water was generated 
by a Milli-Q Advantage® A10 and Millipore Elix® water purification system. 
 
2.2. Instrumentation 
Pteridine derivatives were separated using a Luna phenyl-hexyl column (3.0 μm, 
3.0×150 mm) and accompanying guard column (Phenomenex, Torrance, CA) in 
conjunction with a Shimadzu UFLC system (Columbia, MD) that included a degasser 
(DGU-30A3), two pumps (LC-20 AD XR), a temperature controlled autosampler (SIL-
20AC XR) and a column oven (CTO-20A). Chromatography was performed at 40°C with 
a flow rate of 0.45 mL min-1 using a 50 µL injection volume. A binary gradient flow system 
was used to separate pteridine derivatives using the following mobile phase compositions: 
A: 0.025% (v/v) formic acid in 99% water / 1% acetonitrile; B: methanol. The gradient 
profile included an initial two-minute period in which the composition of mobile phase B 
was increased linearly from 7% to 20%, followed by another two-minute period in which 
mobile phase B was held at 20%, and rapidly returned to 7% for the final two minutes. A 
one-minute pre-equilibration as well as a 200 µL post-injection needle rinse procedure 
were added to reduce carryover effects between biological samples. The total run-to-run 
time was 7.0 minutes. Samples were stored in the autosampler at 4°C for a period lasting 
no longer than six hours. 
 
An AB Sciex 4000 QTrap MS/MS system (Foster City, CA, USA) was used to 
quantify pteridine derivatives. The ion source was operated in positive-ion ESI mode with 
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the following flow injection parameters: ion spray voltage: +5500 V; source temperature: 
600°C; curtain gas: 45 psi N2; GS1: 25 psi N2; GS2: 35 psi N2; heated interface. Scheduled 
multiple reaction monitoring (MRM) experiments were operated with 44 second scan 
windows and individual target scan times of 0.7 seconds to quantify selected ions 
transitions. Collisionally-activated dissociation (CAD) of pteridine derivatives was 
achieved using 12 psi ultra-pure N2 gas in the collision chamber. 
 
2.3. Standard Preparation 
Between 2 and 5 mg of each pteridine standard was dissolved in in 13 mL of 
ultrapure water and 500 µL of 2 N ammonium hydroxide in amber glass vials. Sonication 
was used to enhance dissolution of poorly soluble species, namely, 6,7-dimethylpterin, 6-
methylpterin, pterin, and leucopterin. Dilutions from these individual standard stock 
solutions were used for direct infusion analysis to optimize MS/MS conditions. A stock 
mixture solution was similarly prepared at 10 mg/L each component from these individual 
stock solutions using ultra-pure water. Aliquots of the individual and stock mixture 
solutions were wrapped in aluminum foil and were stored at -80°C. Fresh calibration 
standards were prepared from these aliquots daily using serial dilutions in ultra-pure water 
and/or 1% synthetic urine. 
 
2.4. Analysis of Urine Samples 
Urine specimens (n = 50) were collected from consenting women 33-87 years of 
age (mean: 60.0 years) at Mercy Breast Center – Springfield (Springfield, MO) between 
October 2014 and December 2014 in a consecutive case series manner. Selection criteria 
included women referred to the medical center for biopsy characterization with no co-
present medical conditions or previous history of cancer. Participants were drawn from a 
local patient population with the following demographics: 88.7% Caucasian, 3.3% 
Hispanic or Latino, 3.2% African American, 1.8% Asian, and 3% other or two or more 
races. Spot urine specimens consisting of first morning and second morning voids were 
collected prior to biopsy and immediately stored at -20°C for 1-6 days. Specimens were 
shipped to Missouri University of Science and Technology for analysis via next-day frozen 
ground freight. Upon arrival, specimens were thawed, aliquoted, and refrozen at -80°C 
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until analysis. Mercy Breast Center pathologists disclosed anonymized diagnostic reports 
at the conclusion of the study. 
 
Under dark conditions, urine sample aliquots were gradually thawed to room 
temperature and thoroughly vortexed. The urine specific gravity (USG) was determined 
from 200 µL sample using a temperature-corrected Reichert TS 400 clinical refractometer. 
USG was used to adjust urinary pteridine concentrations to patient hydration-dilution status 
and time since last urination in accordance with prior work [30]. Another 100 µL sample 
was diluted tenfold in ultra-pure water in a yellow centrifuge tube. Diluted samples were 
centrifuged at 3000 g for 20 minutes at 4°C and filtered with a 0.22 µm Nylon membrane 
to remove sediment, proteins, and epithelial cells. Another tenfold dilution in ultra-pure 
water was made into a 1.5 mL amber glass vial and was subsequently vortexed and 
submitted to HPLC-MS/MS analysis. The total dilution factor for urine samples was 100-
fold. 
 
3. RESULTS AND DISCUSSION 
3.1. MS/MS Optimization 
Individual pteridine derivatives were infused at a concentration of 100 µg L-1 in 
mobile phase A (0.025% (v/v) formic acid in 99% water / 1% acetonitrile) at a flow rate of 
0.2 mL hour-1. Ion source conditions included: ion spray voltage: +5500 V; source 
temperature: 30°C; curtain gas: 10 psi N2; GS1: 10 psi N2; GS2: 10 psi N2; heated interface. 
A combination of quadrupole (Q1) and linear ion trap (EMS) survey scans operating under 
Multiple Channel Analyzer (MCA) mode were used to study pseudomolecular ions. 
Sodiated and ammoniated molecular ions were present in standard stock solutions, owing 
to the dissolution of pteridine derivatives in ammonium hydroxide and ubiquitous sodium, 
respectively. The relative contributions of these adducts were consistent with previous 
reports [29], which may be generalized as the following: pteridines with electron 
withdrawing substituents favored the formation of ammoniated molecular ions whereas 
unsubstituted pteridines and pteridines with electron donating substituents favored the 
formation of sodiated molecular ions. Since molecular adducts contribute to decreased 
sensitivity and may require complicated ion summing procedures, infusion analysis of 
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pteridine standards in 1% synthetic urine was performed to study adduct formation under 
simulated salt concentrations. In this case, ammoniated molecular ions were not 
significantly observed while sodiated molecular ions remained prevalent. Sodiation was 
effectively controlled by applying sufficiently high declustering potentials to the orifice, 
which was automatically optimized by the Analyst 1.5.2 software. 
 
In addition to pteridine ammoniation and sodiation, 6-formylpterin exhibited in-
source oxidation to 6-carboxypterin (approximately 60% of the [M+H]+ molecular ion) as 
well as significant [M+15]+ and [M+H+32]+ molecular ions in the presence of methanol 
(representing 20% and 50% of the [M+H]+ molecular ion, respectively). The latter two ions 
were attributed to gas-phase aldol reactions between protonated aromatic aldehydes and 
methanol in the ion source [56]. These two species also did not appear in the linear ion trap 
EMS scans. Co-infusion of 100 µM ascorbic acid or dithiothreitol was found to limit its in-
source oxidation to 6-carboxypterin. Furthermore, 6-formylpterin and 6,7-dimethylpterin 
are isobaric compounds with nearly identical fragmentation spectra with the exceptions of 
m/z 106 derived from 6,7-dimethylpterin and m/z 67, 92, and 119 derived from 6-
formylpterin. Commonly used ion transitions for these compounds, such as 192  147 and 
192  165, should be avoided since these two pteridine derivatives have similar 
chromatographic retention times on conventional columns [29, 43]. In addition to its 
negligible solubility in aqueous solutions, leucopterin suffered poor ionization efficiencies 
where only high declustering potentials resulted in a weak [M+H]+ molecular ion and a 
weak [M-36]+ molecular ion related to loss of water from its two ketone functionalities. 
For these reasons, leucopterin was not added to the current HPLC-MS/MS method. 7,8-
Dihydroxanthopterin was found to have exhibited negligible in-source oxidation to 
xanthopterin (<5% of the [M+H]+ molecular ion). The limited extent of this in-source 
oxidation was contradictory to recent reports by Van Daele and co-workers who suggested 
a thermally facilitated oxidative process [43]. However, infusion at higher temperatures 
(e.g. 500°C) did not meaningfully increase in-source oxidation rates; rather, in-source 
oxidation of 7,8-dihydroxanthopterin appeared to be solvent mediated and may be 
manipulated by additive selection (e.g. acetic acid). A more detailed discussion on the 
oxidation of 7,8-dihydroxanthopterin and its derivatives is provided in the following 
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sections. The optimized MRM transitions have been summarized in Table 2. Flow 
injection analysis was performed for these optimized MRM transitions to enable systematic 
optimization of the ion source parameters. 
 
Table 2. Optimized ion pairs for MRM detection. Unlabeled ion pairs located directly 













6-Carboxypterin 208.1/164.3 46 23 10 
 208.1/190.1 46 21 12 
6,7-Dimethylpterin 192.2/165.2 11 31 10 
 192.2/106.2 11 39 6 
6-Formylpterin 192.1/147.2 76 31 8 
 192.1/149.2 76 29 8 
6-Hydroxylumazine 181.1/164.2 76 23 10 
 181.1/108.1 76 35 6 
6-Hydroxymethylpterin 194.1/106.1 61 37 18 
 194.1/176.2 61 23 12 
6-Methylpterin 178.2/106.1 1 41 6 
 178.2/133.2 1 31 8 
7,8-Dihydroxanthopterin 182.1/126.2 71 29 22 
 182.1/154.2 71 25 10 
7-Hydroxylumazine 181.1/110.1 76 31 6 
 181.1/55.2 76 49 8 
Biopterin 238.1/220.2 66 23 14 
 238.1/178.3 66 29 12 
Folic Acid 442.2/176.3 56 55 10 
 442.2/295.4 56 21 8 
Isoxanthopterin 180.1/135.1 71 33 8 
 180.1/163.2 71 27 10 
Lumazine 165.1/69.1 71 55 12 
 165.1/93.1 71 41 4 
Monapterin 254.1/206.1 71 27 14 
 254.1/236.3 71 21 16 
Neopterin 254.0/206.2 76 27 12 
 254.0/236.3 76 23 16 
Pterin 164.1/92.1 71 43 4 
 164.1/119.1 71 33 6 
Sepiapterin 238.1/192.3 61 23 12 
 238.1/165.3 61 33 10 
XantHopterin 180.1/135.2 76 31 24 






3.2. HPLC Optimization 
 Separation parameters were initially adapted from a previously developed HPLC 
method using a Luna phenyl-hexyl column [29]. However, using 0.1% aqueous formic acid 
and acetonitrile resulted in co-elution of three of the four structural isomer pairs. 
Adaptation of the selective HPLC technique developed by Girón and colleagues, in which 
the prescribed Zorbax Eclipse XDB-C18 column was substituted with a Kinetex C18 
column (2.6 μm, 3.0×150 mm), similarly failed to separate isobaric compounds and at 
greatly increased run times. Since acetonitrile and formic acid contain pi electrons that can 
suppress pi-pi interactions between analytes and phenyl bonded phases, the Luna phenyl-
hexyl column was reevaluated using methanol and lower formic acid compositions. 
Separation of the neopterin/monapterin and 6-hydroxylumazine/7-hydroxylumazine 
isomer pairs were inversely affected by solvent composition, where high formic acid 
concentrations (>0.1% v/v) promoted neopterin/monapterin separation and high 
acetonitrile compositions promoted 6-hydroxylumazine/7-hydroxylumazine separation. 
Overall method selectivity was greatly improved using methanol and sufficient amounts of 
formic acid for efficient analyte ionization. Therefore, trace amounts of acetonitrile were 
added to the aqueous phase to enable separation of the hydroxylumazines. The optimal 
solvent composition that permitted separation of isobaric pairs at minimal run times was 
determined to be 0.025% v/v formic acid in 99:1% water:acetonitrile and pure methanol.  
 
Furthermore, elevated column temperatures enhanced the separation of the 
hydroxylumazines, xanthopterin and isoxanthopterin, but partially merged neopterin and 
monapterin. It should be noted that 6-formylpterin and folic acid exhibited large peak 
widths and asymmetry on the reversed-phase Luna phenyl-hexyl column, which have been 
reported elsewhere [57]. The Kinetex C18 column meanwhile demonstrated superior 
selectivity and retention for these compounds. However, since the abundance of folic acid 
in urine relative to its primary degradation products, para-aminobenzoylglutamate (pABG) 
and para-acetamidobenzoylglutamate (apABG), is minimal [58], and 6-formylpterin is 
considered a reactive species that is not appreciably present in urine, both folic acid and 6-
formylpterin were excluded from the validated method. Future studies aiming to quantify 
folic acid degradation byproducts such as 6-formylpterin should utilize alkyl- or polar-
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bonded phases. An optimized overlaid extraction ion chromatogram (XIC) of the 




Figure 2. Overlaid extracted ion chromatograms (XIC) of the quantitative ion pairs of 




 Since urine is a complex matrix, potential interferences with equivalent MRM 
transitions and precursor ions were identified using unscheduled MRM experiments and 
linear ion trap enhanced product ion (EPI) scans. The EPI results were used in combination 
with MassBank spectral databases and chemical reference standards to make tentative 
assignments. Special attention was given to the presence of reduced pteridine derivatives, 
such as 5,6,7,8-tetrahydrobiopterin, that were not included in the pteridine panel 
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investigated in this study. For example, 7,8-dihydrobiopterin was observed at 
approximately 2.85 min in untreated urine. In-source oxidation of 5,6,7,8-
tetrahydrobiopterin chemical reference standard and EPI fragmentation patterns that 
matched those reported by Fismen et al [52] strongly suggested that this compound was 
7,8-dihydrobiopterin. Similarly, a small peak at 2.1 min was observed using the MRM 
transition for neopterin/monapterin. Survey scans at this chromatographic time point 
suggested the presence of 7,8-dihydroneopterin, as evidenced by major fragmentation 
patterns that included 256  165, 178 [43]. An unidentified compound that partially eluted 
with pterin was found to have the following ion transitions 164  61, 73, 87, 101, 103, 
119, 147, including the shared 164  119 transition. For this reason, the less abundant m/z 
92 fragment of pterin was selected as the quantitation ion. Tentative assignments were 
made for 7-methylguanine (R.T. = 3.15 min) and phenylalanine (R.T. = 4.10 min) while 
searching for 7,8-dihydropterin (m/z 166). Tyrosine (R.T. = 3.1 min) was also identified at 
m/z 182 with dissimilar fragmentation to 7,8-dihydroxanthopterin. Interestingly, a 
significant peak was located at m/z 180 at 4.2 min with a fragmentation pattern analogous 
to xanthopterin and isoxanthopterin. Further characterization revealed major fragmentation 
pathways of 180  71, 110 and minor fragmentation pathways of 180  68, 80, 93, 108, 
135, and 137. This pattern appeared to be indicative of pyrazine ring opening in 
xanthopterin, although its occurrence could not be modulated by triiodide and UV 
oxidative pretreatments. Further characterization will be required for structural assignment. 
 
3.3. Comparative Study of Oxidative Pretreatments 
 As Tomšíková and co-workers recently reviewed, a remarkably large number of 
oxidative and antioxidative pretreatments have been used to quantify pteridines in 
biological matrices [50]. Since comparative studies of these pretreatments have been 
incomplete or lacking, particularly in regard to semi-reduced and folate-derived pteridines 
like 7,8-dihydroxanthopterin, the newly developed HPLC-MS/MS method was used to 
quantify the oxidative efficiency of several commonly used techniques, including Lugol’s 
solution (I3
-), manganese dioxide, and potassium permanganate. Specifically, Lugol’s 
solution, comprising a 4%:2% (w/v) mixture of potassium iodide-iodine, is the most 
commonly used oxidative pretreatment for pteridine analysis and was evaluated herein in 
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both alkaline and acidic environments per previously developed protocol [27, 35, 37]. 
Permanganate and acidic manganese dioxide oxidative efficiency were also investigated 
using earlier developed methods [28, 44]. A summarized comparison of the effects of these 
pretreatments on pteridine standards prepared in synthetic urine has been provided in Table 
3. From these data it becomes clear that oxidative pretreatment leads to degradation of both 
aromatic and reduced pteridine derivatives. Alkaline triiodide was considered the gentlest 
pretreatment strategy with the exceptions of pteridines with electron withdrawing 
substituents at the 6-position, such as xanthopterin, 6-carboxypterin, and 6-
hydroxylumazine. However, the oxidation of 7,8-dihydroxanthopterin was remarkably 
complex with mass balance calculations indicating that the oxidative efficiency of the 
preferred conversion to xanthopterin was only 7%. Infusion of untreated and oxidized 7,8-
dihydroxanthopterin revealed possible oxidative byproducts centered at m/z 175, 205, and 
213, although the structures of these compounds remain undefined. An additional 5% of 
7,8-dihydroxanthopterin was lost to in-source oxidation during ionization. Acidic triiodide 
performed similarly to alkaline triiodide with the notable absence of xanthopterin which 
eluted much later (R.T. = 7.2 min). The effect of triiodide concentration was also 
considered by comparing a typical addition of 150 µM to 15 µM where higher 
concentrations led to increased pteridine degradation. The possibility that this observation 
may be attributed to ion suppression rather than an oxidative reaction was rejected since 
iodide ions were found to elute at the column dead time under similar chromatographic 
conditions. Permanganate pretreatments resulted in substantial loss of both aromatic and 
semi-reduced pteridines. These permanganate findings generally agreed with those 
reported by Kośliński and colleagues, and were attributed to opening of the pteridine ring 
system [28]. Similarly, pretreatments using manganese dioxide contributed to relative 
losses for most pteridine derivatives. 
In another experiment, we examined the effect of urine concentration-dilution on 
oxidative efficiency and pteridine degradation. Since synthetic urine lacks the pool of 
oxidizable species present in real urine matrices, it was necessary to investigate this effect 
using real urine samples. Alkaline triiodide was selected as the model oxidant owing to its 
widespread use and its relatively gentle oxidation. Urine concentration-dilution was 






















































































































































































































































































































































































































































































































































































































































































































































 The percentage of pteridine derivative remaining in oxidized urine specimens, 
relative to corresponding untreated urine specimens, were compared with sample USG 
ranging from 1.005 to 1.027. Urine specimens (n = 10) were spiked with a 5 µg L-1 mixture 
of pteridine standards to ensure detection of all pteridine derivatives. Briefly, xanthopterin 
oxidation exhibited a strong positive correlation (Pearson’s r = 0.9949) with urine 
concentration-dilution, ranging from 50% to 648% initial levels. Similarly, 6-biopterin 
oxidation positively correlated with urine concentration-dilution (Pearson’s r = 0.9566) 
and ranged from 135% to 186% initial levels. These correlations were attributed to the 
oxidation of reduced derivatives of xanthopterin and 6-biopterin. However, neopterin 
oxidation was inversely related to urine concentration-dilution (Pearson’s r = -0.9957), 
ranging from 72% in the 1.027 USG sample to 101% in the 1.005 USG sample. Other 
pteridine derivatives that exhibited correlations to urine concentration-dilution included 6-
hydroxymethylpterin (Pearon’s r = 0.9781), monapterin (Pearson’s r = -0.9104), and pterin 
(Pearson’s r = 0.7211). The oxidative effects on the other pteridines were generally similar 
to those determined in synthetic urine found in Table 3. These new findings are significant 
because previous research efforts have questioned whether triiodide ions have been 
provided in excess to ensure complete reduced pteridine oxidation [27, 35]. This oxidative 
pretreatment dependence on urine concentration-dilution marks a novel discovery and 
questions the validity of using oxidative pretreatments for pteridine quantitation. 
Moreover, the discovery of complicated oxidation mechanisms in the case of 7,8-
dihydroxanthopterin casts further doubts on the utility of oxidative pretreatments. While 
other analytical techniques have foregone pretreatment to simplify analysis or to preserve 
reduced species [38, 39, 42, 43], the present work has now provided compelling and 
quantitative evidence that currently used oxidative pretreatments are inefficient for 
quantitative pterinomics. 
 
3.4. Method Performance 
 Performance characteristics for the newly described HPLC-MS/MS method have 
been summarized in Table 4. Analytical sensitivity, assessed in terms of method detection 
limits (MDLs) and lower limits of quantitation (LLOQs), was comparable or superior to 
existing techniques for pteridine quantitation with MDLs ranging from 0.025 µg L-1to 0.5 
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µg L-1. Pteridine signal response exhibited considerable linearity (R2 > 0.99) over a wide 
linear range that spanned several orders of magnitude. The abundance of 7,8-
dihydroxanthopterin in urine specimens, which is discussed below, necessitated a higher 
operating range up to 1000 µg L-1. Method accuracy was evaluated with spiked recoveries 
in a pooled urine specimen (USG = 1.015) which ranged from 88% for low concentrations 
of 6-carboxypterin to 112% for high concentrations of 7,8-dihydroxanthopterin. The 
method possessed excellent precision that remained below 6% relative standard deviation 
for all pteridine derivatives on both intra-daily and inter-daily bases (n = 5). This level of 
precision was consistent across concentrations as indicated by the spiked recovery study.  
 
3.5. Analysis of Urine Specimens 
 The new pterinomics workflow was applied to 50 clinical urine specimens from 
women who were diagnosed with either breast cancer or a benign fibrocystic conditions. 
This application was selected based on prior reports on the molecular epidemiology of 
pteridines in breast cancer [26, 30], but also to determine whether untreated pteridine 
derivatives were present in urine at detectable concentrations. The latter investigation is 
novel because prior studies either have monitored reduced pteridine derivatives in other 
biological fluids or have used inferior methodologies that lack selectivity [39, 43]. At 100-
fold dilution, ten of the fifteen pteridine derivatives were reliably quantified in all urine 
specimens (Figure 3). Those derivatives and their encountered concentration range were 
as follows: sepiapterin (22 nM – 4500 nM), isoxanthopterin (250 nM – 2010 nM), 
xanthopterin (320 nM – 6000 nM), 6-biopterin (0.1 µM – 9.7 µM), neopterin (0.2 µM – 26 
µM), lumazine (190 nM – 1000 nM), 7-hydroxylumazine (67 nM – 465 nM), monapterin 
(50 nM – 2400 nM), pterin (150 nM – 2340 nM), and 7,8-dihydroxanthopterin (5 µM – 
112 µM). 6-Carboxypterin was present in most urine specimens, but at levels that were not 
quantifiable (signal-to-noise range: 0 – 4.2), an observation that supports earlier research 
findings [29]. Similarly, 6-hydroxymethylpterin was observed in a majority of samples, 
but at unquantifiable levels (signal-to-noise range: 0 – 2.9). Incomplete separation of 
neopterin and monapterin coupled with large concentration differences complicated the 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Detection of trace pteridines was improved by using lesser dilutions, such as 20-
fold dilutions; however, a 100-fold dilution was preferable in order to increase longevity 
of the column and mass spectrometer [29]. Non-parametric Mann-Whitney U group 
comparison tests revealed that no pteridine derivatives were substantially altered between 
the two patient groups, although isoxanthopterin (p-value = 0.063) was non-significantly 
increased in the breast cancer group. Hence, future studies that aim to quantify urinary 
levels of 6,7-dimethylpterin, 6-carboxypterin, 6-methylpterin, 6-hydroxymethylpterin, and 





Figure 3. Overlaid extracted ion chromatograms (XIC) of the quantitative and confirmation 






 Finally, much attention has been given to the stability and interconversion of 
reduced and aromatic pteridine derivatives in oxygenated and aqueous environments [50]. 
Prior work has shown that aromatic pteridines are generally stable at low temperatures, 
while the stability of semi-reduced pteridines is considerably less, but still significant [59]. 
This led us to investigate whether the pteridine profile of fresh urine specimens 
significantly differed from that of aged urine specimens. Interestingly, 7,8-
dihydroxanthopterin was present in fresh urine and accumulated over a period of weeks 
and months. This phenomenon was attributed to the non-specific oxidation and hydration 
of reduced pteridine derivatives to 7,8-dihydroxanthopterin [59]. For this reason, the 
pterinomic profile of a biological sample can be reasonably expected to change over time. 
For this reason, future studies should utilize either fresh urine specimens or store specimens 
at -80°C to prevent non-specific oxidation of reduced pteridine derivatives. 
 
4. CONCLUSION 
A new pterinomics workflow for the simultaneous determination of 15 pteridine 
derivatives in urine using HPLC-MS/MS has been described. The methodology expands 
on previous techniques by characterizing molecular adduction in ESI sources, separating 
five structural isomers, and investigating potential interferences present in complex urine 
matrices for the first time. The validated method possessed excellent sensitivity and 
precision that was suitable for comprehensive pteridine analysis in urine. The method was 
applied to a comparative study of commonly used oxidative pretreatments for pteridine 
analysis, revealing that oxidative mechanisms were inefficient, complex, and concentration 
dependent. These quantitative findings compellingly demonstrate that oxidative 
pretreatments are problematic for pterinomics approaches. In addition, 50 clinical urine 
specimens were examined with the new technique wherein 10 pteridine derivatives were 
quantified and population ranges have been given. The urinary levels reported in this study 
were generally consistent with previous work and indicated the suitability of the new 
technique for urinary pteridine analysis. Finally, this technique can be used to examine 
pteridine molecular epidemiology and biochemistry to support related research 
applications, and may further be readily extended to additional pteridine derivatives and 
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The work presented in this dissertation explored the application of urinary 
metabolomics approaches to cancer biomarker discovery. The first two papers discussed 
novel enzymatic methods for the determination of sarcosine, a putative biomarker for 
prostate cancer. These studies highlighted the growing need to both identify and eliminate 
potential interferences from analytical methods. The next several studies presented new 
bioanalytical and clinical translational methods for the determination of urinary pteridines 
as putative biomarkers for breast cancer. These studies were embedded with several 
innovations, including new methods for the adjustment of urinary biomarkers to urine 
concentration-dilution and particularly within the context of clinical breast cancer 
screening, mass spectrometry-based methods to minimize undesirable adduction as a 
means to enhance method sensitivity, and a novel study design employing rigorous 
statistical workflows for the characterization of the biological variation of urinary 
metabolites in relation to circadian rhythms and vitamin supplementation. The pterinomics 
workflow presented in the final paper additionally outlines the development of a high-
throughput method to support investigation of a composite panel of biomarkers for 
increased diagnostic accuracy. Finally, the proof-of-concept work presented in Paper VI 
that explores the feasibility of using urinary metals as disease biomarkers has introduced 
urinary metallomics as a potentially transformative new subfield of urinary metabolomics. 
Taken together, this body of work makes significant contributions to the applicability of 
urinary metabolomics as a biomarker discovery platform for early cancer detection and 
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